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ABSTRACT
Daniel J. Luckett: Machine Learning for Data-driven Biomedical Decision Making
(Under the direction of Michael Kosorok)
The big data age has brought with it challenges and opportunities for biomedical decision
making. New technologies allow for collecting large data sets that can be used to tailor treatment.
In this dissertation, we develop machine learning methods for data-driven biomedical decision
making with the goal of leveraging patient heterogeneity to make more precise treatment deci-
sions.
Many problems in biomedical decision making can be expressed as classification problems.
The costs of false positives and false negatives differ across application domains and this trade-
off is often displayed using a receiver operating characteristic (ROC) curve. In the first chapter,
we develop an ROC curve estimator using a weighted support vector machine (SVM).
Precision medicine is the paradigm of incorporating individual patient factors into treatment
decisions, formalized through individualized treatment regimes (ITR’s), or maps from the co-
variate space into the treatment space. The optimal ITR is defined as that which maximizes the
mean of a clinical outcome. The estimation of an optimal ITR from mobile health data is com-
plicated by the fact that observations occur over time at a fine granularity and there is no definite
time horizon. In the second chapter, we develop an estimation method for optimal ITR’s in mo-
bile health.
Clinical decision making often requires balancing trade-offs between multiple outcomes
while accounting for patient preferences, creating a disconnect with the traditional definition of
the optimal ITR. If an instrument to elicit patient preferences is available, one can construct a
composite outcome to identify the optimal ITR. However, such an instrument is often unavailable.
iii
In the third chapter, we introduce a method for estimating a composite outcome from treatment
decisions in observational data under the assumption that clinicians act approximately optimally.
Direct search methods, such as outcome weighted learning (OWL), estimate the optimal ITR
by maximizing an inverse probability weighted estimator (IPWE) over a class of ITR’s. In the
final chapter, we show that the IPWE objective function is a profile log-likelihood for a semipara-
metric model. We use this characterization to develop efficient computational algorithms and ex-
ploratory data analysis techniques for estimating the optimal ITR.
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CHAPTER 1: INTRODUCTION
Technological advancements have lead to an increased capacity for collecting and storing
large, complex data sets. These data can be used to improve the way we diagnose and treat dis-
ease, thus having potential to improve patient outcomes in a variety of therapeutic areas. How-
ever, taking full advantage of this potential requires the development of novel statistical methods.
In this dissertation, we look at a number of problems relating to data-driven biomedical decision
making and develop machine learning techniques to incorporate large and complex data sets into
the way we make decisions.
The research in this dissertation involves precision medicine. Precision medicine is the paradigm
of tailoring treatment based on individual patient characteristics (Hamburg and Collins, 2010).
Distinct from the traditional idea of personalized medicine, precision medicine should be data-
driven, rigorous, and reproducible in the sense that the discovered biomarkers, diagnostic tests,
and rules for treatment assignment should work on future patients (Collins and Varmus, 2015).
Because patients may exhibit significant heterogeneity in response to treatment, precision medicine
has the potential to improve patient outcomes by leveraging heterogeneity when making treat-
ment decisions. The idea of precision medicine can be formalized through treatment regimes
(equivalently, individualized treatment regimes, dynamic treatment regimes, or policies). A treat-
ment regime is a set of functions, one per stage of clinical intervention, mapping up-to-date pa-
tient information into a recommended treatment. The optimal treatment regime is defined as
that which optimizes the mean of a scalar clinical outcome when used to make decisions in a
population of interest. Much of the discussion of precision medicine in the statistical literature
involves estimating the optimal treatment regime (Murphy, 2003; Robins, 2004; Moodie et al.,
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2007; Kosorok and Moodie, 2015; Chakraborty and Moodie, 2013). However, additional statisti-
cal tasks in precision medicine include accounting for patient covariates in diagnosis and screen-
ing, discovering biomarkers that can be used to tailor treatment, identifying a subgroup that will
benefit from treatment, and estimating treatment regimes to balance multiple outcomes.
In Chapter 2, we develop a fully nonparametric approach to weighted classification and show
that placing unequal weight on false positives and false negatives can improve classification in
many settings. Machine learning methods such as the support vector machine (SVM) are widely
used in classification problems (Cortes and Vapnik, 1995; Steinwart and Christmann, 2008). Dis-
playing the trade-off between false positives and false negatives is often accomplished using a
receiver operating characteristic (ROC) curve (Zhou et al., 2002; Pepe, 2003). Veropoulos et al.
(1999) first considered estimating an ROC curve using a weighted SVM. We build on the work
of Veropoulos et al. (1999) by proposing a method to construct confidence bands for the SVM
ROC curve. We prove a number of theoretical results pertaining to the weighted SVM, including
uniform consistency of the risk function. We demonstrate the SVM ROC curve and confidence
bands in simulation experiments and through applications to hepatitis C and breast cancer data
sets.
Chapter 3 introduces an estimator for infinite horizon dynamic treatment regimes that is ap-
plicable to mobile health. The emerging area of mobile health provides a platform for assisting
patients with disease management (Free et al., 2013; Steinhubl et al., 2013). Because mobile tech-
nologies offer the capability of collecting patient data in real time, mobile health offers a wealth
of opportunity for developing deeply tailored interventions. However, there are a number of chal-
lenges associated with estimating dynamic treatment regimes from mobile health data. The mo-
mentary signal may be weak and may not directly measure the distal outcome of interest and mo-
bile health data feature a large number of time points per individual and no definite time horizon.
Previous approaches, such as variants of Q-learning (Ertefaie, 2014) may not adequately address
these challenges. We propose a new reinforcement learning method, V-learning, to address some
of these challenges. We develop an estimating equation for the mean of a discounted sum of fu-
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ture rewards given that patients follow a specific policy and maximize the resulting estimator over
a class of policies. We show that the proposed estimators are consistent and asymptotically nor-
mal under mild conditions and demonstrate the performance of V-learning through a suite of sim-
ulation studies and an application to a type 1 diabetes data set.
In Chapter 4, we approach the problem of precision medicine in the presence of multiple
outcomes. The traditional definition of the optimal treatment regime, that which optimizes the
mean of a scalar outcome, precludes direct application of existing methods in the presence of
multiple outcomes. If there are two competing outcomes (e.g., symptom reduction and severity
of side effects), neither optimal treatment regime may be acceptable. One could elicit a compos-
ite outcome, or summary measure of the multiple outcomes, from a domain area expert and use
the composite outcome to identify an optimal treatment regime. However, such a composite out-
come may not account for heterogeneity in patient preferences. If a high-quality instrument to
elicit preferences is available (e.g., a questionnaire given in conjunction with a clinical trial) then
a patient-specific composite outcome can be constructed (Butler et al., 2017). However, in many
cases, such an instrument may not be available. We propose a method for estimating a compos-
ite outcome from observational data. The proposed method requires the assumption that clini-
cians act with the intent to optimize an unknown patient-specific composite outcome but do so in
a noisy way. Under this assumption, observed decisions can be used to estimate the underlying
composite outcome and associated optimal policy. Thus, rather than seeking a transformation un-
der which observational data can be analyzed like a data from a randomized study, we propose
to take advantage of the fact that treatment assignment in an observational study is not random-
ized. This represents a new way of thinking about precision medicine and observational data. Our
approach involves maximizing a nonsmooth pseudo-likelihood function. We show that the maxi-
mum pseudo-likelihood estimators have a nonregular asymptotic distribution and that a paramet-
ric bootstrap procedure provides valid inference. We demonstrate the method using data from an
observational study of bipolar disorder.
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Finally, in Chapter 5, we discuss a connection between machine learning methods and max-
imum likelihood estimation and use this connection to derive new methods for estimating the
optimal treatment regime. Direct search methods for the optimal treatment regime (Zhang et al.,
2012b; Zhao et al., 2012; Zhou et al., 2017), represent an attractive alternative to regression-
based estimators as they offer robustness to model misspecification. Direct search methods in-
volve constructing an inverse probability weighted estimator (IPWE) for the mean outcome under
a specific treatment regime and maximizing this estimator over a prespecified class of regimes.
We show that the IPWE objective function is a profile log-likelihood function for a specific class
of semiparametric models. Thus, a class of direct estimators for the optimal treatment regime can
be expressed as maximum likelihood estimators. This establishes a link between machine learn-
ing and maximum likelihood, or alternatively, a link between direct search and regression-based
estimators. There are a number of practical advantages of this approach. First, the theoretical
properties of this class of estimators can be studied by studying the class of semiparametric mod-
els. Second, this approach permits a framework for discussing the efficiency of treatment regime
estimators in terms of the data-generating model. Finally, this approach allows for exploratory
data analysis techniques, information criteria for model selection, and a modeling setup that may
be more familiar to applied researchers than an IPWE. We develop an algorithm for maximizing
the proposed likelihood and demonstrate the algorithm using simulations and an application to a
bipolar disorder clinical trial.
As technological advances continue to provide increased access to data, there is an increas-
ing need for rigorous statistical methodology to incorporate data into biomedical decision mak-
ing. The methods presented in this dissertation address a wide range of problems in precision
medicine, which we hope will be useful to applied researchers. The case studies presented here
provide examples of applying precision medicine in practice, which we hope will motivate fur-
ther clinical and translational research projects. The rest of this dissertation is organized as fol-
lows. In Chapters 2, 3, 4, and 5, we present the four topics introduced briefly above. In Chapter 6,
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we offer a discussion and suggestions for future research. Proofs and additional simulation results
are given in the Appendices.
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CHAPTER 2: RECEIVER OPERATING CHARACTERISTIC CURVES AND
CONFIDENCE BANDS FOR SUPPORT VECTOR MACHINES
2.1 Introduction
Many important problems in biomedical decision making can be expressed as binary classi-
fication problems. For example, one may wish to identify infants infected with hepatitis C virus
from a sample of infants born to infected mothers (Shebl et al., 2009), screen for prostate cancer
using prostate-specific antigen (Etzioni et al., 1999), or predict which breast cancer patients will
respond to treatment based on genetic characteristics (Fan et al., 2011). In many scenarios, clas-
sification can be improved by placing unequal weights on false positives and false negatives. We
present an approach to estimating the optimal receiver operating characteristic (ROC) curve us-
ing a weighted support vector machine (SVM) and introduce a bootstrap method for constructing
confidence bands for the SVM ROC curve.
The support vector machine of Cortes and Vapnik (1995) is a popular classification algorithm
based on risk minimization (see also Krzyz˙ak et al., 1996; Lin, 2002; Zhang, 2004; Steinwart
and Christmann, 2008). When applying classification methods in practice, it may be important
to place unequal weights on false positives and false negatives. For example, misdiagnosing a
diseased patient as non-diseased often has different consequences from misdiagnosing a non-
diseased patient as diseased. The trade-off between false positives and false negatives is often dis-
played using an ROC curve (Zhou et al., 2002; Pepe, 2003). Various methods for modeling and
estimating ROC curves have been proposed (Pepe, 1997, 2000; Cai and Pepe, 2002; McIntosh
and Pepe, 2002; Cai and Dodd, 2008; Chrzanowski, 2014). Confidence bands for ROC curves
have been developed by Ma and Hall (1993), Jensen et al. (2000), Claeskens et al. (2003), Mac-
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skassy et al. (2005), and Horva´th et al. (2008), among others. The preceding methods all assume
a scalar biomarker.
A number of authors have developed methods to adapt machine learning techniques to al-
low for unequal weighting of false positives and false negatives. In Example 2.5 of Steinwart
and Christmann (2008), the authors discuss classification using a weighted SVM but do not vary
the weights to estimate an ROC curve to inform the optimal choice of weights. Veropoulos et al.
(1999) propose using weights to control the sensitivity and specificity of the SVM and estimate
an ROC curve, but provide no theoretical justification or inference methods. As such, the weighted
SVM has not yet been extensively applied in practice. In this paper, we build on the work of
Veropoulos et al. (1999) by developing a bootstrap method for constructing confidence bands for
the SVM ROC curve and providing a theoretical justification for ROC curves estimated using a
weighted SVM.
There are numerous applications to motivate this work. Diagnostic tests for infant hepati-
tis C virus (HCV) exhibit poor sensitivity for predicting which infants will become chronically
infected. A weighted SVM using multiple biomarkers is able to improve performance over stan-
dard HCV diagnostic tests. Predicting which breast cancer patients will respond to treatment is an
important problem in precision medicine. Genomic data provide a wealth of information for this
purpose. However, the high dimension of genomic data makes it difficult to correctly specify a
model. A weighted SVM is robust to model misspecification and provides improved performance
over standard classification methods.
In Section 2.2, we present the method developed by Veropoulos et al. (1999) and introduce
a method for bootstrap confidence bands. In Section 2.3, we show that many standard theoretical
results hold for the weighted SVM. We also show that the risk of the estimated decision function
is uniformly consistent across the weight parameter, providing the theoretical justification for es-
timating ROC curves using a weighted SVM. In Section 2.4, we present a series of simulation
experiments comparing the performance of the weighted SVM to standard methods in diagnos-
tic medicine including logistic regression (McIntosh and Pepe, 2002) and semiparametric ROC
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curves (Cai and Moskowitz, 2004) and to evaluate the operating characteristics of the proposed
bootstrap confidence bands. In Section 2.5, we present illustrative case studies and we conclude
in Section 2.6. Proofs and additional simulation results are provided in Appendix A.
2.2 Weighted Support Vector Machines
2.2.1 ROC Curve Estimation
Assume the available data are (Ai,Xi), i = 1, . . . , n, which comprise n i.i.d. copies of
(A,X), where A ∈ {−1, 1} is a class label (e.g., in diagnostic medicine, A = 1 corresponds to a
diseased individual and A = −1 corresponds to a non-diseased individual) and X ∈ X ⊆ Rp are
covariates. The goal is to estimate a classifier that correctly identifies a patient’s class label based
on that patient’s covariates. Consider minimizing the expected weighted misclassification, where
each misclassification event is weighted by the cost function Ca(α) = {1 + (2α− 1)a} /2 =
α1(a = 1) + (1 − α)1(a = −1), where Ca(α) is the cost of misclassification when the true class
label is A = a. In diagnostic medicine, with A = 1 corresponding to disease and A = −1 corre-
sponding to non-disease, α determines the relative weight placed on the sensitivity and specificity
of the test. When α = 1/2, sensitivity and specificity are given equal weight and the cost function
reduces to zero-one misclassification error. The optimal classifier in a class, D, is
D˜α = argmin
D∈D
E
[
1{D(X) 6= A}CA(α)
]
, (2.1)
where D is a class of functions mapping X into {−1, 1}.
For fixed α ∈ (0, 1) and a classifier D, the observed data can be used to approximate the
weighted misclassification in (2.1) as En1{D(X) 6= A}CA(α), where En is the empirical mea-
sure of the observed data. Note that any classifier D(X) can be represented as sign
{
f(X)
}
for
some decision function f ; we will assume that the decision boundary is smooth and thus f be-
longs to a class of smooth functions, F . For example, we can let F be the space of linear func-
tions, the space of quadratic or polynomial functions, or the reproducing kernel Hilbert space
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(RKHS) associated with the Gaussian kernel (Steinwart and Christmann, 2008). Minimizing the
empirical risk is difficult due to the discontinuity of the indicator function. Using the hinge loss,
φ(u) = max(0, 1 − u), as a surrogate loss function (Bartlett et al., 2006), an estimator for the
optimal decision function is
f̂α = argmin
f∈F
[
Enφ{Af(X)}CA(α) + λn‖f‖2
]
, (2.2)
where ‖ · ‖ is a norm on F and λn is a penalty parameter. The problem of estimating the optimal
classifier in (2.2) can be solved using the SVM introduced by Cortes and Vapnik (1995).
We estimate the optimal classifier, D˜α, using D̂α(X) = sign
{
f̂α(X)
}
. For any α ∈ (0, 1),
we can estimate the sensitivity and specificity of the estimated classifier using the empirical es-
timators given by ŝe
(
f̂α
)
= En1
[
A = sign
{
D̂α(X)
}
= 1
]
/En1(A = 1) and ŝp
(
f̂α
)
=
En1
[
A = sign
{
D̂α(X)
}
= −1
]
/En1(A = −1). Plotting ŝe
(
f̂α
)
against 1 − ŝp
(
f̂α
)
as func-
tions of α will yield a nonparametric estimator of the optimal ROC curve. There are a number of
methods which can be used to select a desired value of α, say α∗. For example, one could choose
the α∗ that leads to the point on the ROC curve closest to (0, 1) in Euclidean distance, the α∗ that
maximizes the sum of estimated sensitivity and specificity, or the α∗ that maximizes estimated
sensitivity for a fixed minimum specificity estimate (Lo´pez-Rato´n et al., 2014). The choice of α∗
will depend on the clinical application of interest. We classify an individual presenting with co-
variates X as D̂α∗(X). This is an equivalent formulation to the method proposed in Section 2.1 of
Veropoulos et al. (1999).
Remark 2.1. The optimal classifier over all functions mapping X into {−1, 1}, also known as
the Bayes classifier (Duda et al., 2012), can be expressed as
D∗α(X) = sign
{
αPr(A = 1|X)− (1− α)Pr(A = −1|X)}. (2.3)
Thus, D∗α(X) is equal to 1 when Pr(A = 1|X)/Pr(A = −1|X) > (1 − α)/α or, using Bayes
theorem, p(X|A = 1)/p(X|A = −1) > (1 − α)(1 − ρ)/αρ ≡ kα, and −1 otherwise, where
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ρ = Pr(A = 1). Thus, the optimal classifier given in (2.3) has the same form as the Neyman–
Pearson test of H0 : A = −1 against H1 : A = 1. If we fix kα (or equivalently, fix α) to
have fixed specificity sp0, then the Neyman–Pearson lemma ensures that D∗α(X) maximizes sen-
sitivity across all classifiers with specificity equal to sp0. Therefore, the ROC curve for D∗α(X),
ROC∗(u), has the property that ROC∗(u) ≥ ROC(u) for all u ∈ (0, 1), where ROC(u) is the
ROC curve corresponding to any other classifier. This is analogous to the result given by McIn-
tosh and Pepe (2002) (see also page 169 of Pepe, 2003).
Remark 2.2. The optimal decision function in F is
f˜α = argmin
f∈F
E (1[sign{f(X)} 6= A]CA(α))
= argmin
f∈F
[ραPr{f(X) < 0|A = 1}+ (1− ρ)(1− α)Pr{f(X) > 0|A = −1}]
= argmin
f∈F
[ρα{1− se(f)}+ (1− ρ)(1− α){1− sp(f)}]
= argmax
f∈F
{ραse(f) + (1− ρ)(1− α)sp(f)} ,
where se(f) and sp(f) are the sensitivity and specificity of the decision rule D = sign(f). Thus,
the true optimal decision function maximizes a weighted sum of sensitivity and specificity where
the weights are determined by the population prevalence, ρ, and a user chosen weight, α.
2.2.2 Confidence Bands
In this section, we present a method for constructing confidence bands for the ROC curve of
f̂α, which provide an indication of how well the estimated classifier will perform in future sam-
ples. The following result characterizes the asymptotic distribution of the estimated sensitivity of
f̂α. A proof is provided in Appendix A.
Theorem 2.1. Let se
(
f̂α
)
be the true sensitivity of f̂α and let ŝe
(
f̂α
)
be the estimated sensitiv-
ity of f̂α, where f̂α is estimated using a linear or polynomial kernel. Then,
√
n
{
ŝe
(
f̂α
)
− se
(
f̂α
)}
 G(α)
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as n→∞, where G(α) is a mean zero Gaussian process with covariance
E
(
ρ−21(A = 1)
[
1
{
f˜α1(X) > 0
}
− se
(
f˜α1
)] [
1
{
f˜α2(X) > 0
}
− se
(
f˜α2
)])
− E
(
ρ−11(A = 1)
[
1
{
f˜α1(X) > 0
}
− se
(
f˜α1
)])
× E
(
ρ−11(A = 1)
[
1
{
f˜α2(X) > 0
}
− se
(
f˜α2
)])
,
where f˜α is defined as in Remark 2.2.
An analogous result holds for the estimated specificity.
Let fpf
(
f̂α
)
= 1 − sp
(
f̂α
)
be the false positive fraction for the decision function f̂α.
Define fpf−1(·) such that fpf−1
{
fpf
(
f̂α
)}
= α, i.e., fpf−1(u) is the weight α such that
1 − sp
(
f̂α
)
= u. Let 0 < δ < 1/2 be fixed. A quantile bootstrap algorithm for constructing an
asymptotically correct (1− γ)100% confidence band for the ROC curve, se {fpf−1(u)}, δ < u <
1, is as follows:
1. Set a large number of bootstrap replications, B, a grid δ = z1 < . . . < zK = 1 and a grid
0 = α1 < . . . < αM = 1.
2. For m = 1, . . . ,M , compute R̂(αm) =
{
1− ŝp
(
f̂αm
)
, ŝe
(
f̂αm
)}
, the estimated ROC
curve.
3. For k = 1, . . . , K, compute ŷ(zk) by linearly interpolating R̂(αm).
4. For b = 1, . . . , B:
(a) Generate a weight vector Wb,n,i = ξi/ξ¯, where ξi, . . . , ξn are independent standard
exponential random variables and ξ¯ = n−1
∑n
i=1 ξi.
(b) For m = 1, . . . ,M , set
s˜eb
(
f̂α
)
= En
(
Wb,n1 (A = 1) 1
[
sign
{
f̂α(X)
}
= 1
])
/
En {Wb,n1(A = 1)} ,
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s˜pb
(
f̂α
)
= En
(
Wb,n1 (A = −1) 1
[
sign
{
f̂α(X)
}
= −1
])
/
En {Wb,n1(A = −1)} ,
and R˜b(αm) =
{
1− s˜pb
(
f̂αm
)
, s˜eb
(
f̂αm
)}
.
(c) For k = 1, . . . , K, compute y˜b(zk) by linearly interpolating R˜b(αm).
5. Let y˜p(zk) be the p-th quantile of {y˜b(zk) : b = 1, . . . , B} and let p∗ be the largest p ∈ [0, 1]
such that y˜p∗/2(zk) ≤ y˜b(zk) ≤ y˜1−p∗/2(zk) for all k = 1, . . . , K for at least (1 − γ)B
bootstrap samples.
6. Set yℓ(zk) = y˜p
∗/2(zk) and yu(zk) = y˜1−p
∗/2(zk).
We can also use alternate choices for the weights, for example, a multinomial weight vector Wb,n =
(Wb,n,1, . . . ,Wb,n,n)
⊺
with probabilities (1/n, . . . , 1/n) and n trials.
By Lemmas 12.7 and 12.8 of Kosorok (2008), taking the inverse of a bounded, monotone
function is Hadamard differentiable under mild regularity conditions. Thus, by Theorem 2.1
above and Theorem 2.6 of Kosorok (2008), {yℓ(zk), yu(zk)} will cover ŷ(zk) across k = 1, . . . , K
with probability 1 − γ for large enough n and B. In addition to the linear and polynomial SVM,
this procedure will work for any classifier such that the estimated decision function is in a VC
class, such as a logistic regression classifier.
2.3 Theoretical Results
For any α ∈ (0, 1), the estimated classifier is the sign of f̂α, the minimizer of the empirical
hinge loss in a class F as defined in (2.2). For any f , define Rα(f) = E (1[sign{f(X)} 6= A]CA(α))
to be the risk of f , and the φ risk of f to be Rα,φ(f) = E [φ{Af(X)}CA(α)]. Let R∗α = inffRα(f)
and R∗α,φ = inffRα,φ(f). Finally, define f˜α = argminf∈FRα(f) and f ∗α = argminfRα(f), i.e.,
f˜α minimizes the risk over F and f ∗α minimizes the risk over all measurable functions mapping
X into R. None of our results require that the true minimizer, f ∗α, be contained in F ; thus, we are
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able to consistently estimate the best classifier in the class even when the model is not correctly
specified.
When α = 0, the optimal classifier assigns −1 uniformly and when α = 1, the optimal clas-
sifier assigns 1 uniformly. Focusing on α ∈ (0, 1) will enable us to avoid these trivial extremes.
Nonetheless, many of our results hold for all α ∈ [0, 1]. We will make this distinction explicit as
needed. Throughout, we assume that all requisite expectations exist.
2.3.1 Excess Risk and Consistency
The following result gives a bound on the excess risk in terms of the excess φ risk. The proof
is similar to that of Theorem 3.2 of Zhao et al. (2012) and uses Theorem 1 and Example 4 of
Bartlett et al. (2006). We omit the proof here. This result will be used later to show uniform con-
sistency of the risk of the estimated decision function.
Lemma 2.1. For any measurable f : X → R and any distribution P of (X, A), Rα(f) − R∗α ≤
Rα,φ(f)−R∗α,φ.
This result implies that the difference between the φ risk of the estimated decision function and
the optimal φ risk is no smaller than the difference between the risk of the estimated decision
function and the optimal risk. Therefore, we can consider the φ risk when proving convergence
results.
Next, we establish a number of consistency results for the risk of the estimated decision func-
tion. We begin with Fisher consistency. This result implies that estimation using either the hinge
loss or the zero-one loss will yield the true optimal classifier given an infinite sample, providing
justification for using the proposed surrogate loss function. The proof follows from an extension
to the proof of Proposition 3.1 of Zhao et al. (2012) and is in Appendix A.
Theorem 2.2. For any α ∈ [0, 1], if f ∗α,φ minimizes Rα,φ, then D∗α(x) = sign
{
f ∗α,φ(x)
}
for
almost all x ∈ X .
The following result establishes consistency of the risk of the estimated decision function
when estimation takes place within a RKHS. We then extend this consistency by showing that
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it is uniform in α. The proof of the following result closely follows the proof of Theorem 3.3 of
Zhao et al. (2012) and is in Appendix A.
Theorem 2.3. Let α ∈ [0, 1] be fixed and let λn be a sequence of positive, real numbers such that
λn → 0 and nλn → ∞. Let Hk be a RKHS with kernel function k and let H¯k denote the closure
of Hk. Then, for any distribution P of (X, A), we have that
∣∣∣Rα (f̂α)− inff∈H¯k Rα(f)∣∣∣ P−→ 0 as
n→∞.
We next strengthen the consistency stated above by showing that the convergence is uniform
in α when estimation uses a linear, quadratic, polynomial, or Gaussian kernel (see Steinwart
and Christmann, 2008, for a discussion of kernel functions used with the SVM). The following
lemma indicates that the estimated decision function lies in a Glivenko–Cantelli class (Kosorok,
2008) indexed by α, which will help us to extend the consistency stated above to uniform consis-
tency in α. The proof is in Appendix A.
Lemma 2.2. Let f̂α be estimated using a linear, quadratic, polynomial, or Gaussian kernel func-
tion. Then,
{
f̂α : α ∈ [0, 1]
}
is contained in a Glivenko–Cantelli (GC) class.
Given that f̂α and −f̂α are contained in a GC class, we have by Corollary 9.27 (iii) of Kosorok
(2008), that φ
(
f̂α
)
and φ
(
−f̂α
)
are contained in a GC class because φ is continuous. By Corol-
lary 9.27 (ii) of Kosorok (2008), we have that 1(A = 1)φ
(
f̂α
)
and 1(A = −1)φ
(
−f̂α
)
are
contained in a GC class and thus, Lα,φ
(
f̂α
)
is contained in a GC class by Corollary 9.27 (i) of
Kosorok (2008), where Lα,φ(f) = φ(Af)CA(α). It follows that
sup
α∈[0,1]
∣∣∣R̂α,φ (f̂α)−Rα,φ (f̂α)∣∣∣ P−→ 0,
where R̂α,φ(f) = Enφ{Af(X)}CA(α). This convergence will be used in the proof of Theo-
rem 2.4, which is given in Appendix A.
Theorem 2.4. Assume that f̂α is estimated using a linear, quadratic, polynomial, or Gaussian
kernel. For any sequence λn of positive, real numbers satisfying λn → 0 and nλn → ∞ and any
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distribution P of (X, A),
sup
α∈[0,1]
∣∣∣∣Rα (f̂α)− inf
f∈H¯k
Rα(f)
∣∣∣∣ P−→ 0 (2.4)
as n→∞, where Hk is the RKHS associated with f̂α.
Note that we do not allow the sequence λn to depend on α, which is reflected in the implementa-
tion in Section 2.4 below.
2.3.2 Continuity
Here, we prove a number of continuity and convergence results regarding the ROC curve
and risk function for f˜α and f̂α. We begin with the following result which indicates that the ROC
curve of the Bayes classifier, D∗α, is continuous. We require Pr(A = 1|X) to be a continuous
random variable; however, Pr(A = 1|X) does not need to be a continuous function of X. The
proof is included in Appendix A.
Lemma 2.3. Let se∗(α) = Pr{D∗α(X) = 1|A = 1} and sp∗(α) = Pr{D∗α(X) = −1|A = −1}
be the sensitivity and specificity of D∗α. Then, se∗(α) and sp∗(α) are continuous in α whenever
Pr(A = 1|X) is a continuous random variable with support (0, 1).
Thus, ROC∗(u) is monotone nondecreasing and continuous except possibly at 0. It follows from
Lemma 2.3 and Remark 2.2 that Rα(f ∗α) is continuous in α. This is used in the proof of the fol-
lowing result, which is deferred to Appendix A.
Theorem 2.5. Under the assumptions of Lemma 2.3, Rα
(
f˜α
)
, is continuous in α.
Finally, we state two corollaries pertaining to the sensitivity and specificity of the estimated
decision rule. These results show that the ROC curve of the estimated decision function con-
verges uniformly to the ROC curve of the optimal decision function in F . The proof of Corol-
lary 2.2 relies on a novel empirical process result which is included in Appendix A.
Corollary 2.1. Let f̂α be estimated using a linear, quadratic, polynomial, or Gaussian kernel
function. Let se
(
f̂α
)
= Pr
{
f̂α(X) > 0|A = 1
}
be the sensitivity let the specificity be sp
(
f̂α
)
=
Pr
{
f̂α(X) < 0|A = −1
}
of the decision rule d̂α = sign
(
f̂α
)
. Then, there exist s˜eα and s˜pα so
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that αρs˜eα+(1−α)(1−ρ)s˜pα = αρse
(
f˜α
)
+(1−α)(1−ρ)sp
(
f˜α
)
and supα∈[0,1]
∣∣∣se(f̂α)− s˜eα∣∣∣ P−→
0 and supα∈[0,1]
∣∣∣sp(f̂α)− s˜pα∣∣∣ P−→ 0 as n→∞.
Note that Corollary 2.1 does not require f˜α to be unique. We can only say that the sensitivity
and specificity of f̂α converge to the sensitivity and specificity of a function in the same equiva-
lence class as f˜α, i.e., a function with optimal risk.
Corollary 2.2. Define ŝe
(
f̂α
)
and ŝp
(
f̂α
)
as in Section 2.2 and s˜eα and s˜pα as in Corollary 2.1.
Then, supα∈[0,1]
∣∣∣ŝe(f̂α)− s˜eα∣∣∣ P−→ 0, and supα∈[0,1] ∣∣∣ŝp(f̂α)− s˜pα∣∣∣ P−→ 0 as n→∞.
2.4 Simulation Experiments
To investigate the performance of classification using a weighted SVM and the resulting
ROC curves and confidence bands, we use the following generative model. Let X be generated
according to X ∼ Np(µZ, σ2I), where Z is equal to a vector of ones with probability q and a
vector of negative ones with probability 1 − q and I is a p × p identity matrix. Thus, X is a mix-
ture of multivariate normal distributions with mixing probability q. Let π(X) = expit (X⊺β)
for a p by 1 vector β. Given X, we let A be equal to 1 with probability π(X) and −1 with prob-
ability 1 − π(X). Because π(X) depends on X only through a linear function of X, we refer to
this model below as the linear generative model. We also consider a generalization of the above
model where π(X) = expit (X⊺β +X21 +X22 + 4X1X2), which we refer to below as the nonlin-
ear generative model.
We implement the weighted SVM in MATLAB software using the LIBSVM library of Chang
and Lin (2011). We use both linear and Gaussian kernels. The Gaussian kernel function is k(x,y) =
exp(−γ‖x − y‖2) (Steinwart and Christmann, 2008). The bandwidth parameter, γ, and the
penalty parameter, λn, are estimated using cross-validation when α = 0.5 and the resulting tuning
parameters are used to fit the weighted SVM for all α on a grid over (0, 1). Comparison meth-
ods are implemented in R software (R Core Team, 2016). Each simulated data set is divided into
training and testing sets with 70% of the data used for training.
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We compare the performance of the weighted SVM to standard methods in diagnostic medicine,
including logistic regression (McIntosh and Pepe, 2002) and semiparametric ROC curves (Cai
and Moskowitz, 2004). Logistic regression and the SVM combine multiple biomarkers while the
semiparametric ROC curve is calculated for a single biomarker (the first component of X). These
four methods are applied to simulated data from the linear and nonlinear generative models with
n = 250, 500, p = 2, 5, 10, q = 0.05, 0.25, σ = 0.75, and µ = 0.25. When p = 2, 5, we use β =
(2, 1)⊺ and β = (2, 1, . . . , 1)⊺, respectively. When p = 10, we use β = (2, 1, 1, 1, 1, 0, . . . , 0)⊺,
i.e., noise variables are introduced for the case where p = 10. We report the mean area under the
ROC curve (AUC) and the Monte Carlo standard deviation of AUC as well as optimal sensitivity
and specificity across 100 replications. Optimal sensitivity and specificity are calculated as the
point on the ROC curve closest to (0, 1) in Euclidean distance (see Lo´pez-Rato´n et al., 2014, for a
discussion of different methods for selecting the optimal point on the ROC curve).
Table 2.1 below contains estimated AUC’s averaged across replications and Monte Carlo
standard deviations of AUC’s for the four methods when the true generative model is nonlinear.
The Gaussian SVM outperforms the other methods except in the case where there are noise vari-
n p q Linear SVM Gaussian SVM Logistic Semiparametric
250 2 0.05 0.61 (0.07) 0.78 (0.06) 0.58 (0.08) 0.58 (0.04)
0.25 0.64 (0.07) 0.81 (0.05) 0.62 (0.06) 0.62 (0.03)
5 0.05 0.71 (0.06) 0.75 (0.06) 0.71 (0.07) 0.56 (0.03)
0.25 0.74 (0.05) 0.77 (0.06) 0.74 (0.06) 0.62 (0.03)
10 0.05 0.70 (0.06) 0.56 (0.05) 0.70 (0.06) 0.57 (0.04)
0.25 0.74 (0.06) 0.56 (0.05) 0.74 (0.06) 0.62 (0.04)
500 2 0.05 0.61 (0.05) 0.81 (0.04) 0.59 (0.05) 0.58 (0.02)
0.25 0.65 (0.04) 0.81 (0.04) 0.61 (0.05) 0.61 (0.02)
5 0.05 0.72 (0.04) 0.78 (0.04) 0.72 (0.05) 0.57 (0.02)
0.25 0.77 (0.04) 0.80 (0.04) 0.75 (0.03) 0.62 (0.02)
10 0.05 0.71 (0.04) 0.60 (0.05) 0.71 (0.04) 0.56 (0.03)
0.25 0.75 (0.04) 0.60 (0.04) 0.74 (0.04) 0.62 (0.02)
Table 2.1: Average AUC across simulations when true model is nonlinear.
ables. The linear SVM slightly outperforms logistic regression in most cases. Table A.1 in Ap-
pendix A contains optimal sensitivities and specificities for the four methods when the true gen-
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erative model is nonlinear, averaged across replications. Table A.2 in Appendix A contains esti-
mated sensitivities and specificities of an unweighted SVM when the true model is nonlinear. The
unweighted SVM often fails to achieve a balance between sensitivity and specificity. In particular,
the linear SVM often achieves low specificity. The imbalance between sensitivity and specificity
is often worse when q is small, indicating that proper balance is difficult to achieve when there
is an imbalance between true class labels in the data. These results highlight the importance of
estimating the full ROC curve and selecting the weight to achieve the desired balance between
sensitivity and specificity; unweighted classification may not achieve satisfactory performance in
many settings. Tables A.3, A.4, and A.5 in Appendix A contain results when the true generative
model is linear.
Next, we examine the performance of the bootstrap confidence band method for the linear
SVM. Independent testing sets of size 100,000 were used to calculate se
(
f̂α
)
and sp
(
f̂α
)
, giv-
ing us an approximation to the true ROC curve for each f̂α. The method introduced in Section 2.2.2
was used to construct 90% confidence bands using 1000 bootstrap samples. We report the propor-
tion of 100 Monte Carlo replications for which the true ROC curve is fully contained within the
confidence band across [0.01, 0.99] along with the average area between the upper and lower con-
fidence bands. Table 2.2 contains these results. We observe that, across n, p, and q, the proposed
Coverage probability Area between curves
n p q Linear model Nonlinear model Linear model Nonlinear model
250 2 0.05 0.92 0.89 0.31 0.36
0.25 0.93 0.89 0.29 0.37
5 0.05 0.91 0.93 0.27 0.38
0.25 0.83 0.97 0.25 0.37
10 0.05 0.88 0.93 0.29 0.39
0.25 0.64 0.90 0.26 0.37
500 2 0.05 0.97 0.94 0.24 0.27
0.25 0.97 0.91 0.22 0.27
5 0.05 0.95 0.97 0.20 0.29
0.25 0.94 0.94 0.18 0.26
10 0.05 0.94 0.93 0.22 0.29
0.25 0.87 0.97 0.19 0.27
Table 2.2: Average coverage probabilities and area between confidence bands in simulation.
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quantile bootstrap method provides approximately 90% coverage with the area between curves
decreasing for larger sample sizes.
Figure 2.1 below contains bootstrap confidence bands for one simulated replication for the
linear and nonlinear generative model when n = 500, p = 2, and q = 0.25. The true ROC
curve, calculated from a large testing set of size 100,000, is also plotted. These figures demon-
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Figure 2.1: Example ROC curves and confidence bands when true model is linear (left) and
nonlinear (right) in one simulated replication.
strate that the proposed quantile bootstrap produces confidence bands that capture the true ROC
curve and are sufficiently narrow as to provide useful inference about the future performance of
an estimated SVM classifier.
2.5 Applications to Data
2.5.1 Breast Cancer Genomics
We apply the weighted SVM to the problem of predicting treatment response among pa-
tients with breast cancer. The full data consist of 587 patients. For each patient, we observe 512
gene signatures, called modules, each of which is a function of patient genetic data which can
be used to predict response to neoadjuvant chemotherapy. We also observe a variety of clinical
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variables. Figure 2.2 contains ROC curves for predicting response to treatment using the linear
and Gaussian SVM, logistic regression with LASSO penalty (Tibshirani, 1996), and random
forests (Breiman, 2001). Confidence bands for the linear SVM are also plotted. Each method
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Figure 2.2: ROC curves for predicting response to breast cancer treatment using several methods.
performs equally well, with each ROC curve falling within the confidence bands for the linear
SVM. Table 2.3 contains AUC and optimal sensitivity and specificity for each method along with
the sensitivity and specificity of the unweighted versions of each method. On these data, the lin-
Method AUC ŝe (optimal) ŝp (optimal) ŝe (unweighted) ŝp (unweighted)
Gaussian SVM 0.74 0.67 0.72 0.10 1.00
Linear SVM 0.79 0.90 0.63 0.19 0.97
Random forest 0.74 0.82 0.65 0.05 0.99
Logistic LASSO 0.75 0.73 0.72 0.00 1.00
Table 2.3: AUC, sensitivity, and specificity of several methods applied to breast cancer data.
ear SVM achieves the best AUC. Each method achieves a better balance between sensitivity and
specificity after proper weighting. Unweighted classification results in close to perfect specificity
at the expense of very low sensitivity for each method. This is likely due to the imbalance in the
data (only 22% of patients in the sample respond).
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2.5.2 Diagnosis of Infant Hepatitis C
Finally, we apply the proposed methods to data from the cohort study of mother-to-infant
hepatitis C transmission of Shebl et al. (2009). In this study, 1863 mother-infant pairs in three
Egyptian villages were studied to assess risk factors for vertical transmission of hepatitis C virus
(HCV). Of this sample, 33 infants were positive for both HCV RNA and HCV antibodies at the
end of the study. We use data from infant follow-up visits at 2-4 months and 10-12 months. At
each follow-up visit, infants were tested for HCV RNA using a polymerase chain reaction (PCR)
test and HCV antibodies using an enzyme-linked immunosorbent assay (ELISA) test. Mothers
in the study were also tested for HCV RNA and antibodies during pregnancy. In pediatric infec-
tious diseases, it is of interest to diagnose infected infants as early in life as possible so that they
can benefit from early treatment with antivirals as they become approved for children— that is,
we seek a highly sensitive test. We use a weighted SVM to estimated a classifier based on the
mother’s test results during pregnancy and infant’s test results at 2-4 months. While a PCR test at
2-4 months detects HCV viremia, it cannot predict which children subsequently become chroni-
cally infected, and a PCR test at 10-12 months remains the gold standard.
In this study, the PCR test achieved a sensitivity of 0.4167 and a specificity of 0.9911. The
ELISA test achieved a sensitivity of 0.5833 and a specificity of 0.9571. Due to a variety of fac-
tors, diagnosis during the early months of life is difficult. Both PCR and ELISA suffer from low
sensitivity at 2-4 months for detecting which infants will become chronically infected later. It is
of interest to see if diagnosis via a weighted SVM can provide even a modest improvement in per-
formance, particularly an increase in sensitivity, thereby reducing the need for a repeat test after
10-12 months of age.
We apply the weighted SVM and evaluate performance using 5-fold cross validation. Aver-
aging the estimated sensitivity and specificity for each value of α over the 5 folds yields the ROC
curve found in Figure 2.3, plotted with bootstrap confidence bands. We plot the sensitivity and
specificity of the individual PCR and ELISA tests as points in the figure. The closest point on
the ROC curve to (0, 1) yields an estimated sensitivity of 0.6011 and an estimated specificity of
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Figure 2.3: ROC curve and confidence bands for the linear SVM applied to diagnosing HCV.
0.8000, which provides increased sensitivity and a better balance between sensitivity and speci-
ficity when compared to the usual diagnostic tests. Classification is difficult due to the imbalance
of infections and non-infections in the data, but a weighted SVM provides increased performance
compared to either diagnostic test available.
2.6 Conclusion
A wide variety of problems in biomedical decision making can be expressed as classifica-
tion problems, such as diagnosing disease and predicting response to treatment. In some clinical
applications, false positives may have very different consequences from false negatives; classi-
fication methods which can properly weight sensitivity and specificity and estimate the optimal
ROC curve are needed, along with inference methods for the ROC curve. Estimating the optimal
ROC curve using a weighted SVM has been considered by Veropoulos et al. (1999). We have es-
tablished the theoretical justification for estimating the ROC curve with a weighted SVM, demon-
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strated its performance in simulation studies, and provided a bootstrap confidence band method
for the SVM ROC curve.
The applications of the weighted SVM in diagnostic medicine are numerous. We have demon-
strated, for example, that this method can be used to improve early infant diagnosis of hepatitis C.
Early detection of childhood infectious diseases is an important public health problem; reliable
early diagnosis identifies children who could transmit the virus and would benefit from treatment
with antivirals. We have also demonstrated that the weighted SVM accommodates high dimen-
sional data and can be used to predict response to neoadjuvant breast cancer treatment using ge-
nomic information.
Because machine learning techniques are well suited to binary classification, there is great
potential for research in applying machine learning to diagnostic medicine and other biomedi-
cal decision making problems. Developing methods of variable selection for the weighted SVM
(Dasgupta et al., 2015) is an important step forward for this research as our simulations indicate
that the performance of the Gaussian SVM is hindered by noise variables. Other areas of future
work may include developing methods to accommodate biomarker measurements that are taken
at different time points from the same patient.
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CHAPTER 3: ESTIMATING DYNAMIC TREATMENT REGIMES IN MOBILE HEALTH
USING V-LEARNING
3.1 Introduction
The use of mobile devices in clinical care, called mobile health (mHealth), provides an effec-
tive and scalable platform to assist patients in managing their illness (Free et al., 2013; Steinhubl
et al., 2013). Advantages of mHealth interventions include real-time communication between
a patient and their health-care provider as well as systems for delivering training, teaching, and
social support (Kumar et al., 2013). Mobile technologies can also be used to collect rich longitu-
dinal data to estimate optimal dynamic treatment regimes and to deliver treatment that is deeply
tailored to each individual patient. We propose a new estimator of an optimal treatment regime
that is suitable for use with with longitudinal data collected in mHealth applications.
A dynamic treatment regime provides a framework to administer individualized treatment
over time through a series of decision rules. Dynamic treatment regimes have been well-studied
in the statistical and biomedical literature (Murphy, 2003; Robins, 2004; Moodie et al., 2007;
Kosorok and Moodie, 2015; Chakraborty and Moodie, 2013) and furthermore, statistical con-
siderations in mHealth have been studied by, for example, Liao et al. (2015) and Klasnja et al.
(2015). Although mobile technology has been successfully utilized in clinical areas such as dia-
betes (Quinn et al., 2011; Maahs et al., 2012), smoking cessation (Ali et al., 2012), and obesity
(Bexelius et al., 2010), mHealth poses some unique challenges that preclude direct application
of existing methodologies for dynamic treatment regimes. For example, mHealth applications
typically involve a large number of time points per individual and no definite time horizon; the
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momentary signal may be weak and may not directly measure the outcome of interest; and esti-
mation of optimal treatment strategies must be done online as data accumulate.
This work is motivated in part by our involvement in a study of mHealth as a management
tool for type 1 diabetes. Type 1 diabetes is an autoimmune disease wherein the pancreas pro-
duces insufficient levels of insulin, a hormone needed to regulate blood glucose concentration.
Patients with type 1 diabetes are continually engaged in management activities including monitor-
ing glucose levels, timing and dosing insulin injections, and regulating diet and physical activity.
Increased glucose monitoring and attention to self-management facilitate more frequent treatment
adjustments and have been shown to improve patient outcomes (Levine et al., 2001; Haller et al.,
2004; Ziegler et al., 2011). Thus, patient outcomes have the potential to be improved by diabetes
management tools which are deeply tailored to the continually evolving health status of each pa-
tient. Mobile technologies can be used to collect data on physical activity, glucose, and insulin
at a fine granularity in an outpatient setting (Maahs et al., 2012). There is great potential for us-
ing these data to create comprehensive and accessible mHealth interventions for clinical use. We
envision application of this work for use before the artificial pancreas (Weinzimer et al., 2008;
Kowalski, 2015; Bergenstal et al., 2016) becomes widely available.
The sequential decision making process can be modeled as a Markov decision process (Put-
erman, 2014) and the optimal treatment regime can be estimated using reinforcement learning al-
gorithms such as Q-learning (Murphy, 2005; Zhao et al., 2009; Tang and Kosorok, 2012; Schulte
et al., 2014). Ertefaie (2014) proposed a variant of greedy gradient Q-learning (GGQ) to estimate
optimal dynamic treatment regimes in infinite horizon settings (see also Maei et al., 2010). In
GGQ, the form of the estimated Q-function dictates the form of the estimated optimal treatment
regime. Thus, one must choose between a parsimonious model for the Q-function at the risk of
model misspecification or a complex Q-function that yields unintelligible treatment regimes. Fur-
thermore, GGQ requires modeling a nonsmooth function of the data, which creates complications
(Laber et al., 2014a; Linn et al., 2017). We propose an alternative estimation method for infinite
horizon dynamic treatment regimes that is suited to mHealth applications. Our approach, which
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we call V-learning, involves estimating the optimal policy among a prespecified class of policies
(Zhang et al., 2012b, 2013). It requires minimal assumptions about the data-generating process
and permits estimating a randomized decision rule that can be implemented online as data accu-
mulate.
In Section 3.2, we describe the setup and present our method for offline estimation using data
from a micro-randomized trial or observational study. In Section 3.3, we extend our method for
application to online estimation with accumulating data. Theoretical results, including consis-
tency and asymptotic normality of the proposed estimators, are presented in Section 3.4. We com-
pare the proposed method to GGQ using simulated data in Section 3.5. A case study using data
from patients with type 1 diabetes is presented in Section 3.6 and we conclude with a discussion
in Section 3.7. Proofs of technical results are in Appendix B.
3.2 Offline Estimation From Observational Data
We assume that the available data are
{(
S1i , A
1
i ,S
2
i , . . . ,S
Ti
i , A
Ti
i ,S
Ti+1
i
)}n
i=1
, which com-
prise independent, identically distributed trajectories (S1, A1,S2, . . . ,ST , AT ,ST+1), where:
St ∈ Rp denotes a summary of patient information collected up to and including time t; At ∈ A
denotes the treatment assigned at time t; and T ∈ Z+ denotes the (possibly random) patient
follow-up time. In the motivating example of type 1 diabetes, St could contain a patient’s blood
glucose, dietary intake, and physical activity in the hour leading up to time t and At could de-
note an indicator that an insulin injection is taken at time t. We assume that the data-generating
model is a time-homogeneous Markov process so that St+1 ⊥ (At−1,St−1, . . . , A1,S1)∣∣(At,St)
and the conditional density p(st+1|at, st) is the same for all t ≥ 1. Let Lt ∈ {0, 1} denote
an indicator that the patient is still in follow-up at time t, i.e., Lt = 1 if the patient is being
followed at time t and zero otherwise. We assume that Lt is contained in St so that P (Lt+1 =
1|At,St, . . . , A1,S1) = P (Lt+1 = 1|At,St) and Lt = 0 implies Lt+1 = 0 with probabil-
ity one. Furthermore, we assume a known utility function u : Rp × A × Rp → R so that
U t = u(St+1, At,St) measures the ‘goodness’ of choosing treatment At in state St and sub-
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sequently transitioning to state St+1. In our motivating example, the utility at time t could be a
measure of how far the patient’s average blood glucose concentration deviates from the optimal
range over the hour preceding and following time t. The goal is to select treatments to maximize
expected cumulative utility; treatment selection is formalized using a treatment regime (Schulte
et al., 2014; Kosorok and Moodie, 2015) and the utility associated with any regime is defined us-
ing potential outcomes (Rubin, 1978).
Let B(A) denote the space of probability distributions over A. A treatment regime in this
context is a function π : domSt → B(A) so that, under π, a decision maker presented with state
St = st at time t will select action at ∈ A with probability π(at; st). Define at = (a1, . . . , at) ∈
At, and a∞ = (a1, a2, . . .) ∈ A∞. The set of potential outcomes is
W∗ =
{
S1,S∗2(a1), . . . ,S∗T
∗(a∞)(aT
∗(a∞)−1) :
T ∗(a∞) = inf
{
t ≥ 1 : L∗t(at−1) = 0} , a∞ ∈ A∞},
where S∗t(at−1) is the potential state and L∗t(at−1) is the potential follow-up status at time t un-
der treatment sequence at−1. Thus, the potential utility at time t is
U∗t(at) = u
{
S∗(t+1)(at), at,S∗t(at−1)
}
.
For any π, define {ξtπ(·)}t≥1 to be a sequence of independent, A-valued stochastic processes in-
dexed by domSt such that P {ξtπ(st) = at} = π(at; st). The potential follow-up time under π
is
T ∗(π) =
∑
t≥1
∑
at∈At
t1
{
supat+1T
∗(at, at+1) = t
} t∏
v=1
1
[
ξvπ
{
S∗v(av−1)
}
= av
]
,
where at+1 = (at+1, at+2, . . .). The potential utility under π at time t is
U∗t(π) =

∑
at∈At U
∗t (at)
∏t
v=1 1 [ξ
v
π {S∗v(av−1)} = av] , if T ∗(π) ≥ t
0, otherwise,
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where S∗1(a0) = S1. Thus, utility is set to zero after a patient is lost to follow-up. However, in
certain situations, utility may be constructed so as to take a negative value at the time point when
the patient is lost to follow-up, e.g., if the patient discontinues treatment because of a negative
effect associated with the intervention. Define the state-value function
V (π, st) = E
{∑
k≥0
γkU∗(t+k)(π)
∣∣St = st}
(Sutton and Barto, 1998), where γ ∈ (0, 1) is a fixed constant that captures the trade-off between
short- and long-term outcomes. For any distribution R on domS1, define the value function with
respect to reference distribution R as VR(π) =
∫
V (π, s)dR(s); throughout, we assume that this
reference distribution is fixed. The reference distribution can be thought of as a distribution of
initial states and we estimate it from the data in the implementation in Sections 3.5 and 3.6. For a
prespecified class of regimes, Π, the optimal regime, πoptR ∈ Π, satisfies VR(πoptR ) ≥ VR(π) for all
π ∈ Π.
To construct an estimator of πoptR , we make a series of assumptions that connect the potential
outcomes in W∗ with the data-generating model.
Assumption 3.1. Strong ignorability, At ⊥ W∗∣∣St for all t.
Assumption 3.2. Consistency, St = S∗t(At−1) for all t and T = T ∗(A∞).
Assumption 3.3. Positivity, there exists c0 > 0 so that P (At = at|St = st) ≥ c0 for all at ∈ A,
st ∈ domSt, and all t.
In addition, we implicitly assume that there is no interference among the experimental units.
These assumptions are common in the context of estimating dynamic treatment regimes (Robins,
2004; Schulte et al., 2014). Assumptions 3.1 and 3.3 hold by construction in a micro-randomized
trial (Klasnja et al., 2015; Liao et al., 2015).
Let µt(at; st) = P (At = at|St = st) for each t ≥ 1. In a micro-randomized trial, µt(at; st)
is a known randomization probability; in an observational study, it must be estimated from the
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data. The following lemma characterizes VR(π) for any regime, π, in terms of the data-generating
model (see also Lemma 4.1 of Murphy et al., 2001). A proof is provided in Appendix B.
Lemma 3.1. Let π denote an arbitrary regime and γ ∈ (0, 1) a discount factor. Then, under
assumptions 3.1-3.3 and provided interchange of the sum and integration is justified, the state-
value function of π at st is
V (π, st) =
∑
k≥0
E
[
γkU t+k
{
k∏
v=0
π(Av+t;Sv+t)
µv+t(Av+t;Sv+t)
}∣∣∣∣St = st
]
. (3.1)
The preceding result will form the basis for an estimating equation for VR(π). Write the right
hand side of (3.1) as
V (π,St) = E
{
π(At;St)
µt(At;St)
(
U t + γ
∑
k≥0
E
[
γkU t+k+1
{
k∏
v=0
π(Av+t+1;Sv+t+1)
µv+t+1(Av+t+1;Sv+t+1)
}
∣∣∣∣St+1
])∣∣∣∣St
}
= E
[
π(At;St)
µt(At;St)
{
U t + γV (π,St+1)
} ∣∣∣∣St] ,
from which it follows that
0 = E
[
π(At;St)
µt(At;St)
{
U t + γV (π,St+1)− V (π,St)} ∣∣∣∣St] .
Subsequently, for any function ψ defined on domSt, the state-value function satisfies
0 = E
[
π(At;St)
µt(At;St)
{
U t + γV (π,St+1)− V (π,St)}ψ(St)] , (3.2)
which is an importance-weighted variant of the well-known Bellman optimality equation (Sutton
and Barto, 1998).
Let V (π, s; θπ) denote a model for V (π, s) indexed by θπ ∈ Θ ⊆ Rq. We assume that the
map θπ 7→ V (π, s; θπ) is differentiable everywhere for each fixed s and π. Let ∇θπV (π, s; θπ)
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denote the gradient of V (π, s; θπ) and define
Λn(π, θ
π) =
1
n
n∑
i=1
Ti∑
t=1
π(Ati;S
t
i)
µt(Ati;S
t
i)
{
U ti + γV (π,S
t+1
i ; θ
π)− V (π,Sti; θπ)
}
×∇θπV (π,Sti; θπ). (3.3)
Given a positive definite matrix Ω ∈ Rq×q and penalty function P : Rq → R+, define θ̂πn =
argminθπ∈Θ {Λn(π, θπ)⊺ΩΛn(π, θπ) + λnP(θπ)}, where λn is a tuning parameter. Subsequently,
V
(
π, s; θ̂πn
)
is the estimated state-value function under π in state s. Thus, given a reference dis-
tribution, R, the estimated value of a regime, π, is V̂n,R(π) =
∫
V
(
π, s; θ̂πn
)
dR(s) and the esti-
mated optimal regime is π̂n = argmaxπ∈Π V̂n,R(π). The idea of V-learning is to use estimating
equation (3.3) to estimate the value of any policy and maximize estimated value over a class of
policies; we will discuss strategies for this maximization in Section 3.5.
V-learning requires a parametric class of policies. Assuming that there are K possible treat-
ments, a1, . . . , aK , we can define a parametric class of policies as follows. Define
π(aj; s, β) = exp(s
⊺βj)/
{
1 +
K−1∑
k=1
exp(s⊺βk)
}
for j = 1, . . . , K − 1, and
π(aK ; s) = 1/
{
1 +
K−1∑
k=1
exp(s⊺βk)
}
.
This defines a class of randomized policies parametrized by β = (β⊺1 , . . . , β
⊺
K−1)
⊺
, where βk is
a vector of parameters for the k-th treatment. Under a policy in this class defined by β, actions
are selected stochastically according to the probabilities π(aj; s, β), j = 1, . . . , K. In the case
of a binary treatment, a policy in this class reduces to π(1; s, β) = exp(s⊺β)/ {1 + exp(s⊺β)}
and π(0; s, β) = 1/ {1 + exp(s⊺β)} for a p × 1 vector β. This class of policies is used in the
implementation in Sections 3.5 and 3.6.
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V-learning also requires a class of models for the state value function indexed by a parameter,
θπ. We use a basis function approximation. Let Φ = (φ1, . . . , φq)⊺ be a vector of prespecified
basis functions and let Φ(sti) = {φ1(sti), . . . , φq(sti)}⊺. Let V (π, sti; θπ) = Φ(sti)⊺θπ. Under this
working model,
Λn(π, θ
π) =
[
n−1
n∑
i=1
Ti∑
t=1
π(Ati;S
t
i)
µt(Ati;S
t
i)
{
γΦ(Sti)Φ(S
t+1
i )
⊺ − Φ(Sti)Φ(Sti)⊺
}]
θπ
+n−1
n∑
i=1
Ti∑
t=1
{
π(Ati;S
t
i)
µt(Ati;S
t
i)
U tiΦ(S
t
i)
}
.
Computational efficiency is gained from the linearity of V (π, sti; θπ) in θπ; flexibility can be
achieved through the choice of Φ. We examine the performance of V-learning using a variety of
basis functions in Sections 3.5 and 3.6.
3.3 Online Estimation From Accumulating Data
Suppose we have accumulating data {(S1i , A1i ,S2i , . . .)}ni=1, where Sti and Ati represent the
state and action for patient i = 1, . . . , n at time t ≥ 1. At each time t, we estimate an optimal pol-
icy in a class, Π, using data collected up to time t, take actions according to the estimated optimal
policy, and estimate a new policy using the resulting states. Let π̂tn be the estimated policy at time
t, i.e., π̂tn is estimated after observing state St+1 and before taking action At+1. If Π is a class of
randomized policies, we can select an action for a patient presenting with St+1 = st+1 according
to π̂tn(·; st+1), i.e., we draw At+1 according to the distribution P (At+1 = a) = π̂tn(a; st+1). If a
class of deterministic policies is of interest, we can inject some randomness into π̂tn to facilitate
exploration. One way to do this is an ǫ-greedy strategy (Sutton and Barto, 1998), which selects
the estimated optimal action with probability 1 − ǫ and otherwise samples equally from all other
actions. Because an ǫ-greedy strategy can be used to introduce randomness into a deterministic
policy, we can assume a class of randomized policies.
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At each time t ≥ 1, let θ̂πn,t = argminθπ∈Θ {Λn,t(π, θπ)⊺ΩΛn,t(π, θπ) + λnP(θπ)}, where Ω,
λn, and P are as defined in Section 3.2 and
Λn,t(π, θ
π) =
1
n
n∑
i=1
t∑
v=1
π(Avi ;S
v
i )
π̂v−1n (A
v
i ;S
v
i )
{
U vi + γV (π,S
v+1
i ; θ
π)− V (π,Svi ; θπ)
}
×∇θπV (π,Svi ; θπ) (3.4)
with π̂0n some initial randomized policy. We note that estimating equation (3.4) is similar to (3.3),
except that π̂v−1n replaces µv as the data-generating policy. Given the estimator of the value of
π at time t, V̂n,R,t(π) =
∫
V
(
π, s; θ̂πn,t
)
dR(s), the estimated optimal policy at time t is π̂tn =
argmaxπ∈ΠV̂n,R,t(π). In practice, we may choose to update the policy in batches rather than
at every time point. An alternative way to encourage exploration through the action space is to
choose π̂tn = argmaxπ∈Π
{
V̂n,R,t(π) + α
tψ̂t(π)
}
for some sequence αt ≥ 0, where ψ̂t(π) is a
measure of uncertainty in V̂n,R,t(π). An example of this is upper confidence bound sampling, or
UCB (Lai and Robbins, 1985).
It some settings, when the data-generating process may vary across patients, it may be de-
sirable to allow each patient to follow an individualized policy that is estimated using only that
patient’s data. Suppose that n patients are followed for an initial T1 time points after which the
policy π̂1n is estimated. Then, suppose that patient i follows π̂1n until time T2, when a policy π̂2i is
estimated using only the states and actions observed for patient i. This procedure is then carried
out until time TK for some fixed K with each patient following their own individual policy which
is adapted to match the individual over time. We may also choose to adapt the randomness of the
policy at each estimation. For example, we could select ǫ1 > ǫ2 > . . . > ǫK and, following esti-
mation k, have patient i follow policy π̂ki with probability 1− ǫk and policy π̂1n with probability ǫk.
In this way, patients become more likely to follow their own individualized policy and less likely
to follow the initial policy over time, reflecting increasing confidence in the individualized policy
as more data become available. The same class of policies and model for the state value function
can be used as in Section 3.2.
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3.4 Theoretical Results
In this section, we establish asymptotic properties of θ̂πn and π̂n for offline estimation. Through-
out, we assume assumptions 3.1-3.3 from Section 3.2.
Let θ̂πn = argminθπ∈Θ {Λn(π, θπ)⊺Λn(π, θπ) + λn(θπ)⊺θπ}. Thus, we use the squared Eu-
clidean norm of θ as the penalty function; we will assume that λn = oP (n−1/2). For simplic-
ity, we let Ω be the identity matrix. Assume the working model for the state value function in-
troduced in Section 3.2, i.e., V (π, sti; θπ) = Φ(sti)⊺θπ. For fixed π, denote the true θπ by θπ0 ,
i.e., V (π, s) = Φ(s)⊺θπ0 . Let ν =
∫
Φ(s)dR(s) so that VR(π) = ν⊺θπ0 . Define V̂n,R̂(π) =
{EnΦ(S)}⊺ θ̂πn, where En denotes the empirical measure. Let Π = {πβ : β ∈ B} be a parametric
class of policies and let π̂n = πβ̂n where β̂n = argmaxβ∈B V̂n,R̂(πβ).
Our main results are summarized in Theorems 3.1 and 3.2 below. Because each patient tra-
jectory is a stationary Markov chain, we need to use asymptotic theory based on stationary pro-
cesses; consequently, some of the required technical conditions are more difficult to verify than
those for i.i.d. data. Define the bracketing integral for a class of functions, F , by J[] {δ,F , Lr(P )} =∫ δ
0
√
logN[] {ǫ,F , Lr(P )}dǫ, where the bracketing number for F , N[] {ǫ,F , Lr(P )}, is the num-
ber of Lr(P ) ǫ-brackets needed such that each element of F is contained in at least one bracket
(see Chapter 2 of Kosorok, 2008). For any stationary sequence of possibly dependent random
variables, {X t}t≥1, let Mcb be the σ-field generated by Xb, . . . , Xc and define
ζ(k) = E
[
sup
m≥1
{|P (B|Mm1 )− P (B)| : B ∈M∞m+k}] .
We say that the chain {X t}t≥1 is absolutely regular if ζ(k) → 0 as k → 0 (also called β-mixing
in Chapter 11 of Kosorok, 2008). We make the following assumptions.
Assumption 3.4. There exists a 2 < ρ <∞ such that
1. E|U t|3ρ <∞, E‖Φ(St)‖3ρ <∞, and E‖St‖3ρ <∞.
2. The sequence {(St, At)}t≥1 is absolutely regular with
∑∞
k=1 k
2/(ρ−2)ζ(k) <∞.
33
3. The bracketing integral of the class of policies, J[] {∞,Π, L3ρ(P )} <∞.
Assumption 3.5. There exists some c1 > 0 such that
inf
π∈Π
c⊺E
[
π(At;St)
µt(At;St)
{
Φ(St)Φ(St)⊺ − γ2Φ(St+1)Φ(St+1)⊺}] c ≥ c1‖c‖2
for all c ∈ Rq.
Assumption 3.6. The map β 7→ VR(πβ) has a unique and well separated maximum over β in the
interior of B; let β0 denote the maximizer.
Assumption 3.7. The following holds: sup‖β1−β2‖≤δ E‖πβ1(A;S)− πβ2(A;S)‖ → 0 as δ ↓ 0.
Remark 3.1. Assumption 3.4 requires certain finite moments and that the dependence between
observations on the same patient vanishes as observations become further apart. In Lemma B.2
in Appendix B, we verify part 3 of assumption 3.4 and assumption 3.7 for the class of policies
introduced in Section 3.2. However, note that the theory holds for any class of policies satisfy-
ing the given assumptions, not just the class considered here. Assumption 3.5 is needed to show
the existence of a unique θπ0 uniformly over Π and assumption 3.6 requires that the true optimal
decision in each state is unique (see assumption A.8 of Ertefaie, 2014). Assumption 3.7 requires
smoothness on the class of policies.
The main results of this section are stated below. Theorem 3.1 states that there exists a unique
solution to 0 = EΛn(π, θπ) uniformly over Π and that the estimator θ̂n converges weakly to a
mean zero Gaussian process in ℓ∞(Π).
Theorem 3.1. Under the given assumptions, the following hold.
1. For all π ∈ Π, there exists a θπ0 ∈ Rq such that EΛn(π, θπ) has a zero at θπ = θπ0 . Moreover,
supπ∈Π ‖θπ0‖ <∞ and sup‖β1−β2‖≤δ
∥∥θπβ10 − θπβ20 ∥∥→ 0 as δ ↓ 0.
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2. Let G(π) be a tight, mean zero Gaussian process with covariance E {G(π1)G(π2)} =
w1(π1)
−1w0(π1, π2)w1(π2)
−⊺
, indexed by Π, where
w0(π1, π2) = E
[
π1(A
t;St)π2(A
t;St)
µt(At;St)2
{
U t + γΦ(St+1)θπ10 − Φ(St)θπ10
}
×{U t + γΦ(St+1)θπ20 − Φ(St)θπ20 }Φ(St)Φ(St)⊺]
and
w1(π) = E
[
π(At;St)
µt(At;St)
Φ(St)
{
Φ(St)− γΦ(St+1)}⊺] .
Then,
√
n
(
θ̂πn − θπ0
)
 G(π) in ℓ∞(Π).
3. Let G(π) be as defined in part 2. Then,
√
n
{
V̂n,R̂(π)− VR(π)
}
 ν⊺G(π) in ℓ∞(Π).
Theorem 3.2 below gives us that the estimated optimal policy converges in probability to the
true optimal policy over Π and that the estimated value of the estimated optimal policy converges
to the true value of the estimated optimal policy.
Theorem 3.2. Under the given assumptions, the following hold.
1. Let β̂n = argmaxβ∈BV̂n,R̂(πβ) and β0 = argmaxβ∈BVR(πβ). Then,
∥∥∥β̂n − β0∥∥∥ P−→ 0.
2. Let σ20 = ν⊺w1(πβ0)−1w0(πβ0 , πβ0)w1(πβ0)−⊺ν. Then,
√
n
{
V̂n,R̂
(
πβ̂n
)
− VR
(
πβ̂n
)}
 N(0, σ20).
3. A consistent estimator for σ20 is
σ̂2n =
{
EnΦ(S
t)
}
⊺
ŵ1
(
πβ̂n
)−1
ŵ0
(
πβ̂n , πβ̂n
)
ŵ1
(
πβ̂n
)−⊺ {
EnΦ(S
t)
}
,
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where
ŵ0(π1, π2) = En
[
π1(A
t;St)π2(A
t;St)
µt(At;St)2
{
U t + γΦ(St+1)θ̂π1n − Φ(St)θ̂π1n
}
×
{
U t + γΦ(St+1)θ̂π2n − Φ(St)θ̂π2n
}
Φ(St)Φ(St)⊺
]
and
ŵ1(π) = En
[
π(At;St)
µt(At;St)
Φ(St)
{
Φ(St)− γΦ(St+1)}⊺] .
Proofs of the above results are in Appendix B along with a result on bracketing entropy that
is needed for the proof of Theorem 3.1 and a proof that the class of policies introduced above
satisfies the necessary bracketing integral assumption.
3.5 Simulation Experiments
In this section, we examine the performance of V-learning on simulated data. Section 3.5.2
contains results for offline estimation and Section 3.5.3 contains results for online estimation. We
begin by discussing an existing method for infinite horizon dynamic treatment regimes in Sec-
tion 3.5.1
3.5.1 Greedy Gradient Q-learning
Ertefaie (2014) introduced greedy gradient Q-learning (GGQ) for estimating dynamic treat-
ment regimes in infinite horizon settings (see also Maei et al., 2010; Murphy et al., 2016). Here
we briefly discuss this method.
Define Qπ(st, at) = E
{∑
k≥0 γ
kU t+k(π)
∣∣∣St = st, At = at}. The Bellman optimality equa-
tion (Sutton and Barto, 1998) is
Qopt(st, at) = E
{
U t + γmax
a∈A
Qopt(St+1, a)
∣∣∣St = st, At = at} . (3.5)
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Let Q(s, a; ηopt) be a parametric model for Qopt(s, a) indexed by ηopt ∈ H ⊆ Rq. In our im-
plementation, we model Q(s, a; ηopt) as a linear function with interactions between all state vari-
ables and treatment. The Bellman optimality equation motivates the estimating equation
Dn
(
ηopt
)
=
1
n
n∑
i=1
Ti∑
t=1
{
U ti + γmax
a∈A
Q(St+1i , a; η
opt)−Q(Sti, Ati; ηopt)
}
×∇ηoptQ(Sti, Ati; ηopt). (3.6)
For a positive definite matrix, Ω, we estimate ηopt with η̂optn = argminη∈HDn(η)⊺ΩDn(η). The
estimated optimal policy in state s selects action π̂n(s) = maxa∈AQ(s, a; η̂optn ). This optimization
problem is nonconvex and nondifferentiable in ηopt. However, it can be solved with a generaliza-
tion of the greedy gradient Q-learning algorithm of Maei et al. (2010), and hence is referred to as
GGQ by Ertefaie (2014) and in the following.
The performance of GGQ has been demonstrated in the context of chronic diseases with
large sample sizes and a moderate number of time points. However, in mHealth applications, it
is common to have small sample sizes and a large number of time points, with decisions occur-
ring at a fine granularity. In GGQ, the estimated policy depends directly on η̂optn and, therefore,
depends on modeling the transition probabilities of the data-generating process. Furthermore,
estimating equation (3.6) contains a nonsmooth max operator, which makes estimation difficult
without large amounts of data (Laber et al., 2014a; Linn et al., 2017). V-learning only requires
modeling the policy and the value function rather than the data-generating process and directly
maximizes estimated value over a class of policies, thereby avoiding the nonsmooth max oper-
ator in the estimating equation (compare equations (3.3) and (3.6)); these attributes may prove
advantageous in mHealth settings.
3.5.2 Offline Simulations
Our implementation of V-learning follows Section 3.2. Maximizing V̂n,R(π) is done using
a combination of simulated annealing and the BFGS algorithm as implemented in the optim
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function in R software (R Core Team, 2016). We note that V̂n,R(π) is differentiable in π, thereby
avoiding some of the computational complexity of GGQ. However, the objective is not necessar-
ily convex. In order to avoid local maxima, simulated annealing with 1000 function evaluations
is used to find a neighborhood of the maximum; this solution is then used as the starting value for
the BFGS algorithm.
We use the class of policies introduced in Section 3.2. Although we maximize the value over
a class of randomized policies, the true optimal policy is deterministic. To prevent the coefficients
of β̂n from diverging to infinity, we add an L2 penalty when maximizing over β. To prevent over-
fitting, we use an L2 penalty when computing θ̂πn, i.e., P(θπ) = (θπ)⊺θπ. Tuning parameters
can be used to control the amount of randomness in the estimated policy. For example, increas-
ing the penalty when computing β̂n is one way to encourage exploration through the action space
because β = 0 defines a policy where each action is selected with equal probability.
We consider three different models for the state-value function: (i) linear; (ii) second degree
polynomial; and (iii) Gaussian radial basis functions (RBF). The Gaussian RBF is φ(x;κ, τ 2) =
exp {−(x− κ)2/2τ 2}. We use τ = 0.25 and κ = 0, 0.25, 0.5, 0.75, 1 to create a basis of functions
and apply this basis to the state variables after scaling them to be between 0 and 1. Each model
also implicitly contains an intercept.
We begin with the following simple generative model. Let the two-dimensional state vector
be Sti = (Sti,1, Sti,2)⊺, i = 1, . . . , n, t = 1, . . . , T . We initiate the state variables as independent
standard normal random variables and let them evolve according to
Sti,1 = (3/4)(2A
t−1
i − 1)St−1i,1 + (1/4)St−1i,1 St−1i,2 + ǫt1,
and
Sti,2 = (3/4)(1− 2At−1i )St−1i,2 + (1/4)St−1i,1 St−1i,2 + ǫt2,
where Ati takes values in {0, 1} and ǫt1 and ǫt2 are independent N(0, 1/4) random variables. De-
fine the utility function by U ti = u(St+1i , Ati,Sti) = 2St+1i,1 + St+1i,2 − (1/4)(2Ati − 1). At each time
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t, we must make a decision to treat or not with the goal of maximizing the components of S while
treating as few times as possible. Treatment has a positive effect on S1 and a negative effect on
S2. We generate Ati from a Bernoulli distribution with mean 1/2. In estimation, we assume that
the generating model for treatment is known, as would be the case in a micro-randomized trial.
We generate samples of n patients with T time points per patient from the given generative
model after an initial burn-in period of 50 time points. The burn-in period ensures that our simu-
lated data is sampled from an approximately stationary distribution. We estimate policies using
V-learning with three different types of basis functions and GGQ. After estimating optimal poli-
cies, we simulate 100 patients following each estimated policy for 100 time points and take the
mean utility under each policy as an estimate of the value of that policy. Estimated values are
found in Table 3.1 with Monte Carlo standard errors along with observed value. Recall that larger
values are better. The policies estimated using V-learning produce better outcomes than the ob-
n T Linear VL Polynomial VL Gaussian VL GGQ Observed
25 24 0.118 (0.0892) 0.091 (0.0825) 0.110 (0.0979) 0.014 (0.0311) −0.005
36 0.108 (0.0914) 0.115 (0.0911) 0.112 (0.0919) 0.029 (0.0280) −0.004
48 0.106 (0.0705) 0.071 (0.0974) 0.103 (0.0757) 0.031 (0.0350) 0.000
50 24 0.124 (0.0813) 0.109 (0.1045) 0.118 (0.0879) 0.016 (0.0355) −0.005
36 0.126 (0.0818) 0.134 (0.0878) 0.136 (0.0704) 0.027 (0.0276) 0.003
48 0.101 (0.0732) 0.109 (0.0767) 0.115 (0.0763) 0.020 (0.0245) 0.000
100 24 0.117 (0.0895) 0.135 (0.0973) 0.140 (0.0866) 0.019 (0.0257) 0.011
36 0.113 (0.0853) 0.105 (0.1033) 0.139 (0.0828) 0.021 (0.0312) 0.012
48 0.111 (0.0762) 0.143 (0.0853) 0.114 (0.0699) 0.031 (0.0306) −0.001
Table 3.1: Monte Carlo value estimates for offline simulations with γ = 0.9.
servational policy and the policy estimated using GGQ. V-learning produces the best outcomes
using Gaussian basis functions.
Next, we simulate cohorts of patients with type 1 diabetes to mimic the mHealth study of
Maahs et al. (2012). Maahs et al. (2012) followed a small sample of youths with type 1 diabetes
and recorded data at a fine granularity using mobile devices. Blood glucose levels were tracked
in real time using continuous glucose monitoring, physical activity was measured continuously
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using accelerometers, and insulin injections were logged by an insulin pump. Dietary data were
recorded by 24-hour recall over phone interviews.
In our simulation study, we divide each day of follow-up into 60 minute intervals. Thus, for
one day of follow-up, we observe T = 24 time points per simulated patient and a treatment de-
cision is made every hour. Our hypothetical mHealth study is designed to estimate an optimal
dynamic treatment regime for the timing of insulin injections based on patient blood glucose,
physical activity, and dietary intake with the goal of controlling future blood glucose as close
as possible to the optimal range. To this end, we define the utility at time t as a weighted sum of
hypo- and hyperglycemic episodes in the 60 minutes preceding and following time t. Weights are
−3 when glucose ≤ 70 (hypoglycemic), −2 when glucose > 150 (hyperglycemic), −1 when
70 < glucose ≤ 80 or 120 < glucose ≤ 150 (borderline hypo- and hyperglycemic), and 0
when 80 < glucose ≤ 120 (normal glycemia). Utility at each time point ranges from −6 to
0 with larger utilities (closer to 0) being more preferable. For example, a patient who presents
with an average blood glucose of 155 mg/dL over time interval t − 1, takes an action to correct
their hyperglycemia, and presents with an average blood glucose of 145 mg/dL over time interval
t would receive a utility of U t = −3. Weights were chosen to reflect the relative clinical con-
sequences of high and low blood glucose. For example, acute hypoglycemia, characterized by
blood glucose levels below 70 mg/dL, is an emergency that can result in coma or death.
Simulated data are generated as follows. At each time point, patients are randomly chosen
to receive an insulin injection with probability 0.3, consume food with probability 0.2, partake in
mild physical activity with probability 0.4, and partake in moderate physical activity with prob-
ability 0.2. Grams of food intake and counts of physical activity are generated from normal dis-
tributions with parameters estimated from the data of Maahs et al. (2012). Initial blood glucose
level for each patient is drawn from a normal distribution with mean 100 and standard deviation
25. Define the covariates for patient i collected at time t by (Glti,Diti,Exti)⊺, where Glti is aver-
age blood glucose level, Diti is total dietary intake, and Exti is total counts of physical activity as
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would be measured by an accelerometer. Glucose levels evolve according to
Glt = µ(1−α1)+α1Glt−1+α2Dit−1+α3Dit−2+α4Ext−1+α5Ext−2+α6Int−1+α7Int−2+e, (3.7)
where Int is an indicator of an insulin injection received at time t and e ∼ N(0, σ2). We use the
parameter vector α = (α1, . . . , α7)⊺ = (0.9, 0.1, 0.1,−0.01,−0.01,−2,−4)⊺, µ = 100, and
σ = 5.5 based on a linear model fit to the data of Maahs et al. (2012). The known lag-time in the
effect of insulin is reflected by α6 = −2 and α7 = −4. Selecting α1 < 1 ensures the existence of
a stationary distribution.
We define the state vector for patient i at time t to contain average blood glucose, total di-
etary intake, and total physical activity measured over previous time intervals; we include blood
glucose and physical activity for the previous two time intervals and dietary intake for the previ-
ous four time intervals. Let n denote number of patients and T denote number of time points per
patient. Our choices for n and T are based on what is feasible for an mHealth outpatient study
(dietary data was collected on two days by Maahs et al., 2012). For each replication, the optimal
treatment regime is estimated with V-learning using three different types of basis functions and
GGQ. The generative model for insulin treatment is not assumed to be known and we estimate it
using logistic regression. We record mean outcomes in an independent sample of 100 patients fol-
lowed for 100 time points with treatments generated according to each estimated optimal regime.
Simulation results (estimated values under each regime and Monte Carlo standard errors along
with observed values) are found in Table 3.2. Again, V-learning with Gaussian basis functions
performs the best out of all methods, generally producing large values and small standard errors.
V-learning with the linear model underperforms and GGQ underperforms considerably.
3.5.3 Online Simulations
In practice, it may be useful for patients to follow a dynamic treatment regime that is updated
as new data are collected. Here we consider a hypothetical study wherein n patients are followed
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n T Linear VL Polynomial VL Gaussian VL GGQ Observed
25 24 −2.716 (1.2015) −2.335 (0.9818) −2.018 (1.2011) −3.870 (0.9225) −2.316
36 −2.700 (1.2395) −2.077 (1.0481) −1.760 (0.8468) −3.644 (0.8745) −2.261
48 −2.496 (1.1986) −2.236 (1.1978) −1.751 (0.9887) −2.405 (1.1025) −2.365
50 24 −2.545 (1.1865) −2.069 (1.0395) −1.605 (0.8064) −3.368 (1.0186) −2.263
36 −2.644 (1.1719) −2.004 (0.9074) −1.778 (0.8496) −3.099 (0.9722) −2.336
48 −2.469 (1.1635) −2.073 (0.9870) −2.102 (1.2078) −2.528 (0.9571) −2.308
100 24 −2.350 (1.1171) −2.128 (1.0520) −1.612 (0.7203) −3.272 (0.8636) −2.299
36 −2.547 (1.1852) −2.116 (0.8518) −1.672 (0.8643) −3.232 (0.7951) −2.321
48 −2.401 (1.0643) −2.204 (1.0400) −1.494 (0.5413) −2.820 (0.8442) −2.351
Table 3.2: Monte Carlo value estimates for simulated T1D cohorts with γ = 0.9.
for an initial period of T ′ time points, an optimal policy is estimated, and patients are followed
for an additional T−T ′ time points with the estimated optimal policy being continuously updated.
At each time point, t ≥ T ′, actions are taken according to the most recently estimated policy.
Recall that V-learning produces a randomized decision rule from which to sample actions at each
time point. When selecting an action based on a GGQ policy, we incorporate an ǫ-greedy strategy
by selecting the action recommended by the estimated policy with probability 1− ǫ and otherwise
randomly selecting one of the other actions. At the tth estimation, we use ǫ = 0.5t, allowing ǫ
to decrease over time to reflect increasing confidence in the estimated policy. A burn-in period
of 50 time points is discarded to ensure that we are sampling from a stationary distribution. We
estimate the first policy after 12 time points and a new policy is estimated every 6 time points
thereafter. After T time points, we estimate the value as the average utility over all patients and
all time points after the initial period.
Table 3.3 contains mean outcomes under policies estimated online using data generated ac-
cording to the simple two covariate generative model introduced at the beginning of Section 3.5.2.
There is some variability across n and T regarding which type of basis function is best, but V-
learning with a polynomial basis generally produces the best outcomes. GGQ performs well in
large samples but underperforms somewhat otherwise.
Next, we study the performance of online V-learning in simulated mHealth studies of type 1
diabetes by following the generative model described in (3.7). Mean outcomes are found in Ta-
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n T Linear VL Polynomial VL Gaussian VL GGQ
25 24 0.0053 0.0149 −0.0100 −0.0081
36 0.0525 0.0665 0.0310 0.0160
48 0.0649 0.0722 0.0416 0.0493
50 24 0.0164 0.0117 0.0037 0.0058
36 0.0926 0.0791 0.0666 0.0227
48 0.1014 0.0894 0.0512 0.0434
100 24 0.0036 −0.0157 0.0200 0.0239
36 0.0766 0.0626 0.0907 0.0540
48 0.0728 0.0781 0.0608 0.0818
Table 3.3: Value estimates for online simulations with γ = 0.9.
ble 3.4. Gaussian V-learning performs the best out of all methods, with GGQ consistently under-
n T Linear VL Polynomial VL Gaussian VL GGQ
25 24 −2.3887 −1.9713 −1.8860 −3.2027
36 −2.3784 −2.1535 −1.7857 −3.5127
48 −2.2190 −2.0679 −1.6999 −3.2280
50 24 −2.3405 −2.2313 −1.7761 −2.8976
36 −2.2829 −2.0922 −1.6016 −3.1589
48 −2.1587 −1.9669 −1.5948 −2.8729
100 24 −2.3229 −2.2295 −1.9138 −3.0865
36 −2.2927 −2.1608 −1.9030 −3.3483
48 −2.2096 −2.0454 −1.8252 −2.9428
Table 3.4: Value estimates for online estimation with simulated T1D cohorts with γ = 0.9.
performing. Across all variants of V-learning, outcomes improve with increased follow-up time.
Finally, we consider online simulations using individualized policies as outlined at the end
of Section 3.3. Consider the simple two covariate generative model introduced above but let state
variables evolve as Sti,1 = µi(2At−1i −1)St−1i,1 +(1/4)St−1i,1 St−1i,2 +ǫt1 and Sti,2 = µi(1−2At−1i )St−1i,2 +
(1/4)St−1i,1 S
t−1
i,2 + ǫ
t
2 where µi is a subject-specific term drawn uniformly between 0.4 and 0.9. In-
cluding µi ensures that the optimal policy differs across patients. Table 3.5 contains mean out-
comes for online simulation where a universal policy is estimated using data from all patients
and where individualized policies are estimated using only a single patient’s data. Because data
is generated in a such a way that the optimal policy varies across patients, individualized policies
achieve better outcomes than universal policies.
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n T Universal policy Patient-specific policy
25 24 0.0282 0.1813
36 0.1025 0.1700
48 0.0977 0.1944
50 24 0.0164 0.2771
36 0.0768 0.2617
48 0.0752 0.3038
100 24 0.0160 0.4230
36 0.0960 0.2970
48 0.1140 0.3197
Table 3.5: Value estimates for online simulations with universal and patient-specific policies with
γ = 0.9.
3.6 Case Study: Type 1 Diabetes
Machine learning is currently under consideration in type 1 diabetes through studies to build
and test a “closed loop” system that joins continuous blood glucose monitoring and subcutaneous
insulin infusion through an underlying algorithm. Known as the artificial pancreas, this technol-
ogy has been shown to be safe in preliminary studies and is making headway from small hospital-
based safety studies to large-scale outpatient effectiveness studies (Ly et al., 2014, 2015). Despite
the success of the artificial pancreas, the rate of uptake may be limited and widespread use may
not occur for many years (Kowalski, 2015). The proposed method may be useful for implement-
ing mHealth interventions for use alongside the artificial pancreas or before it is widely available.
Studies have shown that data on food intake and physical activity to inform optimal decision
making can be collected in an inpatient setting (see, e.g., Cobry et al., 2010; Wolever and Mul-
lan, 2011). However, Maahs et al. (2012) demonstrated that rich data on the effect of food intake
and physical activity can be collected in an outpatient setting using mobile technology. Here, we
apply the proposed methodology to the observational data collected by Maahs et al. (2012).
The full data consist of N = 31 patients with type 1 diabetes, aged 12–18. Glucose lev-
els were monitored using continuous glucose monitoring and physical activity tracked using ac-
celerometers for five days. Dietary data were self-reported by the patient in telephone-based in-
terviews for two days. Patients were treated using either an insulin pump or multiple daily insulin
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injections. We use data on a subset of n = 14 patients treated with an insulin pump for whom
full follow-up is available on days when dietary information was recorded. This represents 28
patient-days of data, with which we use V-learning to estimate an optimal treatment policy.
The setup closely follows the simulation experiments in Section 3.5.2. Patient state at each
time, t, is taken to be average glucose level and total counts of physical activity over the two pre-
vious 60 minute intervals and total food intake in grams over the four previous 60 minute inter-
vals. The goal is to learn a policy to determine when to administer insulin injections based on
prior blood glucose, dietary intake, and physical activity. The utility at time t is a weighted sum
of glycemic events over the 60 minutes preceding and following time t with weights defined in
Section 3.5.2. A treatment regime with large value will minimize the number of hypo- and hy-
perglycemic episodes weighted to reflect the clinical importance of each. We note that because
V (π, s; θπ) is linear in θπ, we can evaluate V̂n,R̂(π) with only the mean of Φ(S) under R. These
were estimated from the data. Because we cannot simulate data following a given policy to es-
timate its value, we report the parametric value estimate V̂n,R̂ (π̂n). Interpreting the parametric
value estimate is difficult because of the effect the discount factor has on estimated value. We can-
not compare parametric value estimates to mean outcomes observed in the data. Instead, we use
En
∑
t≥0 γ
tU t as an estimate of value under the observational policy.
We estimate optimal treatment strategies for two different action spaces. In the first, the only
decision made at each time is whether or not to administer an insulin injection, i.e., the action
space contains a single binary action. In the second, the action space contains all possible combi-
nations of insulin injection, physical activity, and food intake. This corresponds to a hypothetical
mHealth intervention where insulin injections are administered via an insulin pump and sugges-
tions for physical activity and food intake are administered via a mobile app.
Table 3.6 contains parametric value estimates for policies estimated using V-learning for the
two action spaces outlined above with different basis functions and discount factors. These re-
sults indicate that improvements in glycemic control can come from personalized and dynamic
treatment strategies that account for food intake and physical activity. Improvement results from
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Action space Basis γ = 0.7 γ = 0.8 γ = 0.9
Binary Linear −6.20 −9.35 −15.99
Polynomial −3.91 −9.03 −17.50
Gaussian −3.44 −13.09 −25.52
Multiple Linear −6.47 −9.92 −0.49
Polynomial −2.44 −6.80 −14.48
Gaussian −8.45 −3.58 −21.18
Observational policy −6.77 −11.28 −21.79
Table 3.6: Parametric value estimates for V-learning applied to type 1 diabetes data.
a dynamic insulin regimen (binary action space) and in most cases, further improvement results
from a comprehensive mHealth intervention including suggestions for diet and exercise delivered
via mobile app in addition to insulin therapy (multiple action space). When considering multiple
actions, the policy estimated using a polynomial basis and γ = 0.7 achieves a 64% increase in
value and the policy estimated using a Gaussian basis and γ = 0.8 achieves a 68% increase in
value over the observational policy.
Finally, we use an example hyperglycemic patient to illustrate how an estimated policy would
be applied in practice. One patient in the data presented at a specific time with an average blood
glucose of 229 mg/dL over the previous hour and an average blood glucose of 283 mg/dL over
the hour before that. The policy estimated with γ = 0.7 and a polynomial basis recommends
each action according to the probabilities in Table 3.7. Because this patient presented with blood
Action Probability
No action < 0.0001
Physical activity < 0.0001
Food intake < 0.0001
Food and activity < 0.0001
Insulin 0.7856
Insulin and activity 0.2143
Insulin and food 0.0002
Insulin, food, and activity < 0.0001
Table 3.7: Probabilities for each action as recommended by estimated policy for one example
patient.
glucose levels that are higher than the optimal range, the policy recommends actions that would
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lower the patient’s blood glucose levels, assigning a probability of 0.79 to insulin and a probabil-
ity of 0.21 to insulin combined with activity.
3.7 Conclusion
The emergence of mHealth has provided great potential for the estimation and implemen-
tation of dynamic treatment regimes. Mobile technology can be used both in the collection of
rich longitudinal data to inform decision making and the delivery of deeply tailored interven-
tions. The proposed method, V-learning, addresses a number of challenges associated with esti-
mating dynamic treatment regimes in mHealth applications. V-learning directly estimates a pol-
icy which maximizes the value over a class of policies and requires minimal assumptions on the
data-generating process. Furthermore, V-learning permits estimation of a randomized decision
rule which can be used in place of existing strategies (e.g., ǫ-greedy) to encourage exploration in
online estimation. A randomized decision rule can also provide patients with multiple treatment
options. Estimation of an optimal policy for different populations can be handled through the use
of different reference distributions.
V-learning and mobile technology have the potential to improve patient outcomes in a variety
of clinical areas. We have demonstrated, for example, that the proposed method can be used to
estimate treatment regimes to reduce the number of hypoglycemic and hyperglycemic episodes in
patients with type 1 diabetes. The proposed method could also be useful for other mHealth appli-
cations as well as applications outside of mHealth. For example, V-learning could be used to esti-
mate dynamic treatment regimes for chronic illnesses using electronic health records data. Future
research in this area may include increasing flexibility through use of a semiparametric model
for the state-value function. Alternatively, nonlinear models for the state-value function may be
informed by underlying theory or mathematical models of the system of interest. Data-driven se-
lection of tuning parameters for the proposed method may help to improve performance. Finally,
accounting for patient availability and feasibility of a sequence of treatments can be done by set-
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ting constraints on the class of policies. This will ensure that the resulting mHealth intervention
is feasible and that the recommended decisions are consistent with domain knowledge.
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CHAPTER 4: ESTIMATION AND OPTIMIZATION OF COMPOSITE OUTCOMES
4.1 Introduction
Precision medicine is an approach to healthcare that involves tailoring treatment based on
individual patient characteristics (Hamburg and Collins, 2010; Collins and Varmus, 2015). Ac-
counting for heterogeneity by tailoring treatment has the potential to improve patient outcomes in
many therapeutic areas. An individualized treatment regime (ITR) formalizes precision medicine
as a map from the space of patient covariates into the space of allowable treatments (Murphy,
2003; Robins, 2004). Almost all methods for estimating ITR’s have been designed to optimize a
scalar outcome. However, in practice, clinical decision making often requires balancing trade-offs
between multiple outcomes. For example, clinicians treating patients with bipolar disorder must
manage both depression and mania. Antidepressants may help correct depressive episodes but
may also induce manic episodes (Sachs et al., 2007; Ghaemi, 2008; Goldberg, 2008). We propose
a novel method for using observational data to estimate a composite outcome and the associated
optimal ITR.
The estimation of optimal ITR’s has been considered by Qian and Murphy (2011), Zhang
et al. (2012b), and Zhao et al. (2012), among others. One approach to estimating an optimal ITR
is to model an outcome based on treatment and covariates and infer decisions to optimize the out-
come from the model. A widely used example of this approach is Q-learning (Murphy, 2005;
Schulte et al., 2014). These methods were designed for optimizing scalar outcomes. The opti-
mal composite outcome is a patient’s individual utility function and standard methods could be
applied directly if patient utilities were known. When patient utilities are unknown but a high-
quality instrument is available, one can estimate a composite outcome using preference elicitation
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(Butler et al., 2017). However, if no such instrument is available, preference elicitation is difficult
to apply.
We propose a new paradigm for estimating optimal ITR’s from observational data without
eliciting patient preferences. The key premise is that clinicians are trying to act optimally with
respect to each patient’s utility and thus it is natural to use observed treatment decisions to esti-
mate patient utilities. We do not need to assume that clinicians are acting optimally, only that they
approximately follow an optimal policy. This approach allows us to describe the goals of the deci-
sion maker and how these goals vary across patients, determine what makes a patient more or less
likely to be treated optimally under standard care, and estimate the decision rule which optimizes
patient-specific composite outcomes. We develop this approach in the context of a single-stage,
binary decision in the presence of two outcomes.
Other methods for estimating ITR’s in the presence of multiple outcomes include using an
expert-derived composite outcome for all patients (Thall et al., 2002, 2007). However, this does
not account for differences in the utility function across patients and in some cases it may not
be possible to elicit a high-quality composite outcome from an expert. Alternatively, multiple
outcomes can be incorporated using set-valued treatment regimes (Laber et al., 2014b; Lizotte
and Laber, 2016; Wu, 2016), constrained optimization (Linn et al., 2015; Laber et al., 2016), or
inverse preference elicitation (Lizotte et al., 2012). Schnell et al. (2017) extend methods for es-
timating the benefiting subgroup to the case of multiple outcomes using the concept of admissi-
bility (see also Schnell et al., 2016). However, none of these approaches provide a method for
estimating an individual patient’s utility.
This work is closely related to inverse reinforcement learning (Kalman, 1964; Ng et al., 2000;
Abbeel and Ng, 2004; Ratliff et al., 2006), which involves studying decisions made by an expert
and constructing the utility function that is optimized by the expert’s decisions. Inverse reinforce-
ment learning has been successfully applied in navigation (Ziebart et al., 2008) and human loco-
motion (Mombaur et al., 2009). Inverse reinforcement learning methods assume that decisions
are made in a single environment. However, in the context of precision medicine, both the util-
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ity function and the probability of optimal treatment may vary across patients. Our approach is a
version of inverse reinforcement learning with multiple environments.
In Section 4.2, we introduce a pseudo-likelihood method to estimate patient utility functions
from observational data. In Section 4.3, we state a number of theoretical results pertaining to the
proposed method, including consistency and inference for the maximum pseudo-likelihood esti-
mators. Section 4.4 includes simulation experiments and Section 4.5 presents an application to
the STEP-BD bipolar disorder study. Conclusions are given in Section 4.6. Proofs are given in
Appendix C.
4.2 Pseudo-likelihood Estimation of Utility Functions
Assume the available data are (Xi, Ai, Yi, Zi), i = 1, . . . , n, which comprise n indepen-
dent and identically distributed copies of (X, A, Y, Z), where X ∈ X ⊆ Rp are patient co-
variates, A ∈ A = {−1, 1} is a binary treatment, and Y and Z are two real-valued outcomes
for which higher values are more desirable. An individualized treatment regime is a function
d : X → A such that a patient presenting with covariates x will be assigned to treatment d(x).
Define QY (x, a) = E (Y |X = x, A = a) and define doptY (x) = argmaxa∈AQY (x, a) to be the op-
timal ITR for the outcome Y . Define QZ(x, a) and doptZ (x) similarly. Note that d
opt
Y (x) need not
equal doptZ (x); therefore, if both Y and Z are clinically relevant, neither d
opt
Y nor d
opt
Z may be ac-
ceptable. In the following, we assume that observational data are generated by a decision maker
who is implicitly trying to maximize some composite outcome U = u(Y, Z) where u : R2 → R
is some unknown utility function such that u(y, z) measures the “goodness” of the ordered pair
(y, z). The goal is to use observational data to estimate the utility function and associated optimal
policy. We first consider the case where utility is fixed across patients and then the case where
utility varies across patients.
For each patient and each treatment a ∈ A, define the potential outcomes Y ∗(a) and Z∗(a) to
be the outcomes that the patient would have experienced had they been given treatment a (Rubin,
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1978). The optimal policy for maximizing Y can be defined as
doptY (x) = argmaxa∈AE {Y ∗(a)|X = x, A = a}
and the optimal policy for maximizing Z can be defined similarly. We make the following as-
sumptions to connect the potential outcomes to the observed data.
Assumption 4.1. Consistency, Y = Y ∗(A) and Z = Z∗(A).
Assumption 4.2. Positivity, Pr(A = a|X = x) ≥ c > 0 for some constant c and all pairs
(x, a) ∈ X ×A.
Assumption 4.3. Ignorability, {Y ∗(−1), Y ∗(1)}⊥A |X and {Z∗(−1), Z∗(1)}⊥A |X.
These assumptions are standard in causal inference (Robins, 2004; Hernan and Robins, 2010).
Assumption 4.3 is not empirically verifiable in observational studies (Rosenbaum and Rubin,
1983; Rosenbaum, 1984).
It is reasonable to assume that clinicians act with the goal of optimizing each patient’s utility
and that their success in identifying the optimal treatment depends on individual patient covari-
ates. Therefore, we assume that there exists some composite outcome that the clinician is try-
ing to optimize and use the observed decisions to estimate this composite outcome. Assume that
the treatment decisions that generated the data were made by a clinician with the goal of max-
imizing a composite outcome, U = u(Y, Z). Define QU(x, a) = E (U |X = x, A = a) and
doptU (x) = argmaxa∈AQU(x, a). If the clinician were always able to correctly identify the opti-
mal treatment and assign A = doptU (X) for each patient, there would be no need to estimate the
optimal treatment policy (Wallace et al., 2016). Instead, we assume that the decisions of the clin-
ician are imperfect and that Pr
{
A = doptU (x)|X = x
}
= expit (x⊺β) where β is an unknown
parameter. We implicitly assume throughout that X may contain higher order terms, interactions,
or basis functions constructed from the covariates.
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4.2.1 Fixed Utility
We begin by assuming that the utility function is constant across patients and takes the form
u(y, z;ω) = ωy + (1 − ω)z for some ω ∈ [0, 1]. Lemma 1 of Butler et al. (2017) states
that, for a broad class of utility functions, the optimal ITR is equivalent to the optimal regime
for a utility function of this form. Define Qω(x, a) = ωQY (x, a) + (1 − ω)QZ(x, a) and de-
fine doptω (x) = argmaxa∈AQω(x, a). Let Q̂Y,n and Q̂Z,n denote estimators of QY and QZ ob-
tained from regression models fit to the observed data (Qian and Murphy, 2011). For a fixed
value of ω, let Q̂ω,n(x, a) = ωQ̂Y,n(x, a) + (1 − ω)Q̂Z,n(x, a) and subsequently let d̂ω,n(x) =
argmaxa∈AQ̂ω,n(x, a) be the plug-in estimator of doptω (x). Given Q̂Y,n and Q̂Z,n, d̂ω,n(x) can be
computed for each ω ∈ [0, 1].
The joint distribution of (X, A, Y, Z) is
f(X, A, Y, Z) = f(Y, Z|X, A)f(A|X)f(X)
= f(Y, Z|X, A)f(X)exp [X
⊺β1 {A = doptω (X)}]
1 + exp (X⊺β)
.
Assuming that f(Y, Z|X, A) and f(X) do not depend on ω or β, the likelihood for (ω, β) is
Ln(ω, β) ∝
n∏
i=1
exp [X⊺i β1 {Ai = doptω (Xi)}]
1 + exp (X⊺i β)
, (4.1)
which depends on the unknown function doptω . Plugging in d̂ω,n for doptω into (4.1) yields the pseudo-
likelihood
L̂n(ω, β) ∝
n∏
i=1
exp
[
X
⊺
i β1
{
Ai = d̂ω,n(Xi)
}]
1 + exp (X⊺i β)
. (4.2)
If we let ω̂n and β̂n denote the maximum pseudo-likelihood estimators obtained by maximizing
(4.2), then an estimator of the utility function is ûn(y, z) = u (y, z; ω̂n) = ω̂ny + (1 − ω̂n)z and
expit
(
x⊺β̂n
)
is an estimator of the probability that a patient presenting with covariates x would
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be treated optimally under standard care. An estimator of the optimal policy at x is d̂ω̂n,n(x) =
argmaxa∈AQ̂ω̂n,n(x, a).
Because the pseudo-likelihood given in (4.2) is nonsmooth in ω, standard gradient-based op-
timization algorithms cannot be used. However, for a given ω, it is straightforward to compute
the profile pseudo-likelihood estimator β̂n(ω) = argmaxβ∈RpL̂n(ω, β). We can compute the
profile pseudo-likelihood estimator over a grid of values for ω and select the point on the grid
yielding the largest pseudo-likelihood. The algorithm to construct
(
ω̂n, β̂n
)
is as follows.
1. Set a grid 0 = ω0 < ω1 < . . . < ωK = 1
2. For each m = 0, . . . , K:
(a) Set ω = ωm
(b) Compute β̂n(ω) = argmaxβ∈RpL̂n(ω, β)
3. Select m̂n = argmax0≤m≤KL̂n
{
ωm, β̂n(ωm)
}
4. Set
(
ω̂n, β̂n
)
=
{
ωm̂n , β̂n (ωm̂n)
}
.
Step (2b) can be accomplished using logistic regression. The theoretical properties of this estima-
tor are discussed in Section 4.3.
4.2.2 Patient-specific Utility
Outcome preferences can vary widely across patients in some application domains includ-
ing schizophrenia (Kinter, 2009; Strauss et al., 2010) and pain management (Gan et al., 2004).
To accommodate this setting, we assume that the utility function takes the form u(y, z;x, ω) =
ω(x)y + {1− ω(x)} z where ω : X → [0, 1] is a smooth function. For illustration, we let
ω(x; θ) = expit (x⊺θ) where θ is an unknown parameter. Define Qθ(x, a) = ω(x; θ)QY (x, a) +
{1− ω(x; θ)}QZ(x, a) and define doptθ (x) = argmaxa∈AQθ(x, a). Let Q̂Y,n and Q̂Z,n denote es-
timators of QY and QZ from regression models fit to the observed data. For fixed θ, let Q̂θ,n(x, a) =
ω(x; θ)Q̂Y,n(x, a)+{1− ω(x; θ)} Q̂Z,n(x, a) and subsequently let d̂θ,n(x) = argmaxa∈AQ̂θ,n(x, a)
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be the plug-in estimator of doptθ (x). Assume that observed decisions are made according to the
model Pr
{
A = doptθ (x)|X = x
}
= expit (x⊺β). We compute the estimators
(
θ̂n, β̂n
)
of (θ, β)
by maximizing the pseudo-likelihood
L̂n(θ, β) ∝
n∏
i=1
exp
[
X
⊺
i β1
{
Ai = d̂θ,n(Xi)
}]
1 + exp (X⊺i β)
. (4.3)
An estimator for the utility function is ûn(y, z;x) = ω
(
x; θ̂n
)
y +
{
1− ω
(
x; θ̂n
)}
z and an
estimator for the optimal decision function is d̂θ̂n,n.
As before, the pseudo-likelihood given in (4.3) is nonsmooth in θ and therefore, standard
gradient-based optimization methods cannot be used. It is again straightforward to compute the
profile pseudo-likelihood estimator β̂n(θ) = argmaxβ∈RpL̂n(θ, β) for any θ ∈ Rp. However,
because it is computationally infeasible to compute β̂n(θ) for all θ on a grid if θ is of moderate
dimension, we generate a random walk through the parameter space using the Metropolis al-
gorithm as implemented in the metrop function in the R package mcmc (Geyer and Johnson,
2017) and compute the profile pseudo-likelihood for each θ on the random walk. Let L˜n(θ) =
maxβ∈Rp L̂n(θ, β). We can compute L˜n(θ) = L̂n
{
θ, β̂n(θ)
}
by estimating β̂n(θ) using logistic
regression as described in Section 4.2.1. The algorithm to construct a random walk through the
parameter space is as follows.
1. Set a chain length, B, fix σ2 > 0, and initialize θ1 to a starting value in Rp
2. For b = 2, . . . , B:
(a) Generate e ∼ N(0, σ2I)
(b) Set θ˜b+1 = θb + e
(c) Compute p = min
{
L˜n
(
θ˜b+1
)
/L˜n
(
θ˜b
)
, 1
}
(d) Generate U ∼ U(0, 1); if U ≤ p, set θb+1 = θ˜b+1; otherwise, set θb+1 = θb.
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After generating a chain (θ1, . . . , θB), we select the θk that leads to the largest value of L˜n(θk)
as the maximum pseudo-likelihood estimator. Standard practice is to choose the variance of the
proposal distribution, σ2, so that the acceptance proportion is between 0.25 and 0.5 (Geyer and
Johnson, 2017).
4.3 Theoretical Results
Here we state a number of theoretical results pertaining to the proposed estimation method
for utility functions. We state results for a patient-specific utility function; the setting where the
utility function is fixed is a special case. All proofs are deferred to Appendix C.
We assume that Pr
{
A = doptU (x)|X = x
}
= expit(x⊺β0) and that the true utility function is
u(y, z;x, θ0) = ω (X; θ0) y+{1− ω (X; θ0)} z, where ω(X; θ) has bounded continuous derivative
on compact sets and doptθ0 (X) = d
opt
θ (X) almost surely implies θ = θ0, i.e., the model introduced
in Section 4.2.2 is correctly specified with true parameters β0 and θ0. We further assume that the
estimators Q̂Y,n(x, a) and Q̂Z,n(x, a) are pointwise consistent for all ordered pairs (x, a). Along
with assumptions 4.1-4.3, we implicitly assume that the densities f(Y, Z|X, A) and f(X) exist.
The following result states the consistency of the maximum pseudo-likelihood estimators for the
utility function and the probability of optimal treatment. The proof involves verifying the condi-
tions of Theorem 2.12 of Kosorok (2008).
Theorem 4.1. Define the maximum pseudo-likelihood estimators as in Section 4.2.2,
(
θ̂n, β̂n
)
=
argmaxθ∈Rp,β∈BL̂n(θ, β). Assume that B is a compact set with β0 ∈ B and that ‖EX‖ < ∞.
Then,
∥∥∥θ̂n − θ0∥∥∥ P−→ 0 and ∥∥∥β̂n − β0∥∥∥ P−→ 0 as n→∞.
Let Vθ(d) = E {u(Y, Z;X, θ)|A = d(X)} be the mean composite outcome in a population
where decisions are made according to d. The following result establishes the consistency of the
value of the estimated optimal policy. The proof uses general theory developed by Qian and Mur-
phy (2011).
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Theorem 4.2. Let θ̂n be the pseudo-likelihood estimator for θ and let d̂θ̂n,n be the estimated opti-
mal policy. Then, under the given assumptions,
∣∣∣Vθ0 (d̂θ̂n,n)− Vθ0 (doptθ0 )∣∣∣ P−→ 0 as n→∞.
Next, we derive the convergence rate and asymptotic distribution of
(
θ̂n, β̂n
)
. Assume that
X is a bounded subset of Rp and that β0 ∈ Rp with ‖β0‖ < ∞. Let θ0 ∈ Rd with ‖θ0‖ < ∞.
Let ‖ · ‖X be the sup norm over X , i.e., for f : X → R, ‖f‖X = supx∈X |f(x)|. Let ω˙θ(x) =
(∂/∂θ)ω(x; θ). Assume that
∥∥‖ω˙θ0(x)‖∥∥X < ∞ and that limθ→θ0 ∥∥‖ω˙θ(x) − ω˙θ0(x)‖∥∥X = 0.
Define RY (x) = QY (x, 1) − QY (x,−1), RZ(x) = QZ(x, 1) − QZ(x,−1), and R0(x) =
RY (x)−RZ(x). Similarly, define R̂Y,n(x) = Q̂Y,n(x, 1)− Q̂Y,n(x,−1), R̂Z,n(x) = Q̂Z,n(x, 1)−
Q̂Z,n(x,−1), and R̂0,n(x) = R̂Y,n(x)−R̂Z,n(x). Let Dθ(x) = ω(x; θ)RY (x)+{1− ω(x; θ)}RZ(x)
and D̂θ,n(x) = ω(x; θ)R̂Y,n(x) + {1− ω(x; θ)} R̂Z,n(x). Note that doptθ (x) = sign {Dθ(x)} and
d̂θ,n(x) = sign
{
D̂θ,n(x)
}
. Let Pβ(x) = expit(x⊺β), ψi,A =
[
1
{
Ai = d
opt
θ0
(Xi)
}− Pβ0(Xi)]Xi,
In(β) = En [Pβ(X) {1− Pβ(X)}XX⊺], and I0 = E [Pβ0(X) {1− Pβ0(X)}XX⊺]. We need the
following three sets of regularity conditions.
Assumption 4.4. There exist independent and identically distributed influence vectors, denoted
ψ1,Y , ψ2,Y , . . . ∈ Rq1 , and ψ1,Z , ψ2,Z , . . . ∈ Rq2 , and basis functions φY (x) and φZ(x) such that
both ∥∥∥∥∥√n{R̂Y,n(x)−RY (x)}− φY (x)⊺n−1/2
n∑
i=1
ψi,Y
∥∥∥∥∥
X
= oP (1)
and ∥∥∥∥∥√n{R̂Z,n(x)−RZ(x)}− φZ(x)⊺n−1/2
n∑
i=1
ψi,Z
∥∥∥∥∥
X
= oP (1).
Let ZY,n = n−1/2
∑n
i=1 ψi,Y , ZZ,n = n
−1/2
∑n
i=1 ψi,Z , ZA,n = n
−1/2
∑n
i=1 ψi,A, and q = q1 + q2.
Furthermore, assume that ‖RY (x)‖X , ‖RZ(x)‖X ,
∥∥‖φY (x)‖∥∥X , and ∥∥‖φZ(x)‖∥∥X are bounded
by some M < ∞. Let Σ0 = E
[{(
ψ⊺1,Y , ψ
⊺
1,Z , ψ
⊺
1,A
)
⊺
}⊗2] be positive definite and finite, where
u⊗2 = uu⊺.
Assumption 4.5. The following conditions hold:
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1. The random variable Dθ0(X) has a continuous density function f in a neighborhood of 0
with f0 = f(0) ∈ (0,∞);
2. The conditional distribution of X given that |Dθ0(X)| ≤ ǫ converges in distribution as
ǫ ↓ 0;
3. There exist δ1, δ2 > 0 such that
lim
ǫ↓0
inf
t∈Sd
Pr
[|X⊺β0| ≥ δ1, | {RY (X)−RZ(X)} ω˙θ0(X)⊺t| ≥ δ1, |Dθ0(X)| ≤ ǫ] ≥ δ2,
where Sd is the d-dimensional unit sphere.
Assumption 4.6. Define, for ZY ∈ Rq1 , ZZ ∈ Rq2 , and U ∈ Rd,
(ZY , ZZ , U) 7→ k0(ZY , ZZ , U) = E
[
X {2Pβ0(X)− 1} ·
∣∣ω(X; θ0)RY (X)φY (X)⊺ZY+
{1− ω(X; θ0)}RZ(X)φZ(X)⊺ZZ +R0(X)ω˙θ0(X)⊺U
∣∣∣∣∣Dθ0(X) = 0]. (4.4)
Assume that the map U 7→ β⊺0k0(ZY , ZZ , U) has a unique, finite minimum over Rd for every
(Z⊺Y , Z
⊺
Z)
⊺ ∈ Rq.
Let
(
θ̂n, β̂n
)
be the maximum pseudo-likelihood estimators given in Section 4.2.2. We are
now ready for the following theorem, which establishes the asymptotic distribution of
(
θ̂n, β̂n
)
.
Theorem 4.3. Under the given regularity conditions, we have that
√
n
 θ̂n − θ0
β̂n − β0
 
 U
I−10 {ZA − k0(ZY , ZZ , U)}
 ≡
 U
B
 , (4.5)
where (Z⊺Y , Z
⊺
Z , Z
⊺
A)
⊺ ∼ N(0,Σ0), and U = argminu∈Rd β⊺0k0(ZY , ZZ , u).
Let P 
Z∗
denote convergence in probability over Z∗, as defined in Section 2.2.3 and Chapter 10
of Kosorok (2008). Theorem 4.4 below establishes the validity of a parametric bootstrap proce-
dure for approximating the sampling distribution of
(
θ̂n, β̂n
)
.
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Theorem 4.4. Assume Σ̂n = Σ0 + oP (1) and hn = v̂nn−1/6, where v̂n
P−→ v0 ∈ (0,∞).
Assume the regularity conditions given above hold. Let Z∗ ∼ N(0, Ir×r), where Ir×r is an r × r
identity matrix and r = p + q. Let Z˜n = Σ̂1/2n Z∗ =
(
Z˜⊺Y , Z˜
⊺
Z , Z˜
⊺
A
)
⊺
. Let T˜n(X, ZY , ZZ) =
ω
(
X; θ̂n
)
φY (X)
⊺ZY +
{
1− ω
(
X; θ̂n
)}
φZ(X)
⊺ZZ and define
k˜n(ZY , ZZ , U) = En
[
X
{
2Pβ̂n(X)− 1
}
·
∣∣∣T˜n(X, ZY , ZZ)
+
{
R̂Y,n(X)− R̂Z,n(X)
}
ω˙θ̂n(X)
⊺U
∣∣∣h−1n φ0 {D̂θ̂n,n(X)/hn}],
where φ0 is the standard normal density. Define U˜n = argminu∈Rd β̂⊺nk˜n
(
Z˜Y , Z˜Z , u
)
and B˜n =
In
(
β̂n
)−1 {
Z˜A − k˜n
(
Z˜Y , Z˜Z , U˜n
)}
. Then,
 U˜n
B˜n
 P 
Z∗
 U
B
 , (4.6)
where (U⊺, B⊺)⊺ is as defined in Theorem 4.3.
If we fix a large number of bootstrap replications, B, then
(
U˜n,b, B˜n,b
)
, b = 1, . . . , B will
provide an approximation to the sampling distribution of the pseudo-likelihood estimators. In
Sections 4.4 and 4.5, we demonstrate the use of the bootstrap to test for heterogeneity of patient
preferences.
4.4 Simulation Experiments
4.4.1 Fixed Utility Simulations
To examine the finite sample performance of the proposed methods, we begin with the fol-
lowing simple generative model. Let X = (X1, . . . , X5)⊺ be a vector of independent normal
random variables with mean 0 and standard deviation 0.5. Let treatment be assigned accord-
ing to Pr {A = doptω (x)|X = x} = ρ, i.e., the probability that the clinician correctly identifies
the optimal treatment is constant across patients. Let ǫY and ǫZ be independent normal random
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n ω ρ ω̂n ρ̂n Error rate
100 0.25 0.6 0.321 (0.2413) 0.613 (0.0654) 0.114
0.8 0.252 (0.0574) 0.803 (0.0386) 0.028
0.75 0.6 0.656 (0.2614) 0.610 (0.0718) 0.121
0.8 0.752 (0.0519) 0.805 (0.0410) 0.026
200 0.25 0.6 0.272 (0.1618) 0.613 (0.0404) 0.069
0.8 0.250 (0.0273) 0.802 (0.0267) 0.014
0.75 0.6 0.719 (0.1778) 0.610 (0.0441) 0.076
0.8 0.751 (0.0325) 0.800 (0.0280) 0.016
300 0.25 0.6 0.264 (0.1356) 0.610 (0.0300) 0.056
0.8 0.250 (0.0202) 0.802 (0.0214) 0.011
0.75 0.6 0.736 (0.1328) 0.608 (0.0308) 0.057
0.8 0.749 (0.0198) 0.803 (0.0231) 0.011
500 0.25 0.6 0.249 (0.0823) 0.607 (0.0221) 0.034
0.8 0.250 (0.0151) 0.800 (0.0176) 0.008
0.75 0.6 0.750 (0.0855) 0.606 (0.0208) 0.035
0.8 0.751 (0.0127) 0.800 (0.0187) 0.007
Table 4.1: Estimation results for simulation where utility and probability of optimal treatment are
fixed.
variables with mean 0 and standard deviation 0.5 and let Y = A (4X1 − 2X2 + 2) + ǫY and
Z = A (2X1 − 4X2 − 2) + ǫZ . We estimated QY and QZ using linear models, implemented the
proposed method for a variety of n, ω, and ρ values, and examined ω̂n, ρ̂n, and d̂ω̂n,n, across 500
Monte Carlo replications.
Table 4.1 contains mean estimates of ω and ρ across replications along with their associated
root mean squared errors (RMSE), and estimated error rate defined as the proportion of time the
estimated optimal policy does not recommend the true optimal treatment. The pseudo-likelihood
method performs well at estimating both ω and ρ, with estimation improving with larger sample
sizes as expected. Table 4.2 contains estimated values of the true optimal policy, a policy where
the utility function is known and the Q-functions are estimated, a policy where both the utility
and the Q-functions are estimated (the proposed method), a policy where the Q-functions are
estimated and the utility is misspecified, and the standard of care. The policy with misspecified
utility assumes ω = 0, which corresponds to Q-learning for optimizing Z, while ignoring Y .
The value of the standard of care is the mean composite outcome under the generative model. For
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n ω ρ Optimal Known ω Estimated ω Misspecified ω Standard of care
100 0.25 0.6 1.896 1.896 1.723 1.770 0.386
0.8 1.900 1.897 1.889 1.767 1.144
0.75 0.6 1.898 1.902 1.697 0.390 0.380
0.8 1.894 1.896 1.888 0.395 1.145
200 0.25 0.6 1.903 1.897 1.823 1.759 0.381
0.8 1.895 1.896 1.896 1.756 1.133
0.75 0.6 1.902 1.901 1.809 0.390 0.377
0.8 1.894 1.897 1.894 0.381 1.144
300 0.25 0.6 1.899 1.897 1.849 1.764 0.381
0.8 1.898 1.900 1.896 1.767 1.139
0.75 0.6 1.901 1.894 1.848 0.401 0.386
0.8 1.901 1.893 1.903 0.400 1.139
500 0.25 0.6 1.898 1.903 1.877 1.761 0.376
0.8 1.901 1.896 1.898 1.763 1.144
0.75 0.6 1.897 1.900 1.877 0.389 0.375
0.8 1.897 1.899 1.897 0.383 1.141
Table 4.2: Value results for simulation where utility and probability of optimal treatment are
fixed.
each policy, the value is estimated by generating a testing sample of size 500 with treatment as-
signed according to the policy and averaging utilities (calculated using the true ω) in the testing
set. The column labeled “estimated ω” refers to the proposed method. We see that the proposed
method produces values which increase with n and generally come close to those of the policy
where ω is known. In all settings, the proposed method offers significant improvement over the
standard of care. The proposed method also offers significant improvement over the policy where
the utility is misspecified.
To further examine the performance of the proposed method, we allow the probability of op-
timal treatment to depend on patient covariates. Let Pr {A = doptω (X)} = expit(X1). This corre-
sponds to the case where β = (1, 0, . . . , 0)⊺. Let X, Y , and Z be generated as described above. In
this generative model, the probability that a patient is treated optimally in standard care is larger
for patients with positive values of X1 and smaller for patients with negative values of X1. We
applied the proposed method to 500 replications of this generative model for various n and ω. Ta-
ble 4.3 contains mean estimates of ω along with associated RMSE of ω̂n, RMSE of β̂n, and the
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n ω ω̂n RMSE of β̂n Error rate
100 0.25 0.423 (0.3313) 1.410 0.171
0.75 0.586 (0.3339) 1.441 0.173
200 0.25 0.366 (0.2751) 0.887 0.126
0.75 0.639 (0.2745) 0.885 0.136
300 0.25 0.324 (0.2243) 0.674 0.091
0.75 0.698 (0.2131) 0.689 0.099
500 0.25 0.283 (0.1484) 0.470 0.054
0.75 0.736 (0.1483) 0.495 0.068
Table 4.3: Estimation results for simulation where utility is fixed and probability of optimal
treatment is patient-specific.
n ω Optimal Known ω Estimated ω Misspecified ω Standard of care
100 0.25 1.901 1.892 1.576 1.763 -0.110
0.75 1.897 1.898 1.572 0.377 0.144
200 0.25 1.899 1.898 1.676 1.765 -0.107
0.75 1.901 1.894 1.674 0.382 0.140
300 0.25 1.898 1.904 1.755 1.765 -0.101
0.75 1.901 1.902 1.766 0.387 0.150
500 0.25 1.896 1.897 1.827 1.769 -0.108
0.75 1.901 1.894 1.835 0.386 0.153
Table 4.4: Value results for simulation where utility is fixed and probability of optimal treatment
is patient-specific.
error rate. Estimation of the observational policy (as defined by β) improves with larger sample
sizes, with the largest improvement coming from an increase from 100 patients to 200. The prob-
ability that the estimated policy assigns the optimal treatment also increases with the sample size.
The true value of ω does not affect estimation of ω or β.
Table 4.4 contains estimated values of the true optimal policy, a policy where the utility func-
tion is known and the Q-functions are estimated, a policy where both the utility and the Q-functions
are estimated (the proposed method), a policy where the Q-functions are estimated and the utility
is misspecified, and the standard of care. Values are estimated from independent testing sets of
size 500 as described above. The policy with misspecified utility assumes ω = 0. The value
under the standard of care is the mean composite outcome under the generative model. The pro-
posed method (found in the column labeled “estimated ω”) produces values that are close to those
of the policy where the utility function is known in large samples and a significant improvement
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n RMSE of β̂n RMSE of θ̂n Error rate
100 1.959 3.481 0.188
200 1.171 3.418 0.177
300 0.874 3.389 0.167
500 0.613 3.314 0.150
Table 4.5: Estimation results for simulation where utility and probability of optimal treatment are
patient-specific.
over standard of care in small to moderate samples. Again, the proposed method offers signif-
icant improvement over the policy where the utility is misspecified. We note that value under
the standard of care differs across ω. When ω is close to 1, the composite outcome places more
weight on Y , for which the magnitude of the association with X1 is larger. Because patients with
larger values of X1 are more likely to be treated optimally in this generative model, the standard
of care produces larger composite outcomes when ω is closer to 1.
4.4.2 Patient-specific Utility Simulations
Next, we examine the case where the utility function is allowed to vary across patients. Let
X, Y , and Z be generated as above. Again, assume that Pr
{
A = doptθ (X)
}
= expit(X1), i.e.,
β = (1, 0, . . . , 0)⊺. Consider the composite outcome U = ω(X; θ)Y + {1− ω(X, θ)}Z, where
ω(X; θ) = expit (−0.5X1), i.e., θ = (−0.5, 0, . . . , 0)⊺. We implemented the proposed method
for various n and examined estimation of θ and β across 500 replications. Each replication is
based on a simulated Markov chain of length 10,000 as described in Section 4.2.2. Results are
summarized in Table 4.5. Larger sample sizes produce marginal decreases in the RMSE of θ̂n.
Despite the large RMSE’s of θ̂n, the estimated policy assigns the true optimal treatment more
than 80% of the time for all sample sizes and the error rate decreases as the sample size increases.
Table 4.6 contains estimated values of the true optimal policy, the policy estimated using the pro-
posed method, and standard of care. The proposed method produces policies that achieve close to
optimal value in large samples and significant improvement over the standard of care in small to
moderate samples.
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n Optimal Estimated θ Standard of care
100 1.563 1.311 -0.015
200 1.559 1.334 -0.011
300 1.562 1.358 -0.014
500 1.564 1.385 -0.016
Table 4.6: Value results for simulation where utility and probability of optimal treatment are
patient-specific.
n Power under null Power under alternative
100 0.010 0.858
200 0.018 0.904
300 0.044 0.922
500 0.066 0.948
Table 4.7: Simulation results for bootstrap hypothesis test for preference heterogeneity.
Finally, we examine the performance of the parametric bootstrap as described in Section 4.3.
Let X be a bivariate vector of normal random variables with mean 0 and standard deviation 0.5.
Let Y and Z be generated as above and let β = (0, 1, 0)⊺ where the first element of β refers to
an intercept. We use two values of θ, (0, 0, 0)⊺, and (0, 3, 0)⊺. Let θ(1) be the vector θ with the
first element removed. We are interested in testing the null hypothesis H0 :
∥∥θ(1)∥∥ = 0, which
corresponds to a test for heterogeneity of patient preferences. Table 4.7 contains estimated power
across 500 Monte Carlo replications under the null hypothesis, θ = (0, 0, 0)⊺, and an alternative
hypothesis, θ = (0, 3, 0)⊺, at level α = 0.05 for various sample sizes. Each replication is based on
1000 bootstrap samples. The proposed bootstrap procedure produces type 1 error rates near what
is expected and adequate power in large samples.
4.5 Case Study: The STEP-BD Standard Care Pathway
The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) was a
landmark study of the effects of antidepressants in patients with bipolar disorder (Sachs et al.,
2007). In addition to a randomized trial assessing outcomes for patients given an antidepressant
or placebo, the STEP-BD study also included a large-scale observational study, the standard care
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pathway. We apply the proposed method to data from the STEP-BD standard care pathway to
estimate decision rules for the use of antidepressants in patients with bipolar disorder.
Although bipolar disorder is characterized by alternating episodes of depression and mania,
recurrent depression is the leading cause of impairment among patients with bipolar disorder
(Judd et al., 2002). However, the use of antidepressants has not become standard care in bipolar
disorder due to the risk of antidepressants inducing manic episodes in certain patients (Ghaemi,
2008; Goldberg, 2008). Thus, the clinical decision in the treatment of bipolar disorder is whether
to prescribe antidepressants to a specific patient in order to balance trade-offs between symptoms
of depression, symptoms of mania, and other side effects of treatment.
We use the SUM-D score for depression symptoms and the SUM-M score for mania symp-
toms as outcomes. We consider a patient treated if they took any one of ten antidepressants that
appear in the STEP-BD standard care pathway (Deseryl, Serzone, Citalopram, Escitalopram Ox-
alate, Prozac, Fluvoxamine, Paroxetine, Zoloft, Venlafaxine, or Bupropion). Covariates were
screened using linear models and included if there was an interaction with treatment for either
outcome. Covariates used for this analysis were age and substance abuse history (yes/no). Fig-
ure 4.1 contains box plots of SUM-D scores on the log scale by substance abuse and treatment.
Figure 4.2 contains box plots of SUM-M scores on the log scale by substance abuse and treat-
ment. For both outcomes, lower scores are more desirable. Figure 4.1 indicates that those with-
out a history of substance abuse benefit from treatment with antidepressants. However, among
those with a history of substance abuse, patients treated with antidepressants appear to have worse
symptoms of depression. Figure 4.2 indicates that treatment has no effect on symptoms of mania
among those without a history of substance abuse. However, among those with a history of sub-
stance abuse, it appears that treatment may be inducing manic episodes. Thus, a sensible treat-
ment policy would be one that tends to prescribe antidepressants only to patients without a his-
tory of substance abuse.
We analyzed these data using the proposed method for optimizing composite outcomes. Re-
sults are summarized in Table 4.8 below. We estimated policies where both utility and probability
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Figure 4.1: Box plots of log SUM-D score (severity of depression symptoms) by substance abuse
and treatment.
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Figure 4.2: Box plots of log SUM-M score (severity of mania symptoms) by substance abuse and
treatment.
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Policy SUM-D SUM-M Value (% improvement) ω̂n ρ̂n
fixed-fixed 2.320 0.837 4.2% 0.000 0.404
fixed-variable 2.320 0.857 5.6% 0.115 0.403
variable-variable 2.319 0.858 7.4% 0.115 0.404
standard of care 2.480 0.868 0.0% · ·
Table 4.8: Results of analysis of STEP-BD data with SUM-D score and SUM-M score as out-
comes.
of optimal treatment are fixed (fixed-fixed), where utility is fixed but probability of optimal treat-
ment is assumed to vary between patients (fixed-variable) and where both utility and probability
of optimal treatment are assumed to vary between patients (variable-variable). For both the fixed-
variable policy and the variable-variable policy, we report En
{
expit
(
X⊺β̂n
)}
in place of ρ̂n and
for the variable-variable policy, we report En
{
expit
(
X⊺θ̂n
)}
in place of ω̂n. Thus, for parame-
ters that are assumed to vary across patients, Table 4.8 contains the mean estimate in the sample.
Mean outcomes and value functions are averaged over five fold cross validation. For both SUM-
D and SUM-M, lower scores are preferred. Value is reported as the percent improvement over
standard of care, calculated using the estimated utility function. Large percent improvements in
value are preferred. All estimated policies produce more desirable SUM-D scores and SUM-M
scores compared to standard of care and improved value according to the estimated utility. Allow-
ing the probability of optimal treatment to vary between patients leads to further improvements in
value, as does allowing the utility function to vary between patients. All policies produce similar
estimates for the probability of optimal treatment averaged across patients.
The resulting decision rules can be written as the sign of a linear combination of the covari-
ates. As an example, the fixed-fixed policy assigns treatment with antidepressants when
sign {0.207− 0.003(age)− 0.620(substance abuse)}
is equal to 1. The negative coefficient for substance abuse means that a history of substance abuse
indicates that a patient should not be prescribed antidepressants. Prior research has shown that
patients with a history of substance abuse are more likely to abuse antidepressants (Evans and
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Policy SUM-D Side effect score Value (% improvement) ω̂n ρ̂n
fixed-fixed 2.320 0.157 8.4% 0.000 0.483
fixed-variable 2.338 0.164 4.0% 0.034 0.484
variable-variable 2.304 0.158 14.1% 0.127 0.470
standard of care 2.480 0.172 0.0% · ·
Table 4.9: Results of analysis of STEP-BD data with SUM-D score and side effect score as
outcomes.
Sullivan, 2014). This may contribute to the poor outcomes experienced by STEP-BD patients
with a history of substance abuse who were treated with antidepressants. A test for preference
heterogeneity based on 1000 bootstrap replications generated according to Theorem 4.4 yielded a
p-value of 0.0153.
As a secondary analysis, we use the SUM-D score and a side effect score as outcomes. Eight
side effects were recorded in the STEP-BD standard care pathway (tremors, dry mouth, sedation,
constipation, diarrhea, headache, poor memory, sexual dysfunction, and increased appetite). Pa-
tients rated the severity of each side effect from 0 to 4 with larger values indicating more severe
side effects. We took the mean score across side effects as the second outcome. Covariates were
screened as in the above analyses. Patients in the standard care pathway were asked to report the
percent of days over the past week that they experienced mood elevation, irritability, and anx-
iety; these were included as covariates along with age and history of substance abuse. Results
are summarized in Table 4.9, reported analogously to those in Table 4.8. Each estimated policy
produces improved SUM-D scores and improved side effect scores compared to the standard of
care. Each policy also produces improvement in value according to the estimated utility function.
Again, allowing the utility function to vary between patients results in further improvements in
value. Each policy produces similar estimates of the probability that patients are treated optimally
in standard care. The variable-variable policy places more weight on SUM-D scores on average
compared to the other policies. Estimated coefficients in θ̂n are −4.624 for age, −0.430 for sub-
stance abuse history, −1.192 for percent of days with mood elevation, 3.319 for percent days with
irritability, and 0.227 for percent days with anxiety, with an intercept of −0.495. The bootstrap
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procedure for testing the null hypothesis that patient preferences are homogeneous based on 1000
bootstrap replications yielded a p-value < 0.0001.
4.6 Conclusion
The estimation of optimal ITR’s has been well-studied in the statistical literature. Existing
methods have typically defined the optimal treatment regime as optimizing the mean of a fixed
scalar outcome. However, clinical practice often requires consideration of multiple outcomes.
Thus, there is a disconnect between existing statistical methods and current clinical practice. It
is reasonable to assume that clinicians make treatment decisions for each patient with the goal
of maximizing that patient’s utility. Therefore, it is natural to use observational data to estimate
patient utilities from observed clinician decisions. This represents a new paradigm for thinking
about observational data as traditional approaches to analyzing observational data seek transfor-
mations under which the data can be treated like a randomized study.
The proposed methodology offers many opportunities for future research. In this paper, we
have considered only the simplest case— that of one decision time, two outcomes, and two possi-
ble treatments. The proposed methods could be extended to cases with more than two outcomes
or multiple time points. Different computational strategies, such as a Bayesian approach, could
be developed to handle the nonsmooth pseudo-likelihood and potentially improve estimation of
patient-specific utility functions. While we have proposed our utility function estimator inside
the framework of one-stage Q-learning, the pseudo-likelihood utility function estimator could be
used alongside other existing one-stage optimal treatment policy estimators, such as an outcome
weighted learning estimator (Zhao et al., 2012). There is a great future for the development of
methods for optimizing composite outcomes in precision medicine and application of these meth-
ods in clinical studies.
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CHAPTER 5: OUTCOME WEIGHTED LEARNING AND MAXIMUM LIKELIHOOD
ESTIMATION
5.1 Introduction
Precision medicine offers the potential to improve patient outcomes by tailoring treatment
based on individual patient characteristics. An important statistical problem in precision medicine
is the estimation of an optimal individualized treatment regime (ITR), a mapping from the co-
variate space into the treatment space that maximizes the mean of a clinical outcome when used
to assign treatment in a population. There have been a number of methods to estimate the opti-
mal ITR proposed in the literature. Such methods can generally be classified as indirect methods
(Watkins, 1989; Qian and Murphy, 2011; Zhao et al., 2009, 2011; Schulte et al., 2014), which in-
fer the optimal treatment decisions from a regression model, or direct methods (Zhao et al., 2012;
Zhang et al., 2012a,b; Laber and Zhao, 2015; Zhou et al., 2017; Chen et al., 2017) which estimate
the optimal ITR using inverse probability weighting. In this chapter, we show that certain direct
estimators correspond to semiparametric maximum likelihood estimators, establishing a link be-
tween direct and indirect estimators, and use this framework to develop efficient computational
algorithms, information criteria, and exploratory data analysis techniques.
Indirect methods proceed by regressing the outcome of interest on treatment and covariates
and inferring optimal treatment decisions from the fitted regression model. Examples include Q-
learning (Watkins, 1989; Zhao et al., 2009, 2011) and A-learning (Murphy, 2003; Schulte et al.,
2014). The form of the estimated ITR resulting from an indirect estimation method is restricted
by the regression model. Therefore, there is a trade-off between a flexible ITR and a parsimo-
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nious model. In indirect estimation methods, the performance of the estimated optimal ITR is
dependent on the fit of the regression model.
Direct methods (or direct search methods) for the optimal ITR proceed by developing an
inverse probability weighted estimator (IPWE) for the mean outcome under a specific ITR and
maximizing the IPWE over a class of ITR’s. Zhao et al. (2012) proposed outcome weighted learn-
ing (OWL), which approximates the IPWE with a surrogate loss function that can be solved using
a support vector machine (SVM), opening the door to using machine learning techniques to es-
timate optimal ITR’s. Zhang et al. (2012a) proposed approximating the maximizer of the IPWE
using a genetic algorithm. Zhou et al. (2017) proposed residual weighted learning to improve
the finite sample performance of OWL and Chen et al. (2017) proposed a modification of OWL
which permits estimating an optimal ITR for ordinal treatments. Thus, there have been a number
of direct methods proposed in the literature. However, there are few results on efficiency and a
lack of information criteria to assist with model selection.
We show that the IPWE objective function is the log-likelihood function for a certain class of
semiparametric regression models. This establishes a link between direct and indirect estimators
for the optimal ITR. We also show that the surrogate loss function proposed by Zhao et al. (2012)
is not a maximum likelihood estimator for any semiparametric model with a given additive form.
We use the maximum likelihood framework to develop an efficient computational algorithm, in-
formation criteria, and exploratory data analysis techniques that are commonplace in maximum
likelihood settings.
In Section 5.2, we introduce the setting and propose a class of optimal ITR’s. In Section 5.3,
we show that there exists a semiparametric model for which the IPWE objective function is the
profile log-likelihood function and develop an efficient algorithm for maximizing this profile log-
likelihood function. We introduce an Akaike information criteria (AIC) for treatment regimes
based on the profile likelihood in Section 5.4. We demonstrate the proposed algorithm on sim-
ulated data in Section 5.5. In Section 5.6, we apply the proposed methods to estimate ITR’s for
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bipolar disorder using data from the STEP-BD clinical trial. Conclusions are presented in Sec-
tion 5.7 and proofs are included in Appendix D along with additional simulation results.
5.2 Setup and Notation
We assume that the available data are (Xi, Ai, Yi), i = 1, . . . , n which comprise n i.i.d. triples
(X, A, Y ), one for each subject. Here, X ∈ X ⊆ Rp denotes baseline subject information,
A ∈ A = {−1, 1} denotes binary treatment assignment, and Y ∈ R is an outcome coded so
that higher values are better. Because A is binary, there exist real-valued functions on X so that
E(Y |X = x, A = a) = m(x) + ac(x). We will assume that Y = m(X) + Ac(X) + ǫ where ǫ
is a mean zero additive error. For simplicity we will assume that P (A = 1|X = x) = 1/2 with
probability one. This is not essential (see, e.g., Zhang et al., 2012a,b).
An ITR is a function π : X → A that prescribes π(x) to a subject presenting with X = x.
Let EπY denote the expectation of Y when treatments are assigned according to π. The optimal
regime, πopt, satisfies EπoptY ≥ EπY for all π. Qian and Murphy (2011) showed that EπY =
2EY 1{A = π(X)} where 1{ν} is one if ν is true and zero otherwise. This expression is the mo-
tivation for the policy search estimator π̂n = argmaxπ 2EnY 1{A = π(X)} where En denotes
the empirical measure. Maximizing the plug-in estimator is difficult due to the nonsmooth, non-
convex indicator function. Zhao et al. (2012) approximate the arg max in the preceding plug-in
estimator using a convex relaxation of the indicator function, whereas Zhang et al. (2012a) ap-
proximate the arg max using a genetic algorithm. Estimators of this form were coined “outcome
weighted learning estimators” by Zhao et al. (2012)
The expression for πopt above is not unique. The following result is proved in Appendix D.
Lemma 5.1. Assume that Y = m(X)+Ac(X)+ǫ where ǫ has mean zero. Let g be a real-valued,
nonnegative, even function, increasing on [0,∞), and h an arbitrary real-valued function on Rp.
Define πoptg,h = argminπ Eg {Y − h(X)} 1 [sign{Y − h(X)}A 6= π(X)]. Then, for all π,
1. E
[
sign {Y − h(X)} g {Y − h(X)} 1{A = πoptg,h (X)}
] ≥ E[sign {Y − h(X)}
g {Y − h(X)} 1{A = π(X)}];
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2. Eπ
opt
g,hY ≥ EπY .
Thus, the expected outcome under πoptg,h doesn’t depend on the choice of g and h. The preced-
ing lemma suggests a class of potential estimators for πopt indexed by functions g and h. A main
contribution of this paper is to demonstrate that for a chosen class of models, estimators of the
form π̂g,h = argminπ Eng{Y − h(X)}1[sign{Y − h(X)}A 6= π(X)] are maximum likelihood
estimators.
5.3 Outcome Weighted Learning as Maximum Likelihood
For clarity, we consider linear treatment regimes of the form π(x) = sign(x⊺β). Extensions
to nonlinear decision rules are discussed in Remark 5.1. Let g be defined as in Lemma 5.1. We
suppose that g(0) = 0 and
∫
w∈R
|w| exp{−g(w)}dw < ∞. Our results concern the working
model
Y = m(X) + Aq(X)X⊺β∗ + ǫ, (5.1)
where q(x) ≥ 0 for all x ∈ Rp, ||β∗|| = 1, and ǫ has density fǫ(u) ∝ exp{−g(u)}. The following
result is proved in Appendix D.
Lemma 5.2. Assume working model (5.1) and that m(X) is known. Then, the profile log-likelihood
for β∗ is given by ℓ(β) = −Eng {Y −m(X)} 1[sign{Y −m(X)}A 6= sign(X⊺β)].
Corollary 5.1. Assume working model (5.1) and that m(X) is known. Then, the maximum
likelihood estimator of β∗ is β̂n = argminβ∈Sp Eng {Y −m(X)} 1[sign{Y − m(X)}A 6=
sign(X⊺β)], where Sp is the p-dimensional unit sphere.
The preceding result shows that the objective function considered by Zhao et al. (2012) and Zhang
et al. (2012a) is a profile log-likelihood for (5.1) when m(x) ≡ 0 and g(u) = |u| so that ǫ follows
a Laplace (double exponential) distribution. This result also suggests a number of alternative esti-
mators. For example, if the errors are normally distributed, the maximum likelihood estimator is
β̂n = argminβ∈Sp En {Y −m(X)}2 1[sign{Y −m(X)}A 6= sign(X⊺β)].
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Generally, the function m is unknown and must be estimated from data. Given estimates β̂n
of β∗, q̂n of q, and a known function g, an estimator of m is
m̂n = argmin
m∈M
Eng
{
Y − Aq̂n(X)X⊺β̂n −m(X)
}
,
where M is a class of working models. In some settings, it may be desirable to treat g as un-
known and estimate it from the data. For illustration, we describe our estimation algorithm using
a kernel density estimator for the distribution of ǫ, which implies an estimator for g. Alternatively,
g can be held fixed at a value informed by underlying theory or preliminary exploratory data anal-
yses. We use the following iterative algorithm to construct β̂n.
1. Initialize β̂(0)n to a starting vector in Rp, q̂(0)n,1, . . . , q̂
(0)
n,n to starting values in [0,∞), and ĝ(0)n (u)
to − log f0(u) for a starting density f0(u). Set t = 1 and fix σ > 0 and some kernel func-
tion k.
2. Repeat the following steps until convergence:
(a) compute m̂(t)n = argminm∈M
∑n
i=1 ĝ
(t−1)
n
{
Yi − Aiq̂(t−1)n,i X⊺i β̂(t−1)n −m(Xi)
}
;
(b) set q̂(t)n,i = max
[
Ai
{
Yi − m̂(t)n (Xi)
}
/X⊺i β̂
(t−1)
n , 0
]
i = 1, . . . , n;
(c) compute β̂(t)n = argminβ∈Sp
∑n
i=1 ĝ
(t−1)
n
{
Yi − m̂(t)n (Xi)− Aiq̂(t)n,iX⊺i β
}
;
(d) if g is fixed and known, set ĝ(t)n = ĝ(t−1)n ; otherwise define ê(t)n,i = Yi − m̂(t)n (Xi) −
q̂
(t)
n,iX
⊺
i β̂
(t)
n , e¯
(t)
n = n−1
∑n
i=1 ê
(t)
n,i,
f̂ (t)n (e) = (nσ)
−1
n∑
i=1
K
{
(e− ê(t)n,i + e¯(t)n )/σ
}
,
and set ĝ(t)n (x) = − log f̂ (t)n (x).
The above algorithm can be implemented for a standard class of models, M (e.g., linear). In our
implementation we terminated the algorithm when
∥∥∥β̂(t)n − β̂(t−1)n ∥∥∥ was below a small threshold.
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Step 2b follows from the relation
q̂
(t)
n,i = argmin
qi≥0
g
{
Yi − m̂(t)(Xi)− AiqiX⊺i β̂(t)n
}
(see proof in Appendix D) which can be defined arbitrarily when X⊺i β̂(t−1)n = 0.
For g(u) = |u|, the proposed algorithm provides an alternative to the convex relaxation de-
rived by Zhao et al. (2012). However, as we show next, the convex relaxation proposed by Zhao
et al. (2012) cannot correspond to a maximum likelihood estimator under any model of the form
Y = m(X) + AΨ(X, β)η(X) + ǫ where Ψ is an arbitrary function and η is a nuisance parameter.
The following result is proved in Appendix D.
Lemma 5.3. Let φ(u) be a continuous, onto function from R to R+. Let ǫ have density fǫ(u) ∝
exp{−g(u)} where g satisfies the above conditions. There exists no model of the form Y =
m(X) + AΨ(X, β)η(X) + ǫ where, η : Rp → H ⊂ R is unknown, for which
−Eng {Y −m(X)}φ [sign{Y −m(X)}AX⊺β]
is the profile likelihood for β.
We now turn to proving consistency of the maximum profile likelihood estimator. The proof
of the following consistency result, which is included in Appendix D, involves verifying the con-
ditions of Theorem 2.12 of Kosorok (2008). We allow for m to be estimated from the data and
assume that the estimator for m is an element of a Vapnik-Cervonenkis (VC) class (Hastie et al.,
2009).
Theorem 5.1. Let g be a known function satisfying the conditions stated above and further as-
sume that g is continuous. Let m̂n ∈ M be an estimator of m and assume that M is a VC-class.
Let
β̂n = argmin
β∈Sp
Eng {Y − m̂n(X)} 1[sign{Y − m̂n(X)}A 6= sign(X⊺β)]
be the maximum profile likelihood estimator for model (5.1). Then,
∥∥∥β̂n − β∗∥∥∥ P−→ 0 as n→∞.
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We conclude this section with a few brief remarks.
Remark 5.1. We need not restrict ourselves to linear decision rules. Nonlinear decision rules can
be estimated by substituting any parametric or semiparametric function of X in place of X⊺β in
the algorithm above.
Remark 5.2. We can also consider a slightly more general case of working model (5.1). Let L
be a real-valued, odd function which is positive on [0,∞). Then it can be shown that the model
Y = m(X) + Aq(X)L(X⊺β∗) + ǫ has the same profile likelihood for β∗ as model (5.1). This
follows from the relation sign(X⊺β) = sign{L(X⊺β)}.
Remark 5.3. Zhou et al. (2017) introduced residual weighted learning as an alternative to out-
come weighted learning, proposing to approximate the minimizer of En{Y −m(X)}1{π(X) 6=
A} over π for a function m. Assuming E(Y |X = x, A = a) = m(x) + ac(x) and P (A =
1|X = x) = 1/2 with probability one, it is easy to see that m(x) = E(Y |X = x), which can eas-
ily be estimated by regressing Y on X. Zhou et al. (2017) proposed a smoothed ramp loss and a
difference-of-convex algorithm to approximate the minimizer of En {Y − m̂n(X)} 1 {π(X) 6= A}.
Fixing m̂n to be the regression fit of Y on X (ignoring treatment assignment) and proceeding
with the proposed algorithm provides an alternative to the difference-of-convex algorithm pro-
posed by Zhou et al. (2017).
5.4 Information Criteria for Treatment Regimes
A number of techniques for variable selection for treatment regimes have appeared in the
literature. Song et al. (2015) proposed penalized outcome weighted learning (POWL) to select
relevant variables while estimating the optimal ITR. Gunter et al. (2007) proposed an algorithm
to rank variables based on magnitude of interaction with treatment. Xu et al. (2009) proposed an
AIC for semiparametric models using the profile likelihood. Although they develop their method
in the context of the proportional hazards mixed model, it is applicable to general semiparametric
models. We apply it here to develop an AIC for treatment regimes. Let pl(β) = −Eng{Y −
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m(X)}1[sign{Y − m(X)}A 6= sign(X⊺β)] be the profile log-likelihood for β∗ in model (5.1).
The profile AIC (pAIC) defined by Xu et al. (2009) takes the form pAIC = −2pl
(
β̂n
)
+ 2p. In
the current setting, this becomes
pAIC = 2Eng{Y −m(X)}1
[
sign{Y −m(X)}A 6= sign
(
X⊺β̂n
)]
+ 2p. (5.2)
When m is unknown, it can be replaced in (5.4) with its estimator. The derivation is based on the
quadratic expansion of the profile log-likelihood (see Murphy and Van der Vaart, 2000). When
choosing a subset of X, we recommend choosing the model with the smallest value of pAIC.
It can be shown that, under mild regularity conditions, pAIC is asymptotically unbiased for the
Akaike information (Theorem 3 of Xu et al., 2009).
5.5 Simulation Experiments
Here, we investigate the operating characteristics of the proposed method in simulation stud-
ies. We start by generating simulated data sets from the model
Y = X⊺α + A log {1 + exp(X⊺γ)}X⊺β + ǫ, (5.3)
where γ = 1p, α = 1p, and β = (k, k, 0, . . . , 0)⊺. Let A be equal to 1 or −1 with equal probabil-
ity, and X ∼ Np(0, AR1(e)), with AR1(e)ij = e−|i−j|. The value of the two nonzero components
of β is fixed such that E |log {1 + exp(X⊺γ)}X⊺β| = 2. This expectation is calculated numeri-
cally to determine that k = 0.915, 0.613, 0.489 for p = 5, 15, 25, respectively. Let ǫ be a mean
zero error.
We take the following steps to ensure that
∥∥∥β̂n∥∥∥ = 1 for identifiability and to prevent prema-
ture termination of the proposed iterative algorithm. Let β˜(t)n = τ̂ (t)n /
∥∥∥τ̂ (t)n ∥∥∥ where
τ̂n = argmin
τ∈Rp
n∑
i=1
ĝ(t−1)n
{
Yi − m̂(t)n (Xi)− Aiq̂(t)n,iX⊺i τ/‖τ‖
}
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in step 2c of the iterative algorithm. Then, let β̂(t)n = β̂(t−1)n + α
(
β˜
(t)
n − β̂(t−1)n
)
for some learning
rate α < 1. In our implementation, we use α = 0.9. We use multiple starting points for β to avoid
converging to a local maximum, generated randomly using the R package DiceDesign (Dupuy
et al., 2015). In our first simulation setting, we let ǫ have a normal distribution with mean zero
and standard deviation four and apply the following estimators: the proposed MLE algorithm
with g(u) = u2 (MLE-normal), the MLE with g(u) = |u| (MLE-Laplace), the MLE with a kernel
density estimator for the error distribution (MLE-kernel), and the convex relaxation (OWL). The
kernel density estimator uses a Gaussian kernel (Silverman, 1986). We let m be estimated within
the class of linear functions.
Table 5.1 contains estimated mean squared errors (MSE) for data generated from model (5.3)
for each of the three estimators based on 500 replications. For M replications, we estimate the
MSE to be M−1
∑M
j=1
∥∥∥β̂n,j − β∗∥∥∥, where β∗ is the true value and β̂n,j is the estimate of β∗ cal-
culated from the j-th replication, scaled such that
∥∥∥β̂n,j∥∥∥ = 1. The results in Table 5.1 indicate
n p MLE-normal MLE-Laplace MLE-kernel OWL
100 5 0.786 0.830 0.787 1.529
15 0.650 0.774 0.650 1.821
25 0.688 0.811 0.688 2.822
250 5 0.759 0.778 0.762 1.437
15 0.553 0.614 0.553 1.137
25 0.588 0.688 0.588 1.340
500 5 0.754 0.750 0.757 1.481
15 0.527 0.552 0.525 0.871
25 0.540 0.605 0.540 0.932
Table 5.1: Estimated MSE of β̂n across simulations when error distribution is normal.
that the MLE algorithm achieves lower MSE than OWL. Lower MSE’s are achieved when the
error distribution is correctly specified.
The value of a treatment regime, π, is V (π) = EπY . Table 5.2 contains estimated values of
the estimated optimal treatment regimes based on 500 replications. Values are estimated as the
mean outcome in an external simulated data set where treatment assignment is made according to
the estimated treatment regime. Table 5.2 indicates that the MLE algorithm produces estimated
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n p MLE-normal MLE-Laplace MLE-kernel OWL
100 5 1.81 (0.294) 1.73 (0.291) 1.69 (0.306) 1.07 (0.868)
15 1.27 (0.357) 1.50 (0.337) 1.63 (0.321) 0.62 (0.671)
25 1.56 (0.427) 1.60 (0.466) 1.50 (0.429) 0.30 (0.533)
250 5 1.71 (0.239) 1.73 (0.335) 1.84 (0.213) 1.58 (0.599)
15 1.67 (0.608) 1.68 (0.346) 1.83 (0.436) 0.90 (0.668)
25 1.61 (0.470) 1.71 (0.318) 1.52 (0.475) 1.23 (0.604)
500 5 1.86 (0.341) 1.74 (0.401) 1.89 (0.238) 1.62 (0.328)
15 1.52 (0.367) 1.65 (0.289) 1.77 (0.309) 1.38 (0.429)
25 1.64 (0.530) 1.45 (0.606) 1.95 (0.375) 1.13 (0.522)
Table 5.2: Estimated values with Monte Carlo standard errors when error distribution is normal.
optimal ITR’s with better value than those produced by OWL. Simulation results when the true
error distribution is Laplace are included in Appendix D.
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5.6 Application to Data
The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) was a
large scale randomized clinical trial to study the efficacy of antidepressants at controlling episodes
of depression among patients with bipolar disorder (Sachs et al., 2007). Over two million Amer-
icans suffer from bipolar disorder, which is characterized by alternating episodes of mania and
depression (bipolar I disorder) or episodes of hypomania and depression (bipolar II disorder). Pa-
tients with bipolar disorder are routinely treated with medications such as mood stabilizers or psy-
chotherapy. The Randomized Acute Depression (RAD) pathway of STEP-BD was designed to
evaluate the use of antidepressants in addition to mood stabilizers. Patients enrolled in the RAD
pathway received an antidepressant (either Bupropion, Paroxetine, or placebo) in addition to their
usual mood stabilizer.
There are a number of reasons why the use of antidepressants in patients with bipolar disor-
der has been called into question. Treatment with antidepressants has the potential to increase
risk of mania in patients with bipolar disorder. A specific patient’s response to treatment with an-
tidepressants may vary based on severity of depression symptoms, type of bipolar disorder, or
whether the patient experienced a manic episode prior to the depressive episode. Ghaemi (2008)
notes that the treatment of bipolar disorder using antidepressants in specific patients needs evalua-
tion. Additional commentary is given by Goldberg (2008).
We estimate the optimal ITR in two stages. First, we use data on all patients to estimate an
ITR to determine whether a patient should be be given an antidepressant or placebo. Then, we
use data on patients who received active treatment to estimate an ITR to determine which antide-
pressant (Bupropion or Paroxetine) should be given. The primary outcome is the sum of scores
on the SUM-D scale for depression symptoms and the SUM-M scale for mania symptoms at the
end of follow-up. Higher scores are indicative of more severe symptoms. Available covariates
are sex, age, marital status (married or not), living status (live alone or not), income (> 50, 000
annually or not), employment status (laid off in the past year or not), status prior to onset of de-
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pressive episode (remission, manic, or mixed), bipolar type, baseline score on Beck’s depression
inventory (BDI), baseline SUM-M score, and baseline SUM-D score. Using these covariates, we
estimate treatment policies using the proposed maximum likelihood method assuming normal
errors, Laplace errors, and a kernel density estimator for the errors. We also estimate treatment
policies using OWL.
We can use standard exploratory data analysis techniques to evaluate model fit and assump-
tions. As an example, Figure 5.1 features residuals plotted against baseline SUM-M scores for
the model assuming normal errors, which can be used to assess model fit. Figure 5.2 contains a
normal quantile plot of residuals which can be used to assess the assumption that the residuals
follow a normal distribution. Recall that
q̂n(Xi) = max
[
0, Ai {Yi − m̂(Xi)} /X⊺i β̂n
]
.
Observations with q̂n(Xi) > 0, have residual equal to 0; these observations are excluded from the
plots.
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Figure 5.1: Residuals from maximum likelihood fit plotted against SUM-M scores.
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Figure 5.2: Normal quantile plot of residuals from maximum likelihood fit.
Table 5.3 contains estimated values for each policy calculated on an independent testing set.
Recall that lower scores are preferable. We note that the proposed maximum likelihood approach
Policy Value
MLE-normal 3.480
MLE-Laplace 3.577
MLE-kernel 3.914
OWL 4.792
Anti-depressant 3.883
Placebo 3.711
Table 5.3: Values of treatment policies estimated using STEP-BD data.
results in ITR’s with better estimated value than the ITR estimated using OWL. The best esti-
mated treatment regime achieves a 6% improvement in value over treating no patients and a 10%
improvement in value over treating all patients.
Coefficients for each variable in each estimated ITR are found in Table 5.4. Recall that the
estimated treatment regime is the sign of the linear combination of covariates weighted by the
coefficients in Table 5.4. The coefficients can be interpreted in terms of varying effects across
treatments. For example, the positive coefficient for bipolar type in each policy estimated using
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Effect MLE-normal MLE-Laplace MLE-kernel OWL
Intercept -0.0299 -0.0190 -0.0285 -1.1997
Sex (male) -0.1028 -0.0206 -0.0650 -0.3432
Age 0.0889 -0.2826 0.0886 -0.0077
Married 0.1042 0.0019 0.1407 1.1363
Live alone -0.2502 -0.0224 -0.2530 0.6667
Income > 50, 000 0.0301 -0.0085 0.0880 0.5663
Laid off 0.4726 0.0312 0.4703 -0.1601
Prior status: manic 0.5382 0.0400 0.5544 0.0264
Prior status: mixed -0.3685 -0.0329 -0.3242 1.4778
Bipolar type II 0.3762 0.0209 0.3843 -0.3038
Baseline BDI -0.1324 -0.9245 -0.1448 0.0272
Baseline SUM-M 0.2340 -0.0159 0.2538 -0.3010
Baseline SUM-D -0.2089 -0.2444 -0.1696 0.0501
Table 5.4: Coefficient estimates for assigning antidepressant or placebo from STEP-BD data.
the proposed maximum likelihood method indicates that bipolar II disorder is associated with im-
proved outcomes under antidepressant treatment compared to bipolar I disorder. This is sensible,
as patients with bipolar II disorder tend to experience episodes of hypomania, compared with pa-
tients with bipolar I disorder who tend to experience more severe manic episodes (Sachs et al.,
2007).
5.7 Conclusion
Estimating optimal ITR’s is an important statistical problem in precision medicine. Making
treatment decisions based on a high-quality ITR can improve patient outcomes by leveraging het-
erogeneity in response to treatment. Therefore, statistical methods with excellent performance
at estimating the optimal ITR are needed. Direct search methods for estimating the optimal ITR
are becoming more popular. However, the theoretical framework of direct search methods is still
lacking. We have shown that the IPWE objective function considered by Zhao et al. (2012) and
Zhang et al. (2012b) is the profile log-likelihood of a semiparametric model, facilitating a dis-
cussion of the efficiency of treatment regime estimators that has been unavailable until now. The
proposed maximum likelihood approach to estimating treatment regimes allows for efficient com-
putation, model selection using information criteria, and graphical methods to evaluate model fit.
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Furthermore, this work provides a link between regression-based and direct search estimators for
the optimal ITR. This connection may help to express state-of-the-art machine learning methods
such as OWL in a way that is more accessible to applied researchers. The connection between di-
rect and indirect estimation methods also motivates many avenues for future research, including
generalizations of OWL and Bayesian estimators for the optimal treatment regime.
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CHAPTER 6: DISCUSSION AND FUTURE RESEARCH
6.1 Discussion
The arrival of the big data age has created many new nontraditional statistical problems. Tak-
ing full advantage of data-driven decision making requires developing statistical methods to solve
these new problems. We have considered a few such problems in this dissertation. In Chapter 2,
we develop a method for estimating an ROC curve for the SVM and constructing ROC confi-
dence bands, with applications in diagnostic medicine and other classification problems. We
demonstrate the importance of placing unequal weights on false positives and false negatives and
provide methodology to allow for unequal weighting in SVM classification. In Chapter 3, we pro-
pose an estimator for optimal treatment regimes in mobile health with an application to type 1
diabetes. The proposed method, V-learning, represents an extension of direct search methods to
the infinite horizon setting. Chapter 4 discusses an approach to estimating a composite outcome
using observational data, which allows for estimating an ITR in the presence of more than one
outcome. This approach provides a new way of thinking about observational data, taking advan-
tage of treatment assignments that are not randomized. Finally, in Chapter 5, we introduce a link
between machine learning and maximum likelihood estimation and use this link to develop new
techniques for estimating optimal ITR’s. This link helps to elucidate the connections between
direct search and regression-based estimators in precision medicine.
We hope that the methods introduced in this dissertation will be useful to applied researchers
and that the case studies introduced here will provide useful insight and motivate further appli-
cations of precision medicine in practice. However, much of this work has raised new research
questions, which we discuss in the following section.
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6.2 Future Research
6.2.1 Variable Selection for SVM ROC
In Chapter 2, our simulations suggest that the presence of noise variables results in a de-
crease in AUC for the SVM ROC curve. Thus, a natural extension to the research in Chapter 2
is to develop variable selection techniques for use with the SVM ROC curve method. Guyon
et al. (2002) introduced recursive feature elimination (RFE), a variable selection technique for
the SVM that involves iteratively removing the variable that produces the smallest change when
removed, where smallest change is measured by the Hilbert space norm of the estimated decision
function. Dasgupta et al. (2015) proposed a modification to RFE where smallest change is mea-
sured by the objective function evaluated at the estimated decision function and showed that this
modification results in uniform consistency for identifying the true underlying set of important
variables.
There are a number of ways in which the method proposed by Dasgupta et al. (2015) can
be extended the the SVM ROC curve setting. In the simplest case, variable selection can be per-
formed for α = 0.5 and the same subset of variables can be used across α to estimate the ROC
curve. Alternatively, variable selection can be performed separately for each α. Estimating the
ROC curve can be done using the union or intersection of variables selected across α, represent-
ing the set of variables that are found to be important for at least one weight or all weights, re-
spectively. Finally, we can allow the set of variables used to estimate the ROC curve to vary across
α, allowing for certain variables to be more or less important depending on the weight placed on
false positives and false negatives. Simulation experiments are needed to compare these different
approaches and the theoretical results given by Dasgupta et al. (2015) need to be verified for the
weighted SVM.
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6.2.2 Robust V-learning and Average Value Learning
V-learning, as introduced in Chapter 3, requires an estimator of the observational policy,
µt(at; st). If this estimator comes from a regression model (e.g., logistic regression), the model
must be correctly specified in order for the estimating equation given in (3.3) to be unbiased.
Here, we briefly present an alternate formulation of V-learning that is robust to model misspeci-
fication. Let µt(at; st, ζ) denote a model for µt(at; st), V (π, st; θπ) denote a model for V (π, st)
as defined in Section 3.2, and Qπ (st, at; ηπ) denote a model for Qπ(st, at) as defined in Sec-
tion 3.5.1. Similar to the augmented inverse probability weighted estimator (see, e.g., Zhang
et al., 2012b), we propose to use the estimating equation
Λn(π, ζ, θ
π, ηπ) = En
{
T−1∑
t=1
(
π (At;St)
µt (At;St, ζ)
{
U t + γV
(
π,St+1; θπ
)− V (π,St; θπ)}
+
π (At;St)− µt (At;St, ζ)
µt (At;St, ζ)
[
U t + γQπ
{
St+1, π
(
St+1
)
; ηπ
}−Qπ (St, At; ηπ)])
× {∇ζµt (At;St, ζ)⊺ ,∇θπV (π,St; θπ)⊺ ,∇ηπQπ (St, At; ηπ)⊺}⊺}. (6.1)
For any π, estimating equation (6.1) can be used to estimate the parameters (ζ, θπ, ηπ). Estimated
value for π can be calculated from θ̂πn as in Chapter 3 and the maximizer over a class can be taken
as the estimated optimal policy. This estimating equation will be unbiased as long as at least two
of µt(at; st, ζ), V (π, st; θπ), and Qπ (st, at; ηπ) are correctly specified.
As a second extension of the ideas in Chapter 3, we present an estimating equation for aver-
age value. Recall the definition of the state-value function,
V (π, st) = E
{∑
k≥0
γkU∗(t+k)(π)
∣∣St = st} ,
for a discount factor, γ ∈ (0, 1). The discount factor, while mathematically tractable, may be
inconvenient in practice. Specification of a discount factor relies on domain knowledge; however,
experts in a specific domain may not be familiar with the concept of a discounted sum of rewards.
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To alleviate this issue, define
Vavg(π) = lim
T→∞
E
{
T−1
T∑
t=1
U∗t(π)
}
.
Note that if the data-generating process is an ergodic Markov chain, Vavg(π) will be independent
of the initial state. Define
ρ(π, st) = E
[∑
k≥0
{
U∗(t+k)(π)− Vavg(π)
} ∣∣St = st] .
Letting ρ (π, st; ηπ) be a parametric model for ρ(π, st), we can show that
0 = E
[
π (At;St)
µt (At;St)
{
U t − Vavg(π) + ρ
(
π,St+1; ηπ
)− ρ (π,St; ηπ)}
× {1,∇ηπρ (π,St; ηπ)⊺}⊺ ], (6.2)
which can be used to derive an estimating equation for Vavg(π) and ηπ. The estimating equa-
tion must be solved subject to an identifiability constraint. An example of such a constraint is
E
{
π (At;St)µt (At;St)
−1
ρ (π,St; ηπ)
}
= 0. Maximizing the estimator for Vavg(π) over a class
of policies will yield an estimator for the optimal policy. This average value learning may provide
a formulation of V-learning that is more intuitive to applied researchers.
6.2.3 Composite Outcomes in Multiple Stages
The method proposed in Chapter 4 allows for estimating an unknown utility function for a
single decision time. However, clinical decision making often requires making multiple decisions
in sequence. Here, we describe an extension of the utility function estimator proposed in Chap-
ter 4 to multiple stages. We consider both the case where the number of decision times is fixed
and finite (as in Zhao et al., 2011) and the case of an infinite time horizon (as in Ertefaie, 2014).
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In the case of a finite horizon, we have data {(Xi,1, Ai,1, . . . ,Xi,T , Ai,T , Yi, Zi)}, i = 1, . . . , n,
which are n independent and identically distributed copies of (X1, A1, . . . ,XT , AT , Y, Z), where
Xt ∈ Rpt contains covariates collected at time t, At ∈ At is treatment given at time t, and Y and
Z are real-valued outcomes coded so that higher values are more desirable. We will assume that
At is a finite set for all t = 1, . . . , T . Furthermore, we define the history at time t by H1 = X1
and Ht =
(
Xt, At−1
)
for t = 2, . . . , T , where Xt = (X1, . . . ,Xt) and At is defined simi-
larly. The goal is to estimate a dynamic treatment regime for optimizing the composite outcome
U = u(Y, Z), where u is an unknown utility function. That is, we seek to estimate the sequence
of decision rules doptt,U : domHt → At, t = 1, . . . , T such that E
{
U |At = doptt,U (Ht), t = 1, . . . , T
}
is maximized.
As in Chapter 4, assume the existence of a composite outcome U = ωY + (1 − ω)Z for
some unknown ω ∈ [0, 1] such that Pr{At = doptt,ω (ht)|Ht = ht} = expit(h⊺tβt), where doptt,ω (ht) is
the optimal decision rule at time t for optimizing the composite outcome defined by ω. For each
ω ∈ [0, 1], we can define an estimator for doptt,ω (ht) by
d̂t,ω,n(ht) = argmax
at∈At
{
ωQ̂t,Y,n(ht, at) + (1− ω)Q̂t,Z,n(ht, at)
}
, (6.3)
where the estimated Q-functions for Y and Z can be calculated using Q-learning (Zhao et al.,
2009, 2011) applied to the individual outcomes. We estimate (ω, β⊺1 , . . . , β⊺T )⊺ by maximizing the
pseudo-likelihood
L̂n(ω, β1, . . . , βT ) ∝
n∏
i=1
T∏
t=1
exp
[
H⊺i,tβt1
{
Ai,t = d̂t,ω,n(Hi,t)
}]
1 + exp
(
H⊺i,tβt
) . (6.4)
We can easily extend this to the case where the utility function depends on baseline covariates. A
more general version where each patient has their own utility function, ui(y, z) = ωiy + (1 −
ωi)z, can be employed if we pool across patients to estimate the patient-specific utility functions.
This will not produce estimated treatment regimes that are applicable to future patients, as new
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patients will not have enough data to estimate their own utility function. However, this may be
useful as an exploratory analysis to help plan future studies.
The proposed methods for composite outcomes can be extended to the infinite horizon set-
ting by building on the work of Ertefaie (2014). Following the notation of Chapter 3, let
Dn
(
ηoptω
)
=
1
n
n∑
i=1
Ti∑
t=1
{
ωY ti + (1− ω)Zti + γmax
a∈A
Q(St+1i , a; η
opt
ω )−Q(Sti, Ati; ηoptω )
}
×∇ηoptω Q(Sti, Ati; ηoptω ) (6.5)
for any ω ∈ [0, 1] and a parametric model Q (St, At; ηoptω ). Given an estimate η̂ω,n of ηoptω , let
d̂ω,n(s
t) = argmaxa∈AQ (s
t, a; η̂ω,n). The pseudo-likelihood is
L̂n(ω, β) ∝
n∏
i=1
Ti∏
t=1
exp
[
(Sti)
⊺
β1
{
Ai = d̂ω,n(S
t
i)
}]
1 + exp {(Sti)⊺ β}
. (6.6)
We use the following algorithm to estimate ω and β for a positive definite matrix, Ω, and a penalty
function, P .
1. Set a grid 0 = ω0 ≤ . . . ≤ ωK = 1.
2. For m = 0, . . . , K:
(a) Calculate η̂ωm,n by minimizing Dn (ηoptω )⊺ΩDn (ηoptω ) + P (ηoptω ).
(b) Calculate β̂ (ωm) by maximizing L̂n (ωm, β) using the plug-in estimator η̂ωm,n.
3. Select m̂m = argmax0≤m≤KL̂n
{
ωm, β̂n (ωm)
}
.
4. Set
(
ω̂n, β̂n
)
=
{
ωm̂n , β̂n (ωm̂n)
}
.
While the assumption that clinicians are approximately following the optimal policy may be rea-
sonable in the single stage setting of Chapter 4, it may not be reasonable to assume that clinicians
are approximately following the optimal policy for the discounted sum of utilities in an infinite
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horizon setting. Therefore, the above algorithm can be modified under the assumption that clin-
icians act approximately optimally with respect to the proximal utility, U t, or a finite sum of fu-
ture utilities,
∑K
k=0 U
t+k
. One problem to examine in this research is the asymptotic properties of
the proposed estimators as K → ∞. In the setting with multiple stages but a finite time horizon,
the assumption that clinicians act approximately optimally can be altered similarly by assuming
that clinicians act approximately optimally with respect to a surrogate outcome that is observed
following each decision time.
6.2.4 Generalized Hinge Loss and Bayesian Treatment Regimes
Finally, we discuss two extensions of the research introduced in Chapter 5. First, we propose
to further examine estimation of the optimal ITR using the hinge loss (Zhao et al., 2012). Let
φ(u) be a continuous, onto function from R to R+. Then, an outcome weighted learning estima-
tor for β in model (5.1) is
β̂n = argmin
β∈Rp
Eng {Y −m(X)}φ [sign{Y −m(X)}AX⊺β] . (6.7)
For example, Zhao et al. (2012) proposed using the hinge loss, φ(u) = max(0, 1 − u). However,
other choices of surrogate loss functions are available (Bartlett et al., 2006), and little guidance
has been given to assist with selecting an appropriate loss function. Following Lemma 5.3, an es-
timator of the form given in (6.7) is not a maximum likelihood estimator for a model of the form
given in (5.1). However, determining for what model such an estimator is a maximum likelihood
estimator is of interest. This motivates a generalization of outcome weighted learning wherein
the loss function is treated as a nuisance parameter. In this way, the surrogate loss function can
be determined from the data rather than selected a priori. Given a class, C, of positive, convex
functions such that, for each φ ∈ C, φ is decreasing on (−∞, 0) with φ(0) = 1, we propose the
following iterative algorithm for estimating a surrogate loss function from data.
1. Initialize β̂0n to a starting value in Rp and set t = 1.
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2. Repeat the following steps until convergence:
(a) Set φ̂tn = argminφ∈CEng {Y −m(X)}φ
[
sign{Y −m(X)}AX⊺β̂tn
]
.
(b) Set β̂tn = argminβ∈RpEng {Y −m(X)} φ̂tn [sign{Y −m(X)}AX⊺β].
The estimator φ̂n provides a data-driven choice of surrogate loss function and an estimator for the
optimal regime is π̂n(x) = sign
(
x⊺β̂n
)
.
An alternative to the approach we introduce in Chapter 5 is to construct a Bayesian estimator
of β using the likelihood introduced in Theorem 5.2. This requires specifying prior distributions
on the functions m and q and on the finite dimensional parameter β. For example, Gaussian pro-
cess priors can be used for the functional parameters and a multivariate normal prior or a flat im-
proper prior can be used for β. After sampling from the posterior distribution, the posterior mode
can be used as an estimator for β.
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APPENDIX A: TECHNICAL DETAILS FOR CHAPTER 2
Proofs
Proof of Theorem 2.1. Note that
√
n
{
ŝe
(
f̂α
)
− se
(
f̂α
)}
=
√
n
En1
{
f̂α(X) > 0
}
1(A = 1)
En1(A = 1)
−
E1
{
f̂α(X) > 0
}
1(A = 1)
E1(A = 1)

=
√
n
[
En1
{
f̂α(X) > 0
}
1(A = 1)
En1(A = 1)
− E1
{
f̂α(X) > 0
}
1(A = 1)
·
{
1
En1(A = 1)
+
1
E1(A = 1)
− 1
En1(A = 1)
}]
=
√
n
[
En1
{
f̂α(X) > 0
}
1(A = 1)
En1(A = 1)
−
E1
{
f̂α(X) > 0
}
1(A = 1)
En1(A = 1)
−
E1
{
f̂α(X) > 0
}
1(A = 1)
En1(A = 1)
·
{
En1(A = 1)
E1(A = 1)
− E1(A = 1)
E1(A = 1)
}]
=
√
n
(En − E)
[
1
{
f̂α(X) > 0
}
1(A = 1)
]
En1(A = 1)

−√n
E
[
1
{
f̂α(X) > 0
}
1(A = 1)
]
(En − E)1(A = 1)
E1(A = 1)En1(A = 1)

=
√
n (En − E)
[
ρ̂−1n 1
{
f̂α(X) > 0
}
1(A = 1)− ρ̂−1n se
(
f̂α
)
1(A = 1)
]
.
With a linear or polynomial decision function,
{
f̂α : α ∈ [δ, 1− δ]
}
is a Vapnik–Cervonenkis
class for any 0 < δ < 1/2. Thus,
{
1
(
f̂α > 0
)
: α ∈ [δ, 1− δ]
}
is a Donsker class for any
0 < δ < 1/2. We have that
√
n (En − E)
[
ρ̂−1n 1
{
f̂α(X) > 0
}
1(A = 1)− ρ̂−1n se
(
f̂α
)
1(A = 1)
]
 G(α) (A.1)
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where G(α) is a mean zero Gaussian process with covariance
E
(
ρ−21(A = 1)
[
1
{
f˜α1(X) > 0
}
− se
(
f˜α1
)] [
1
{
f˜α2(X) > 0
}
− se
(
f˜α2
)])
− E
(
ρ−11(A = 1)
[
1
{
f˜α1(X) > 0
}
− se
(
f˜α1
)])
× E
(
ρ−11(A = 1)
[
1
{
f˜α2(X) > 0
}
− se
(
f˜α2
)])
,
Proof of Theorem 2.2. First, we note that, for each x ∈ X , the optimal classifier is
D∗α(x) = sign
[
E {1(A 6= −1)CA(α)|X = x} − E {1(A 6= 1)CA(α)|X = x}
]
= sign
{
αPr(A = 1|X = x)− (1− α)Pr(A = −1|X = x)}.
Next, we note that f˜α minimizes
E [max{0, 1− Af(X)}CA(α)|X = x]
= Pr(A = 1|X = x)E[max{0, 1− Af(X)}CA(α)|X = x, A = 1]
+Pr(A = −1|X = x)E[max{0, 1− Af(X)}CA(α)|X = x, A = −1]
= αPr(A = 1|X = x)max{0, 1− f(x)}
+(1− α)Pr(A = −1|X = x)max{0, 1 + f(x)}
= f(x)
{
(1− α)Pr(A = −1|X = x)− αPr(A = 1|X = x)}
+αPr(A = 1|X = x) + (1− α)Pr(A = −1|X = x).
We note that as long as both α and Pr(A = 1|X = x) lie in the open interval (0, 1) for almost all
x, then αPr(A = 1|X = x)φ{f(X)}+ (1− α)Pr(A = −1|X = x)φ{−f(X)} decreases strictly
on (−∞,−1] and increases strictly on [1,∞). Thus, the minimum f˜α must take values in [−1, 1],
which justifies the third equality above. We have that f˜α will be positive when αPr(A = 1|X =
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x) > (1 − α)Pr(A = −1|X = x) and negative otherwise. The extension to α ∈ [0, 1] is trivial
as long as 0 < Pr(A = 1|X = x) < 1 for almost all x. Thus, f˜α(x) has the same sign as D∗α(x),
which completes the proof.
Proof of Theorem 2.3. Let f˜ = argminf∈H¯k Rα,φ(f). Let ‖ · ‖k be the norm associated with Hk.
Note that f̂α = argminf∈H¯k
{
EnLα,φ(f) + λn‖f‖2k
}
, where En denotes the empirical measure
of (X, A). We start by finding a bound for
∥∥∥√λnf̂α∥∥∥2
k
. By definition of f̂α, we have that, for any
f ∈ Hk,
EnLα,φ
(
f̂α
)
+ λn
∥∥∥f̂α∥∥∥2
k
≤ EnLα,φ(f) + λn‖f‖2k.
Setting f ≡ 0 in the above and noting that ‖0‖2k = 0 and φ(0) = 1 yields
EnLα,φ
(
f̂α
)
+ λn
∥∥∥f̂α∥∥∥2
k
≤ EnCA(α).
We have that EnCA(α) = n−1
∑n
i=1 {α1(Ai = 1) + (1− α)1(Ai = −1)} ≤ max(α, 1 − α) and
EnLα,φ
(
f̂α
)
≥ 0. It follows that
∥∥∥√λnf̂α∥∥∥2
k
≤ max(α, 1− α) ≤ 1
Next, we observe that
{√
λnf̂α :
∥∥∥√λnf̂α∥∥∥
k
≤ 1
}
is a unit ball in a RKHS and is contained
within a Donsker class. By a Donsker preservation result (page 173 of Kosorok, 2008),
{√
λnLα,φ
(
f̂α
)
:
∥∥∥√λnf̂α∥∥∥
k
≤ 1
}
is also contained within a Donsker class because φ(Af) is Lipschitz continuous in f .
The definition of P -Donsker gives us that
√
n(En − E)
√
λnLα,φ
(
f̂α
)
= OP (1).
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Thus,
(En − E)Lα,φ
(
f̂α
)
=
√
(nλn)−1
√
n(En − E)
√
λnLα,φ
(
f̂α
)
=
√
(nλn)−1OP (1),
which converges to 0 in probability because nλn →∞.
Next, it follows from the definition of f̂α that
EnLα,φ
(
f̂α
)
≤ EnLα,φ
(
f̂α
)
+ λn
∥∥∥f̂α∥∥∥2
k
≤ EnLα,φ
(
f˜α
)
+ λn
∥∥∥f˜α∥∥∥2
k
.
Taking the lim supn on both sides and using the fact that λn → 0 yields
lim sup
n
EnLα,φ
(
f̂α
)
≤ E
{
Lα,φ
(
f˜α
)}
,
almost surely. Thus, for all n large enough, we have
EnLα,φ
(
f̂α
)
≤ E
{
Lα,φ
(
f˜α
)}
≤ E
{
Lα,φ
(
f̂α
)}
almost surely. For n large enough, we have that
∣∣∣Rα,φ (f̂α)−Rα,φ (f˜α)∣∣∣ ≤ ∣∣∣(En − E)Lα,φ (f̂α)∣∣∣ = oP (1).
By Lemma 1, we have that
∣∣∣∣Rα (f̂α)− inff Rα(f)
∣∣∣∣ ≤ ∣∣∣∣Rα,φ (f̂α)− inff Rα,φ(f)
∣∣∣∣ = oP (1).
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Proof of Lemma 2.2. When the decision function is linear, quadratic, or polynomial, it lies in a
Vapnik–Cervonenkis (VC) class as on page 238 of Hastie et al. (2009). Thus,
{
f̂α : α ∈ [0, 1]
}
is
contained in a GC class by Theorem 9.3 of Kosorok (2008).
Next, we consider the case where the decision function is estimated using a Gaussian kernel.
Because the exponential function is monotone, the class of all functions of the form f(x;y) =
exp(−c‖x − y‖2) is a VC class by Lemma 9.9 (viii) of Kosorok (2008). The RKHS is a VC-
hull class as defined on page 158 of Kosorok (2008). It now follows that
{
f̂α : α ∈ [0, 1]
}
is con-
tained in a GC class by Corollary 9.5 of Kosorok (2008).
Proof of Theorem 2.4. From Lemma Lemma 2.1, the claim will follow if we can show that
sup
α∈[0,1]
∣∣∣∣Rα,φ (f̂α)− inf
f∈H¯k
Rα,φ(f)
∣∣∣∣ P−→ 0.
Following the proof of Theorem 3.3 of Zhao et al. (2012), we have that, for all n large enough,
EnLα,φ
(
f̂α
)
≤ E
{
Lα,φ
(
f˜α
)}
≤ E
{
Lα,φ
(
f̂α
)}
almost surely, where Lα,φ(f) is as defined in Section 2.3. Thus, for all n large enough, we have∣∣∣Rα,φ (f̂α)−Rα,φ (f˜α)∣∣∣ ≤ ∣∣∣(En − E)Lα,φ (f̂α)∣∣∣ almost surely. It follows that, for n large
enough,
sup
α∈[0,1]
∣∣∣Rα,φ (f̂α)−Rα,φ (f˜α)∣∣∣ ≤ sup
α∈[0,1]
∣∣∣(En − E)Lα,φ (f̂α)∣∣∣ P−→ 0,
where the convergence follows from Lemma 2.2 and the arguments in Section 2.3.
Proof of Lemma 2.3. Following Remark 4, D∗α(X) = sign {f ∗α(X)}, where
f ∗α(X) =
Pr(A = 1|X)
1− Pr(A = 1|X) −
1− α
α
.
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Thus, the sensitivity and specificity of D∗α are
se∗α = Pr
{
Pr(A = 1|X)
1− Pr(A = 1|X) −
1− α
α
> 0
∣∣A = 1}
and
sp∗α = Pr
{
Pr(A = 1|X)
1− Pr(A = 1|X) −
1− α
α
< 0
∣∣A = −1} ,
which are continuous in α when Pr(A = 1|X) is a continuous random variable.
Proof of Theorem 2.5. Let αn be a sequence such that αn ∈ [0, 1] for n ≥ 1 and αn → α. As-
sume that lim supn→∞Rαn
(
f˜αn
)
> Rα
(
f˜α
)
. Because f˜α ∈ F , we have by the definition of
f˜αn that Rαn
(
f˜αn
)
≤ Rαn
(
f˜α
)
. However, by continuity of Rα(f) for fixed f , we have that
Rαn
(
f˜α
)
→ Rα
(
f˜α
)
, a contradiction. Next, assume that lim infn→∞Rαn
(
f˜αn
)
< Rα
(
f˜α
)
.
However, we have that
lim infn→∞Rαn
(
f˜αn
)
= lim infn→∞Rα
(
f˜αn
)
≥ Rα
(
f˜α
)
,
by continuity of Rα(f) for fixed f , the definition of f˜α and the fact that f˜αn ∈ F . This yields a
contradiction and we have that Rαn
(
f˜αn
)
→ Rα
(
f˜α
)
, which completes the proof.
Proof of Corollary 2.1. By arguments in the proof of Lemma 2.2, we have that F is a GC class.
By arguments in Section 2.3, we have that {Lα,φ(f) : f ∈ F} is a GC class. Thus,
sup
f∈F
|(En − E)Lα,φ(f)| P−→ 0.
Define f˜α,φ = argminf∈F ELα,φ(f). Because ELα,φ(f) is convex in f and F is a convex set,
f˜α,φ is a unique minimizer. Because ELα,φ(f) is continuous in f , the necessary identifiability
condition holds by Lemma 14.3 of Kosorok (2008) and, by Theorem 2.12 of Kosorok (2008),
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supx∈X
∣∣∣f̂α(x)− f˜α,φ(x)∣∣∣ = oP (1). It follows that ∣∣∣se(f̂α)− se(f˜α,φ)∣∣∣ = oP (1) and
∣∣∣sp(f̂α)− sp(f˜α,φ)∣∣∣ = oP (1).
Define s˜eα = se
(
f˜α,φ
)
and s˜pα = sp
(
f˜α,φ
)
and note that
∣∣∣αρ{se(f̂α)− s˜eα}+ (1− α)(1− ρ){sp(f̂α)− s˜pα}∣∣∣
≤
∣∣∣se(f̂α)− s˜eα∣∣∣+ ∣∣∣sp(f̂α)− s˜pα∣∣∣ = oP (1).
By Theorem 2.3 and Remark 2.2, it must hold that αρs˜eα+(1−α)(1−ρ)s˜pα = αρse
(
f˜α
)
+(1−
α)(1−ρ)sp
(
f˜α
)
. Finally, by Theorem 2.4, it must hold that both supα∈[0,1]
∣∣∣se(f̂α)− s˜eα∣∣∣ P−→ 0
and supα∈[0,1]
∣∣∣sp(f̂α)− s˜pα∣∣∣ P−→ 0.
Proof of Corollary 2.2. First note that
sup
α∈[0,1]
∣∣∣ŝe(f̂α)− s˜eα∣∣∣
≤ sup
α∈[0,1]
∣∣∣ŝe(f̂α)− se(f̂α)∣∣∣+ sup
α∈[0,1]
∣∣∣se(f̂α)− s˜eα∣∣∣
≤ sup
α∈[0,1]
∣∣∣∣∣∣
En1
{
f̂α(X) > 0, A = 1
}
En1(A = 1)
−
En1
{
f̂α(X) > 0, A = 1
}
ρ
∣∣∣∣∣∣
+ sup
α∈[0,1]
∣∣∣∣∣∣
En1
{
f̂α(X) > 0, A = 1
}
ρ
−
E1
{
f̂α(X) > 0, A = 1
}
ρ
∣∣∣∣∣∣
+ sup
α∈[0,1]
∣∣∣se(f̂α)− s˜eα∣∣∣ .
The first piece above is equal to
sup
α∈[0,1]
∣∣∣[En1{f̂α(X) > 0, A = 1}] [{En1(A = 1)}−1 − ρ−1]∣∣∣
≤
[
sup
α∈[0,1]
∣∣∣En1{f̂α(X) > 0, A = 1}∣∣∣] ∣∣{En1(A = 1)}−1 − ρ−1∣∣ = OP (1)oP (1),
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where
∣∣{En1(A = 1)}−1 − ρ−1∣∣ = oP (1) by the continuous mapping theorem and the assumption
that ρ > 0.
Next, let ǫ > 0 and gǫ(x) = ǫ−1 (x+ ∧ ǫ) where x+ = max(x, 0) and ∧ denotes minimum.
Note that, by the lemma below, supα∈[0,1]
∣∣∣(En − E)ρ−1gǫ {f̂α(X)} 1(A = 1)∣∣∣ = oP (1), and
thus, supα∈[0,1]
∣∣∣(En − E)ρ−11{f̂α(X) > 0} 1(A = 1)∣∣∣ ≤ oP (1) + 2ǫ. Since ǫ was arbitrary,
the second piece above is equal to oP (1). The third piece above is equal to oP (1) by Corollary 2.1
above. The proof for specificity is analogous and is omitted.
Lemma A.1. Let F be a GC class and g : R → R be a continuous, bounded function such that
supx∈R |g(x)| = c0, limx→−∞ g(x) = c1, and limx→∞ g(x) = c2. Then, g(F) = {g(f) : f ∈ F}
is a GC class.
Proof of Lemma A.1. By Lemma 8.13 of Kosorok (2008), E‖f − Ef‖∗F < ∞. Fix ǫ > 0 and
find M < ∞ and −∞ < k1 < 0 < k2 < ∞ such that E {1 (‖f − Ef‖∗F > M)} ≤ ǫ/2c0 and
supx≤k1 |g(x)− c1| ≤ ǫ and supx≥k2 |g(x)− c2| ≤ ǫ. Set b1 = k1 − 2M and b2 = k2 + 2M . Then,
g(f) = g(Ef + f − Ef)1 (‖f − Ef‖∗F ≤M) + g(f)1 (‖f − Ef‖∗F > M), and
‖(En − E)g(f)‖F ≤ ‖(En − E)g(f)‖F1 (‖f − Ef‖∗F ≤M) + 2c01 (‖f − Ef‖∗F > M) .
We have that
‖(En − E)g(f)‖F1 (‖f − Ef‖∗F ≤M)
= ‖(En − E)g(Ef + f˙)‖F1 (‖f − Ef‖∗F ≤M)
≤ ‖(En − E)g(f)‖F˙ǫ1 (‖f − Ef‖∗F ≤M) + 2ǫ,
where f˙ = f − Ef and F˙ǫ =
{
c+ f˙ : f ∈ F , b1 ≤ c ≤ b2
}
. Since g is continuous and Cǫ =
{x : b1 ≤ x ≤ b2} is a compact set, there exists some δ > 0 such that
sup
x1,x2∈Cǫ:|x1−x2|≤δ
|g(x1)− g(x2)| ≤ ǫ.
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Let Dǫ be a finite subset of [b1, b2] such that supc∈[b1,b2] inf c˜∈Dǫ |c− c˜| ≤ δ. Now, define F˙∗ǫ ={
c+ f˙ : f ∈ F , c ∈ Dǫ
}
. Let c˜(c) = arg inf c˜∈Dǫ |c− c˜| and note that, provided ‖f −Ef‖∗F ≤M ,
sup
f1∈F˙ǫ
inf
f2∈F˙∗ǫ
‖g(f1)− g(f2)‖ ≤ sup
f∈F ,b1≤c≤b2
∣∣∣g (c+ f˙)− g {c˜(c) + f˙}∣∣∣
≤ sup
x1,x2∈Cǫ:|x1−x2|≤δ
|g(x1)− g(x2)|
≤ ǫ.
This implies that ‖(En − E)g(f)‖F˙ǫ ≤ ‖(En − E)g(f)‖F˙∗ǫ + 2ǫ and ‖(En − E)g(f)‖F˙∗ǫ ≤
maxc∈Dǫ ‖(En − E)g(c + f)‖F˙ , where F˙ = {f − Ef : f ∈ F}. We have that ‖(En − E)g(c +
f)‖F˙1 (‖f − Ef‖∗F ≤M) ≤ ‖(En − E)g(c + f)‖F˙ . Theorem 9.26 of Kosorok (2008) gives us
that
{
g(c+ f) : f ∈ F˙
}
is GC, since the mapping x 7→ g(c + x) is continuous and bounded and
F˙ has an integrable envelope. Thus, ‖(En − E)g(f)‖F ≤ oP (1) + 4ǫ + 2c01 (‖f − Ef‖F > M).
When Pr (‖f − Ef‖F > M) ≤ ǫ and ǫ is arbitrary, ‖(En − E)g(f)‖F = oP (1). Combining this
with Lemma 8.16 of Kosorok (2008), we obtain the desired convergence.
Additional Simulation Results
Table A.1 below contains optimal sensitivities and specificities averaged across replications
for the four methods when the true generative model is nonlinear.
Table A.2 below contains estimated sensitivities and specificities of an unweighted SVM
when the true model is nonlinear.
Table A.3 below contains estimated AUC’s averaged across replications and Monte Carlo
standard deviations of AUC’s for the four methods when the true generative model is linear. The
linear SVM and logistic regression perform the best across n, p, and q. The Gaussian SVM per-
forms poorly when p = 10 due to the presence of noise variables and the semiparametric ROC
curve performs poorly when p > 2 because it only uses a single component of X.
Table A.4 contains optimal sensitivities and specificities averaged across replications for the
four methods when the true generative model is linear. When the true generative model is linear,
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Linear SVM Gaussian SVM Logistic Semiparametric
n p q se sp se sp se sp se sp
250 2 0.05 0.64 0.59 0.70 0.77 0.61 0.58 0.53 0.58
0.25 0.58 0.69 0.73 0.80 0.59 0.66 0.56 0.61
5 0.05 0.69 0.68 0.71 0.72 0.68 0.70 0.51 0.58
0.25 0.69 0.73 0.72 0.75 0.70 0.73 0.56 0.62
10 0.05 0.67 0.70 0.56 0.55 0.67 0.69 0.52 0.59
0.25 0.68 0.74 0.68 0.44 0.69 0.72 0.56 0.62
500 2 0.05 0.64 0.55 0.71 0.78 0.64 0.54 0.53 0.58
0.25 0.60 0.66 0.71 0.78 0.60 0.62 0.56 0.61
5 0.05 0.68 0.68 0.71 0.75 0.66 0.69 0.51 0.59
0.25 0.69 0.73 0.73 0.78 0.69 0.72 0.56 0.62
10 0.05 0.66 0.67 0.63 0.53 0.67 0.67 0.51 0.58
0.25 0.68 0.73 0.72 0.45 0.69 0.70 0.56 0.62
Table A.1: Average optimal sensitivity and specificity when true model is nonlinear.
Linear SVM Gaussian SVM
n p q se sp se sp
250 2 0.05 0.91 0.16 0.74 0.65
0.25 0.88 0.20 0.77 0.65
5 0.05 0.58 0.72 0.64 0.70
0.25 0.70 0.64 0.76 0.61
10 0.05 0.58 0.71 0.18 0.85
0.25 0.69 0.64 0.81 0.24
500 2 0.05 0.93 0.14 0.74 0.69
0.25 0.94 0.10 0.76 0.66
5 0.05 0.60 0.71 0.68 0.72
0.25 0.71 0.67 0.77 0.66
10 0.05 0.59 0.70 0.25 0.82
0.25 0.70 0.65 0.85 0.24
Table A.2: Average sensitivity and specificity of unweighted SVM when true model is nonlinear.
logistic regression and the linear SVM outperform the other methods in terms of sensitivity and
specificity. The Gaussian SVM performs poorly in the presence of noise variables.
Table A.5 contains estimated sensitivities and specificities of an unweighted SVM when the
true model is linear.
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n p q Linear SVM Gaussian SVM Logistic Semiparametric
250 2 0.05 0.83 (0.05) 0.80 (0.05) 0.82 (0.05) 0.80 (0.03)
0.25 0.84 (0.04) 0.82 (0.06) 0.84 (0.05) 0.81 (0.03)
5 0.05 0.87 (0.05) 0.75 (0.06) 0.87 (0.05) 0.77 (0.03)
0.25 0.89 (0.04) 0.79 (0.05) 0.89 (0.03) 0.78 (0.03)
10 0.05 0.85 (0.05) 0.53 (0.03) 0.86 (0.04) 0.77 (0.03)
0.25 0.87 (0.05) 0.54 (0.04) 0.88 (0.04) 0.78 (0.03)
500 2 0.05 0.83 (0.04) 0.82 (0.04) 0.83 (0.04) 0.80 (0.02)
0.25 0.85 (0.03) 0.83 (0.03) 0.84 (0.03) 0.81 (0.02)
5 0.05 0.88 (0.03) 0.79 (0.04) 0.88 (0.03) 0.77 (0.02)
0.25 0.90 (0.03) 0.82 (0.04) 0.89 (0.03) 0.78 (0.02)
10 0.05 0.86 (0.03) 0.55 (0.04) 0.88 (0.03) 0.77 (0.02)
0.25 0.89 (0.03) 0.59 (0.05) 0.89 (0.03) 0.78 (0.02)
Table A.3: Average AUC when true model is linear.
Linear SVM Gaussian SVM Logistic Semiparametric
n p q se sp se sp se sp se sp
250 2 0.05 0.78 0.77 0.76 0.76 0.78 0.77 0.73 0.72
0.25 0.80 0.78 0.78 0.77 0.79 0.78 0.73 0.73
5 0.05 0.81 0.82 0.74 0.71 0.82 0.82 0.70 0.70
0.25 0.83 0.84 0.76 0.75 0.83 0.84 0.71 0.71
10 0.05 0.81 0.81 0.50 0.55 0.83 0.79 0.70 0.69
0.25 0.83 0.82 0.49 0.59 0.82 0.83 0.71 0.71
500 2 0.05 0.77 0.77 0.76 0.76 0.78 0.76 0.73 0.72
0.25 0.78 0.78 0.78 0.77 0.78 0.77 0.74 0.73
5 0.05 0.82 0.81 0.77 0.72 0.82 0.81 0.70 0.70
0.25 0.83 0.83 0.79 0.74 0.82 0.83 0.71 0.71
10 0.05 0.80 0.81 0.45 0.64 0.82 0.80 0.70 0.70
0.25 0.82 0.82 0.57 0.59 0.83 0.81 0.71 0.71
Table A.4: Average optimal sensitivity and specificity when true model is linear.
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Linear SVM Gaussian SVM
n p q se sp se sp
250 2 0.05 0.60 0.86 0.57 0.85
0.25 0.70 0.81 0.68 0.79
5 0.05 0.62 0.89 0.37 0.88
0.25 0.74 0.86 0.54 0.83
10 0.05 0.62 0.88 0.00 1.00
0.25 0.73 0.85 0.02 0.99
500 2 0.05 0.63 0.84 0.61 0.84
0.25 0.72 0.80 0.71 0.79
5 0.05 0.63 0.90 0.45 0.87
0.25 0.74 0.87 0.61 0.82
10 0.05 0.62 0.90 0.00 1.00
0.25 0.73 0.86 0.02 0.99
Table A.5: Average sensitivity and specificity of unweighted SVM when true model is linear.
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APPENDIX B: TECHNICAL DETAILS FOR CHAPTER 3
Proof of Lemma 3.1. Let π be an arbitrary policy and γ ∈ (0, 1) a fixed constant. Suppose we
observe a state St = st at time t and let at−1 = (a1, . . . , at−1) be the sequence of actions resulting
in St = st, i.e., S∗t(at−1) = st. Let ak+1 = (at, . . . , at+k) ∈ Ak+1 be a potential sequence of
actions taken from time t to time t+ k. We have that
V (π, st)
=
∑
k≥0
γkE
{
U∗(t+k)(π)
∣∣∣∣St = st}
=
∑
k≥0
γkE
 ∑
at+k∈At+k
U∗(t+k)(at+k)
t+k∏
v=t
1
[
ξvπ
{
S∗v(av−1)
}
= av
] ∣∣∣∣St = st

=
∑
k≥0
γk
∑
ak+1∈Ak+1
U∗(t+k)(at−1, ak+1)
{
t+k∏
v=t
E
(
1
[
ξvπ
{
S∗v(av−1)
}
= av
] ∣∣∣∣St = st)
}
=
∑
k≥0
γk
∑
ak+1∈Ak+1
U∗(t+k)(at−1, ak+1)
t+k∏
v=t
π
{
av;S∗v(av−1)
} t+k∏
v=t
µv {av;S∗v(av−1)}
µv {av;S∗v(av−1)}
=
∑
k≥0
γkE
[
U t+k
{
k∏
v=0
π(at+v; st+v)
µt+v(at+v; st+v)
}∣∣∣∣St = st
]
,
where we let π(at; st) = 0 for all at and st whenever t > T ∗(π). The last equality uses the consis-
tency and strong ignorability assumptions.
Proof of Theorem 3.1. Proof of part 1: We first note that θπ0 must solve
0 = E
(
π(At;St)
µt(At;St)
[
U t +
{
γΦ(St+1)− Φ(St)}⊺ θπ]Φ(St)) ,
or
E
[
π(At;St)
µt(At;St)
Φ(St)
{
Φ(St)− γΦ(St+1)}⊺] θπ = E{ π(At;St)
µt(At;St)
U tΦ(St)
}
,
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which is equal to w1(π)θπ = w2(π) where w2(π) = E {π(At;St)µt(At;St)−1U tΦ(St)}. We have
that ∥∥∥∥E{ π(At;St)µt(At;St)U tΦ(St)
}∥∥∥∥ ≤ c−10 (E|U t|2)1/2 (E‖Φ(St)‖2)1/2 <∞,
by assumption 3.3, part 1 of assumption 3.4 and the Cauchy–Schwarz inequality. Let c ∈ Rq be
arbitrary and note that
E
{
π(At;St)
µt(At;St)
c⊺Φ(St)Φ(St+1)⊺c
}
≤
[
E
{
π(At;St)
µt(At;St)
c⊺Φ(St)⊗2c
}
· E
{
π(At;St)
µt(At;St)
c⊺Φ(St+1)⊗2c
}]1/2
,
by the Cauchy–Schwarz inequality, where u⊗2 = uu⊺. This implies that
c⊺w1(π)c ≥ E
{
π(At;St)
µt(At;St)
c⊺Φ(St)⊗2c
}
−E
{
π(At;St)
µt(At;St)
c⊺Φ(St)⊗2c
}1/2
E
{
γ2
π(At;St)
µt(At;St)
c⊺Φ(St+1)⊗2c
}1/2
= A− A1/2B1/2
= A1/2(A1/2 −B1/2)
=
A1/2(A− B)
A1/2 + B1/2
,
where we simplify notation by defining A = E {π(At;St)µt(At;St)−1c⊺Φ(St)⊗2c} and B =
E {γ2π(At;St)µt(At;St)−1c⊺Φ(St+1)⊗2c}. We have that
A1/2 + B1/2 ≤ c−1/20 ‖c‖
{
E‖Φ(St)‖2}1/2 + c−1/20 ‖c‖{E‖Φ(St+1)‖2}1/2
= 2c
−1/2
0 ‖c‖
{
E‖Φ(St)‖2}1/2
< ∞,
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by the Cauchy–Schwarz inequality, the fact that E‖Φ(St)‖2 = E‖Φ(St+1)‖2 by time-homogeneity,
and part 1 of assumption 3.4. Also, A ≥ A−B and A−B ≥ c1‖c‖2 by assumption 3.5. Thus,
A− A1/2B1/2 ≥ c
3/2
1 ‖c‖3
2c
−1/2
0 ‖c‖ {E‖Φ(St)‖2}1/2
=
c
1/2
0 c
3/2
1 ‖c‖2
2 {E‖Φ(St)‖2}1/2
,
which finally implies that w1(π) is invertible and thus θπ0 = w1(π)−1w2(π) is well-defined uni-
formly over π ∈ Π. Using the fact that c⊺w1(π)c ≥ k0‖c‖2 for a constant k0 > 0, we can show
that ‖w1(π)−1‖ ≤ k−11 for some constant k1 > 0, where ‖ · ‖ is the usual matrix norm when
applied to a matrix. Therefore,
‖θπ0‖ ≤ k−11 ‖w2(π)‖ ≤ c−10 k−11
{
E(U t)2
}1/2 {
E‖Φ(St)‖2}1/2 <∞.
Finally, it follows from assumptions 3.5 and 3.7 that sup‖β1−β2‖≤δ ‖θπβ1 − θπβ2‖ → 0 as δ ↓ 0.
Proof of part 2: Define
G = {Φ(st)Φ(st)⊺/µt(at; st), γΦ(st)Φ(st+1)⊺/µt(at; st), utΦ(st)/µt(at; st)} .
Let G be an envelope for G, for example G(st+1, at, st) = maxg∈G g(st+1, at, st). By part 1 of
assumption 3.4, EG3ρ < ∞. Part 4 of Lemma B.1 below gives us that G is Donsker. Since Π
satisfies J[] {∞,Π, L3ρ(P )} <∞, we have that
F1 =
{
π(at; st)
µt(at; st)
Φ(st)
{
Φ(st)− γΦ(st+1)}⊺ : π ∈ Π}
satisfies J[] {∞,F1, L3ρ(P )} < ∞ by parts 1 and 2 of Lemma B.1 below. Moreover, F (at, st) =
‖Φ(st)‖ · ‖Φ(st)− γΦ(st+1)‖/µt(at; s⊺) is an envelope for F1 with EF 3ρ <∞ by assumption 3.3
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and part 1 of assumption 3.4. Thus, F1 is Donsker. Let
F2 =
{
π(at; st)
µt(at; st)
utΦ(st) : π ∈ Π
}
.
Similar arguments yield that F2 is Donsker.
Now, let Â(π) = {Enf1π : f1π ∈ F1} and B̂(π) = {Enf2π : f2π ∈ F2}. Let Â′(π) =
Â(π) + λnÂ(π)
−1
. We have that θ̂πn = Â′(π)−1B̂(π). Thus,
√
n
(
θ̂πn − θπ0
)
=
√
n
{
Â′(π)−1B̂(π)− Â′(π)−1Â′(π)θπ0
}
+ oP (1)
= Â′(π)−1
√
n
{
B̂(π)− Â′(π)θπ0
}
+ oP (1)
= Â′(π)−1
√
n
{
B̂(π)− Â(π)θπ0
}
+ Â′(π)−1
√
n
{
Â(π)− Â′(π)
}
θπ0 + oP (1)
= Â′(π)−1
√
n
{
B̂(π)− Â(π)θπ0
}
+ oP (1)
where oP (1) doesn’t depend on π, because Â′(π)−1
P−→ w1(π)−1 < ∞ uniformly over π ∈ Π
by assumption 3.3 and part 1 of assumption 3.4, supπ∈Π ‖θπ0‖ < ∞ by part 1 of this theorem, and
√
n
{
Â(π)− Â′(π)
}
=
√
nλnÂ(π)
−1 = oP (1) because λn = oP (n−1/2). Using arguments
similar to those in the previous paragraph, one can show that
F3 = {f2π − f1πθ : f1π ∈ F1, f2π ∈ F2, π ∈ Π, θ ∈ B∗}
is Donsker, where B∗ is any finite collection of elements of Rq. By part 1 of this theorem, there
exists a bounded, closed set B0 such that θπ0 ∈ B0 for all π ∈ Π. Let Gn(π, θ) =
√
n(En −
E)(f2π − f1πθ). Note that
sup
π∈Π
‖Gn(π, θ1)−Gn(π, θ2)‖ ≤ sup
π∈Π
‖√n(En − E)f1π‖ · ‖θ1 − θ2‖
≤ R∗‖θ1 − θ2‖,
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where R∗ = OP (1) by the Donsker property of F1 and R∗ doesn’t depend on π. Thus, Gn(π, θ)
is stochastically equicontinuous on B0. Combined with the Donsker property of F3 for arbitrary
B∗, we have that the class F4 = {f2π−f1πθ : f1π ∈ F1, f2π ∈ F2, π ∈ Π, θ ∈ B0} is Donsker. Us-
ing Slutsky’s Theorem, Theorem 11.24 of Kosorok (2008), the fact that F1 is Glivenko–Cantelli,
and the fact that θπ0 = (Ef1π)−1Ef2π, we have that
√
n
(
θ̂πn − θπ0
)
= Â′(π)−1Gn(π, θ
π
0 )  
w1(π)
−1
G0(π) in ℓ∞(Π), where G0(π) is a mean zero Gaussian process indexed by Π with co-
variance E {G0(π1)G0(π2)} = w0(π1, π2).
Proof of part 3: We have that
√
n
{
V̂n,R̂(π)− VR(π)
}
=
√
nEnΦ(S
t)
(
θ̂πn − θπ0
)
 ν⊺w1(π)
−1
G0(π)
in ℓ∞(Π) by Slutsky’s Theorem.
Proof of Theorem 3.2. Proof of part 1: Following the proof of part 3 of Theorem 3.1, we can
show that supβ∈B
∣∣∣V̂n,R̂(πβ)− VR(πβ)∣∣∣ P−→ 0. Combining this with the unique and well separated
maximum condition (assumption 3.6), continuity of VR(πβ) in β, and Theorem 2.12 of Kosorok
(2008) yields the result in part 1. Part 2 follows from parts 2 and 3 of Theorem 3.1. The proof of
part 3 follows standard arguments.
Lemma B.1. Let F and G be function classes with respective envelopes F and G. Let ‖F‖u =
(E|F |u)1/u. For any 1 ≤ r, s1, s2 ≤ ∞ with s−11 + s−12 = 1,
1.
J[]{∞,F · G, Lr(P )} ≤ 2 (‖F‖rs1 + ‖G‖rs2)
[
J[]{∞,F , Lrs1(P )}
+ J[]{∞,G, Lrs2(P )}
]
.
2. J[]{∞,F + G, Lr(P )} ≤ 2
[
J[]{∞,F , Lr(P )}+ J[]{∞,G, Lr(P )}
]
.
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3. For any 0 ≤ r ≤ ∞, J[]{∞,F ∪G, Lr(P )} ≤
√
log 2(‖F‖r + ‖G‖r) + J[]{∞,F , Lr(P )}+
J[]{∞,G, Lr(P )}.
4. If G is a finite class, J[]{∞,G, Lr(P )} ≤ 2‖G‖r
√
log |G|, where |G| denotes the cardinality
of G.
Proof of Lemma B.1. Proof of part 1: Let 1 ≤ r, s1, s2 ≤ ∞ with s−11 + s−12 = 1 and let (ℓF , uF )
and (ℓG, uG) be Lrs1(P ) and Lrs2(P ) ǫ-brackets, respectively. Choose ℓF ≤ f1, f2 ≤ uF and
ℓG ≤ g1, g2 ≤ uG and consider the bracket for any f2g2 defined by f1g1±(F |uG − ℓG|+G|uF − ℓF |).
Note that
f1g1+F |uG−ℓG|+G|uF −ℓF |−f2g2 ≥ F |uG−ℓG|+G|uF −ℓF |−F |g1−g2|−G|f1−f2| ≥ 0,
because f2g2 − f1g1 = f2g2 + f2g1 − f2g1 − f1g1 ≤ F |g1 − g2| + G|f1 − f2|. Similarly,
f2g2 + F |uG − ℓG|+G|uF − ℓF | − f1g1 ≥ 0. Thus, these brackets hold all f2g2 for f2 ∈ (ℓF , uF )
and g2 ∈ (ℓG, uG). Now, ‖F |uG − ℓG| + G|uF − ℓF |‖r ≤ ‖F‖rs1ǫ + ‖G‖rs2ǫ by Minkowski’s
inequality and Ho¨lder’s inequality and it follows that
N[] {2ǫ(‖F‖rs1 + ‖G‖rs2),F · G, Lr(P )} ≤ N[] {ǫ,F , Lrs1(P )}N[] {ǫ,G, Lrs2(P )} .
Next we note that
N[] {ǫ,F · G, Lr(P )} ≤ N[]
{
ǫ
2(‖F‖rs1 + ‖G‖rs2)
,F , Lrs1(P )
}
×N[]
{
ǫ
2(‖F‖rs1 + ‖G‖rs2)
,G, Lrs2(P )
}
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and thus
J[] {∞,F · G, Lr(P )}
≤
∫ 2‖F‖rs1‖G‖rs2
0
√
logN[]
{
ǫ
2(‖F‖rs1 + ‖G‖rs2)
,F , Lrs1(P )
}
dǫ
+
∫ 2‖F‖rs1‖G‖rs2
0
√
logN[]
{
ǫ
2(‖F‖rs1 + ‖G‖rs2)
,G, Lrs2(P )
}
dǫ
≤ 2 (‖F‖rs1 + ‖G‖rs2)
[
J[]{∞,F , Lrs1(P )}+ J[]{∞,G, Lrs2(P )}
]
.
The proof of part 2 follows from Lemma 9.25 part (i) of Kosorok (2008) after applying a
change of variables. Proof of part 3: First note that
N[] {ǫ,F ∪ G, Lr(P )} ≤ N[] {ǫ,F , Lr(P )}+N[] {ǫ,G, Lr(P )} ,
whence it follows that
J[] {∞,F ∪ G, Lr(P )}
=
∫ 2(‖F‖r+‖G‖r)
0
√
logN[] {ǫ,F ∪ G, Lr(P )}dǫ
≤
∫ 2(‖F‖r+‖G‖r)
0
√
log
[
N[] {ǫ,F , Lr(P )}+N[] {ǫ,G, Lr(P )}
]
dǫ
≤
∫ 2(‖F‖r+‖G‖r)
0
√
log 2 + logN[] {ǫ,F , Lr(P )}+ logN[] {ǫ,G, Lr(P )}dǫ
≤
∫ 2(‖F‖r+‖G‖r)
0
√
log 2dǫ+ J[] {∞,F , Lr(P )}+ J[] {∞,G, Lr(P )} ,
where the second inequality uses the fact that a+ b ≤ 2ab for all a, b ≥ 1.
Proof of part 4: If G is finite, then N[] {ǫ,G, Lr(P )} ≤ |G|. Thus,
J[] {∞,G, Lr(P )} =
∫ 2‖G‖r
0
√
logN[] {ǫ,G, Lr(P )}dǫ
≤
∫ 2‖G‖r
0
√
log |G|dǫ,
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which completes the proof.
Lemma B.2. Define the class of functions
Π =
{
πβ˜(a; s) =
aJ +
∑J−1
j=1 ajexp(s
⊺
jβj)
1 +
∑J−1
j=1 exp(s
⊺
jβj)
: β˜ = (β⊺1 , . . . , β
⊺
J−1)
⊺, β˜ ∈ B ⊂ Rp(J−1)
}
for a compact set B and 2 ≤ J < ∞ where a = (a1, . . . , aJ)⊺. Then, there exists a b0 < ∞ such
that for any 1 ≤ r ≤ ∞, J[]{∞,Π, Lr(P )} ≤ b0‖S‖r
√
p(J − 1)π, which is finite whenever
‖S‖r <∞. Furthermore, sup‖β˜1−β˜2‖≤δ E‖πβ˜1(A;S)− πβ˜2(A;S)‖ → 0 as δ ↓ 0.
Proof of Lemma B.2. For β˜1, β˜2 ∈ B, define d(β˜1, β˜2) = max1≤j≤J−1‖β˜1j − β˜2j‖ and b0 =
supβ˜1,β˜2∈B ‖β˜1 − β˜2‖ < 0 because B is compact. By the mean value theorem, for any β˜1, β˜2 ∈ B,
there exists a point β˜∗ on the line segment between β˜1 and β˜2 such that
πβ˜1(a; s)− πβ˜2(a; s) =
1
1 +
∑J−1
j=1 exp(s
⊺β˜∗j)
×
[
J−1∑
j=1
{
aj − πβ˜∗(a; s)
}
exp(s⊺β˜∗j)s
⊺(β˜1j − β˜2j)
]
,
which implies that
|πβ˜1(a; s)− πβ˜2(a; s)| ≤ ‖s‖d(β˜1, β˜2). (B.1)
It follows from equation (B.1) that assumption 3.7 holds for this particular class of policies. Now,
N[] {2ǫ‖S‖r,Π, Lr(P )} ≤ N(ǫ,B, d) by Theorem 9.23 of Kosorok (2008). Furthermore,
N(ǫ,B, d) ≤ max{(b0/ǫ)p(J−1), 1} ,
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and thus
J[] {ǫ,Π, Lr(P )} ≤ 2‖S‖r
∫ b0
0
√
p(J − 1) {log b0 + log(1/ǫ)}dǫ
≤ 2‖S‖rb0
√
p(J − 1)
∫ 1
0
√
log(1/ǫ)dǫ
= 2‖S‖rb0
√
p(J − 1)
∫ ∞
0
u1/2exp(−u)du
= ‖S‖rb0
√
p(J − 1)π,
which proves the result.
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APPENDIX C: TECHNICAL DETAILS FOR CHAPTER 4
Proof of Theorem 4.1. The log of the pseudo-likelihood is given by
ℓ̂n(θ, β) = En
[
X⊺β1
{
A = d̂θ,n(X)
}
− log {1 + exp (X⊺β)}
]
.
Let m̂(·, ·; θ, β) : X × A → R be defined by m̂(X, A; θ, β) = X⊺β1
{
A = d̂θ,n(X)
}
−
log {1 + exp (X⊺β)} and consider the class of functions {m̂(·, ·; θ, β) : θ ∈ Rp, β ∈ B}. The
class {log {1 + exp(X⊺β)} : β ∈ B} is contained in a VC class by Lemma 9.9 (viii) and (v) of
Kosorok (2008). By Theorem 9.3 of Kosorok (2008), this is also a Glivenko–Cantelli (GC) class.
Let u(X, A; θ) = ω(X; θ)
{
Q̂Y,n(X, A)− Q̂Z,n(X, A)
}
− Q̂Z,n(X, A), which lies in a VC
class indexed by θ ∈ Rp by Lemma 9.6 and Lemma 9.9 (viii), (vi), and (v) of Kosorok (2008).
We have that
1
{
A = d̂θ,n(X)
}
= 1(A = 1)1 {u(X, 1; θ)− u(X,−1, θ) ≥ 0}
+ 1(A = −1)1 {u(X, 1; θ)− u(X,−1, θ) < 0} ,
and it follows that 1
{
A = d̂θ,n(X)
}
is contained in a GC class indexed by θ ∈ Rp. From Corol-
lary 9.27 (ii) of Kosorok (2008) it follows that X⊺β1
{
A = d̂θ,n(X)
}
lies in a GC class indexed
by (θ, β) ∈ Rp × B as long as X⊺β is uniformly bounded by a function with finite mean, which
holds as long as B is compact and ‖EX‖ <∞. It follows that
sup
(θ,β)∈Rp×B
∣∣∣(En − E) [X⊺β1{A = d̂θ,n(X)}− log {1 + exp(X⊺β)}]∣∣∣ P−→ 0.
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Next, define
M̂(θ, β) = E {m̂(X, A; θ, β)} = E
(
X⊺βE
[
1
{
A = d̂θ,n(X)
}
|X
])
− E log {1 + exp(X⊺β)}
and note that M̂(θ, β) is continuous in β. The inside expectation of the first piece is
E
[
1
{
A = d̂θ,n(X)
}
|X
]
= expit(X⊺β0)1
{
d̂θ,n(X) = d
opt
θ0
(X)
}
+ {1− expit(X⊺β0)} 1
{
d̂θ,n(X) 6= doptθ0 (X)
}
,
using the fact that Pr
{
A = doptθ0 (X)
}
= expit(X⊺β0). Define a(X) = QY (X, 1)−QY (X,−1)−
QZ(X, 1) + QZ(X,−1) and b(X) = QZ(X, 1) − QZ(X,−1). Similarly, define â(X) =
Q̂Y,n(X, 1)− Q̂Y,n(X,−1)− Q̂Z,n(X, 1) + Q̂Z,n(X,−1) and b̂(X) = Q̂Z,n(X, 1)− Q̂Z,n(X,−1).
Then,
1
{
d̂θ,n(X) = d
opt
θ0
(X)
}
= 1
[{
ω(X; θ)â(X) + b̂(X)
}
{ω(X; θ)a(X) + b(X)} ≥ 0
]
= 1
[
ω(X; θ) {ω(X; θ)a(X)â(X) + â(X)b(X)}
+ω(X; θ)a(X)̂b(X) + b̂(X)b(X) ≥ 0
]
,
and thus E
[
1
{
A = d̂θ,n(X)
}
|X
]
is continuous in θ.
Let m(X, A; θ, β) = X⊺β1
{
A = doptθ (X)
} − log {1 + exp (X⊺β)}. Because the model is
identifiable and Ln(θ, β) is a parametric log-likelihood, Em(X, A; θ, β) has unique maximizers
at θ0 and β0. Let θ˜ and β˜ be the maximizers of Em̂(X, A; θ, β). Because E
{
d̂θ,n(X)|X = x
}
=
doptθ (x) for any x ∈ X and θ ∈ Rp,
E
[
1
{
A = d̂θ,n(X)
}
|X
]
= E
[
1
{
A = doptθ (X)
} |X] ,
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which implies that Em(X, A; θ, β) = Em̂(X, A; θ, β). Thus, θ˜ = θ0 and β˜ = β0. The claim now
follows from Lemma 14.3 and Theorem 2.12 of Kosorok (2008).
Proof of Theorem 4.2. Define Qθ0(x, a) and Qθ̂n(x, a) as defined in Section 4.2. Let
u(Y, Z;A,X, θ) = ω(X; θ)QY (X, A) + {1− ω(X; θ)}QZ(X, A).
Under the given assumptions, for some constant 0 < c <∞,
∣∣∣V (d̂θ̂n,n)− V (doptθ0 )∣∣∣
≤ c
∣∣∣∣E{u(Y, Z;A,X, θ0)− Q̂θ̂n,n(X, A)}2 − E {u(Y, Z;A,X, θ0)−Qθ0(X, A)}2∣∣∣∣1/2 (C.1)
by equation (3.1) of Qian and Murphy (2011) (see also Murphy, 2005). The right hand side of
(C.1) converges in probability to 0 by the consistency of θ̂n, consistency of Q̂Y,n and Q̂Z,n, and
the continuous mapping theorem. The result follows.
Proof of Theorem 4.3. By definition of
(
θ̂n, β̂n
)
,
0 ≤ ℓ̂n
(
θ̂n, β̂n
)
− ℓ̂n (θ0, β0)
=
n∑
i=1
[
X
⊺
i β̂n1
{
Ai = d̂θ̂n,n(Xi)
}
−X⊺i β01
{
Ai = d̂θ0,n(Xi)
}
−
(
β̂n − β0
)
⊺
XiPβ0(Xi)
]
− 1
2
√
n
(
β̂n − β0
)
⊺
In(β∗)
√
n
(
β̂n − β0
)
=
√
n
(
β̂n − β0
)
⊺
n−1/2
n∑
i=1
Xi
[
1
{
Ai = d̂θ̂n,n(Xi)
}
− Pβ0(Xi)
]
−1
2
√
n
(
β̂n − β0
)
⊺
In(β∗)
√
n
(
β̂n − β0
)
+
n∑
i=1
X
⊺
i β0
[
1
{
Ai = d̂θ̂n,n(Xi)
}
− 1
{
Ai = d̂θ0,n(Xi)
}]
,
where β∗ is a point between β̂n and β0. Using the definition of a maximizer and letting ûn(θ) =
n−1/2
∑n
i=1Xi
[
1
{
Ai = d̂θ,n(Xi)
}
− Pβ0(Xi)
]
, we have that
√
n
(
β̂n − β0
)
= In(β∗)
−1ûn
(
θ̂n
)
,
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since In(β∗)
P−→ I0 and I0 is positive definite. Next, note that
ûn
(
θ̂n
)
= n−1/2
n∑
i=1
Xi
[
1
{
Ai = d̂θ̂n,n(Xi)
}
− 1{Ai = doptθ0 (Xi)}]+ ZA,n
= Gn
(
X
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}])+ ZA,n
+
√
nE
(
X
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}])
= ZA,n +
√
nE
(
X
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}]) {1 + oP (1)} ,
where Gnf = n1/2(En − E)f(X). We also have 1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)} =
− [2 · 1{A = doptθ0 (X)}− 1] 1{d̂θ̂n,n(X) 6= doptθ0 (X)}, which implies that
√
nE
(
X
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}])
= −√nE
[
X {2Pβ0(X)− 1} 1
{
d̂θ̂n,n(X) 6= d
opt
θ0
(X)
}]
= −√nE
{
X {2Pβ0(X)− 1}
(
1
[
0 ≤ Dθ0(X) < −
{
D̂θ̂n,n(X)−Dθ0(X)
}]
+1
[
−
{
D̂θ̂n,n(X)−Dθ0(X)
}
≤ Dθ0(X) < 0
] )}
= −E
[
X {2Pβ0(X)− 1} ·
∣∣∣√n{D̂θ̂n,n(X)−Dθ0(X)}∣∣∣ ∣∣∣Dθ0(X) = 0] f0 + oP (1)
by Assumption 4.5 and the fact that
∥∥∥D̂θ̂n,n(x)−Dθ0(x)∥∥∥X = oP (1). Note that
√
n
{
D̂θ̂n,n(X)−Dθ0(X)
}
=
√
n
[
ω
(
X; θ̂n
){
R̂Y,n(X)−RY (X)
}
+
{
1− ω
(
X; θ̂n
)}{
R̂Z,n(X)−RZ(X)
}]
+
√
n
{
ω
(
X; θ̂n
)
− ω (X; θ0)
}
{RY (X)−RZ(X)}
= ω (X; θ0)φY (X)
⊺ZY,n + {1− ω (X; θ0)}φZ(X)⊺ZZ,n
+ω˙θ0(X) {RY (X)−RZ(X)}
√
n
(
θ̂n − θ0
)
{1 + oP (1)}
= OP
(
1 +
√
n
∥∥∥θ̂n − θ0∥∥∥) ,
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thus,
∥∥∥ûn (θ̂n)∥∥∥ = OP (1 +√n ∥∥∥θ̂n − θ0∥∥∥). Letting
vn
(
θ̂n, β∗
)
= n−1/2ûn
(
θ̂n
)
⊺
In(β∗)ûn
(
θ̂n
)
,
0 ≤ n−1/2
{
ℓ̂n
(
θ̂n, β̂n
)
− ℓ̂n (θ0, β0)
}
= n−1/2
n∑
i=1
X
⊺
i β0
[
1
{
Ai = d̂θ̂n,n(X)
}
− 1
{
Ai = d̂θ0,n(X)
}]
+ vn
(
θ̂n, β∗
)
/2
= n1/2E
(
X⊺β0
[
1
{
A = d̂θ̂n,n(X)
}
− 1
{
A = d̂θ0,n(X)
}])
+oP
(
1 +
√
n
∥∥∥θ̂n − θ0∥∥∥)
= n1/2E
(
X⊺β0
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}])
−n1/2E
(
X⊺β0
[
1
{
A = d̂θ0,n(X)
}
− 1{A = doptθ0 (X)}])
+oP
(
1 +
√
n
∥∥∥θ̂n − θ0∥∥∥)
= −E
[
X⊺β0 {2Pβ0(X)− 1} ·
∣∣∣√n{D̂θ̂n,n(X)−Dθ0(X)}∣∣∣ ∣∣∣Dθ0(X) = 0] f0rn
+OP (1) + oP
(
1 +
√
n
∥∥∥θ̂n − θ0∥∥∥)
≤ −E
[
X⊺β0 {2Pβ0(X)− 1} ·
∣∣∣{RY (X)−RZ(X)} ω˙θ0(X)⊺√n(θ̂n − θ0)∣∣∣∣∣∣Dθ0(X) = 0]f0rn +OP (1) + oP (1 +√n ∥∥∥θ̂n − θ0∥∥∥)
≤ −δ2δ21
(
exp(δ1)− 1
exp(δ1) + 1
)√
n
∥∥∥θ̂n − θ0∥∥∥ {1 + oP (1)}+OP (1)
+oP
(
1 +
√
n
∥∥∥θ̂n − θ0∥∥∥) ,
where rn = 1 + oP (1). This implies that
√
n
∥∥∥θ̂n − θ0∥∥∥ = OP (1). Let
Mn
(
θ̂n
)
= n−1/2
n∑
i=1
X
⊺
i β0
[
1
{
Ai = d̂θ̂n,n(X)
}
− 1
{
Ai = d̂θ0,n(X)
}]
+ vn
(
θ̂n, β∗
)
/2,
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let M(u) = β⊺0k0(ZY , ZZ , u), and let U = argminu∈RdM(u). We will show that Mn(θ0 +
u/
√
n)  M(u) in ℓ∞(K) for any compact K ⊂ Rd. Then, it will follow from arg max The-
orem (chapter 14 of Kosorok, 2008) that U˜n  U , where U˜n = argminu∈RdMn(θ0+u/
√
n). Let
hn(u) = θ0 + u/
√
n. Similar arguments along with Assumptions 4.6 and 4.5, yield that, for any
compact K ⊂ Rd,
argmin
u∈K
Mn {hn(u)}
= argmin
u∈K
n1/2E
(
X⊺β0
[
1
{
A = d̂hn(u),n(X)
}
− 1{A = doptθ0 (X)}])
= argmin
u∈K
n1/2E
{
X⊺β0 {2Pβ0(X)− 1}
(
1
[
−
{
D̂hn(u),n(X)−Dθ0(X)
}
≤ Dθ0(X) < 0
]
+ 1
[
0 ≤ Dθ0(X) < −
{
D̂hn(u),n(X)−Dθ0(X)
}])}
= argmin
u∈K
E
[
X⊺β0 {2Pβ0(X)− 1}
∣∣∣√n{D̂hn(u),n(X)−Dθ0(X)}∣∣∣∣∣∣Dθ0(X) = 0]f0 + oP (1),
However,
√
n
{
D̂hn(u),n(X)−Dθ0(X)
}
 ω (X; θ0)φY (X)
⊺ZY + {1− ω (X; θ0)}φZ(X)⊺ZZ
+R0(X)ω˙θ0(X)
⊺u
uniformly over X when X has its conditional distribution given Dθ0(X) = 0. This implies that
Mn(θ + u/
√
n)  M(u) in ℓ∞(K) as desired and thus U˜n  U . It is straightforward to verify
the remaining conclusions of the theorem using previous arguments.
Proof of Theorem 4.4. Using the assumptions, the fact that both √n
(
θ̂n − θ0
)
= OP (1) and
√
n
(
β̂n − β0
)
= OP (1), and standard arguments, we obtain that, for any compact K1 ⊂ Rq,
sup(Z⊺
Y
,Z⊺
Z
)⊺∈K1
∥∥∥T˜n {x, Z˜Y (ZY ), Z˜Z(ZZ)}− T0(x, ZY , ZZ)∥∥∥
X
= oP (1), where Z˜Y (ZY ) =
119
Σ̂
1/2
n Σ
−1/2
0 (Z
⊺
Y , 0
⊺, 0⊺)⊺, Z˜Z(ZZ) = Σ̂
1/2
n Σ
−1/2
0 (0
⊺, Z⊺Z , 0
⊺)⊺, and also
T0(x, ZY , ZZ) = ω(x; θ0)φY (x)
⊺ZY + {1− ω(x; θ0)}φZ(x)⊺ZZ .
Furthermore,
∥∥∥{R̂Y,n(x)− R̂Z,n(x)} ω˙θ̂n(x)⊺u− {RY (x)−RZ(x)} ω˙θ0(x)⊺u∥∥∥X
≤
∥∥∥∥ ∥∥∥{R̂Y,n(x)− R̂Z,n(x)} ω˙θ̂n(x)− {RY (x)−RZ(x)} ω˙θ0(x)∥∥∥ ∥∥∥∥
X
· ‖u‖
= OP
(
n−1/2
) ‖u‖,
∥∥∥D̂θ̂n,n(x)−Dθ0(x)∥∥∥X = OP (n−1/2), and ∥∥∥Pβ̂n(x)− Pβ0(x)∥∥∥X = OP (n−1/2). Thus,
sup
(Z⊺
Y
,Z⊺
Z
)⊺∈K1
En
[
‖X‖ ·
∣∣∣{2Pβ̂n(X)− 1} T˜n {X, Z˜Y (ZY ), Z˜Z(ZZ)}∣∣∣
× 1
hn
φ0
{
D̂θ̂n,n(X)
hn
}]
≤ OP (1)En
[
1
hn
φ0
{
D̂θ̂n,n(X)
hn
}]
. (C.2)
However,
En
(
1
hn
[
φ0
{
D̂θ̂n,n(X)
hn
}
− φ0
{
Dθ0(X)
hn
}])
= En
[
1
h3n
∫ 1
0
{
(1− s)Dθ0(X) + sD̂θ̂n,n(X)
}
φ0
{
(1− s)Dθ0(X) + sD̂θ̂n,n(X)
hn
}
ds
{
D̂θ̂n,n(X)−Dθ0(X)
}]
= OP
(
1
h3nn
1/2
)
En
[∫ 1
0
{
(1− s)Dθ0(X) + sD̂θ̂n,n(X)
}
φ0
{
(1− s)Dθ0(X) + sD̂θ̂n,n(X)
hn
}
ds
]
= OP
(
1
h3nn
1/2
)
OP (hn) = OP
(
1
h3nn
1/2
)
= oP (1),
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since |uφ0(u)| ≤ (2π)−1/2e−1 < ∞. Now, since E [h−1n φ0 {Dθ0(X)/hn}] P−→ f0, we have
that (C.2) is equal to OP (1). Thus, if ‖un‖ → ∞,
β̂⊺nk˜n
(
Z˜Y , Z˜Z , un
)
≥ En
[
β̂⊺nX
{
2Pβ̂n(X)− 1
}
·
∣∣∣{R̂Y,n(X)− R̂Z,n(X)} ω˙θ̂n(X)⊺un∣∣∣
· 1
hn
φ0
{
D̂θ̂n,n(X)
hn
}]
−OP (1), (C.3)
where the OP (1) is uniform over K1. Thus, up to the OP (1) added on the right-hand side,
(C.3) ≥ ‖un‖ inf
t∈Sd
En
[
β̂⊺nX
{
2Pβ̂n(X)− 1
} ∣∣∣{R̂Y,n(X)− R̂Z,n(X)} ω˙θ̂n(X)⊺t∣∣∣
× 1
hn
φ0
{
D̂θ̂n,n(X)
hn
}]
≥ ‖un‖
(
oP (1) + inf
t∈Sd
E
[
β⊺0X {2Pβ0(X)− 1} |{RY (X)−RZ(X)} ω˙θ0(X)⊺t|
× 1
hn
φ0
{
Dθ0(X)
hn
}])
= ‖un‖
(
oP (1) + inf
t∈Sd
E
[
β⊺0X {2Pβ0(X)− 1} |{RY (X)−RZ(X)} ω˙θ0(X)⊺t|∣∣∣Dθ0(X) = 0]f0)
≥ ‖un‖
[
oP (1) + δ2δ
2
1
{
exp(δ1)− 1
exp(δ1) + 1
}]
,
with the expectation taken over X. Let
Ûn (ZY , ZZ) = argmin
u∈Rd
β̂⊺nk˜n
{
Z˜Y (ZY ) , Z˜Z (ZZ) , u
}
,
where, if the arg min set has more than one element, one can be chosen randomly or algorithmi-
cally. Since the OP (1) above is uniform over K1, we conclude that
sup
(Z⊺
Y
,Z⊺
Z
)⊺∈K1
∥∥∥Ûn (ZY , ZZ)∥∥∥ = OP (1). (C.4)
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Now, let K2 be any compact subset of Rd. Previous and standard arguments give us that
sup
(Z⊺
Y
,Z⊺
Z
)⊺∈K1
sup
u∈K2
∥∥∥k˜n {Z˜Y (ZY ) , Z˜Z (ZZ) , u}− k0 (ZY , ZZ , u)∥∥∥ = oP (1).
Thus, we also have that
sup
(Z⊺
Y
,Z⊺
Z
)⊺∈K1
sup
u∈K2
∥∥∥β̂⊺nk˜n {Z˜Y (ZY ) , Z˜Z (ZZ) , u}− β⊺0k0 (ZY , ZZ , u)∥∥∥ = oP (1). (C.5)
Define U0(ZY , ZZ) = argmaxu∈Rdβ
⊺
0k0(ZY , ZZ , u). Previous arguments yield that
sup
(Z⊺
Y
,Z⊺
Z
)⊺∈K1
‖U0(ZY , ZZ)‖ = O(1). (C.6)
By Assumption 4.6, the arg min for each (Z⊺Y , Z
⊺
Z)
⊺ ∈ K1 is unique. Fix ǫ > 0. By (C.4), there
exists an m2 < ∞ such that Pr
(
sup(Z⊺
Y
,Z⊺
Z
)⊺∈K1
∥∥∥Ûn (ZY , ZZ)∥∥∥ < m2) ≥ 1 − ǫ for all n large
enough. By (C.6), we can enlarge m2 such that sup(Z⊺
Y
,Z⊺
Z
)⊺∈K1 ‖U0(ZY , ZZ)‖ < m2 < ∞. We
can also find an m1 < ∞ such that K1 ⊂ Kqm1 as defined in Corollary C.1. It is straightforward
to show that (1) and (3) in Corollary C.1 are satisfied by f(Z, u) = β⊺0k0(ZY , ZZ , u), where Z =
(Z⊺Y , Z
⊺
Z)
⊺
. Let fn(Z, u) = β̂⊺nk˜n(ZY , ZZ , u). Standard arguments and the given assumptions
yield that there exists a w1 <∞ such that supZ∈Kqm1 supu∈Kdm2 |fn(Z, u)| < w1 almost surely and
sup
Z1,Z2∈K
q
m1:‖Z1−Z2‖<δ
‖fn(Z1, u)− fn(Z2, u)‖Kdm2 < w1δ
for all δ > 0 and all n ≥ 1 almost surely. Every subsequence in (C.5) has a further subsequence
n′′ on which the convergence in probability to zero can be replaced with almost sure convergence.
Thus, (2) and (4) of Corollary C.1 apply, using the fact that minimizing is equivalent to maximiz-
ing after a change in sign. Setting Û∗n(ZY , ZZ) = argminu∈Kdm2 β̂
⊺
nk˜n
{
Z˜Y (ZY ) , Z˜Z (ZZ) , u
}
,
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Corollary C.1 yields that
sup
(Z⊺Y ,Z
⊺
Z)
⊺
∈Kqm1
∥∥∥Û∗n′′(ZY , ZZ)− U0(ZY , ZZ)∥∥∥→ 0
almost surely. Since this is true for every subsequence, we have that
sup
(Z⊺Y ,Z
⊺
Z)
⊺
∈Kqm1
∥∥∥Û∗n(ZY , ZZ)− U0(ZY , ZZ)∥∥∥ P−→ 0
as n→∞. Note that, on K2, Û∗n(ZY , ZZ) = Ûn(ZY , ZZ) for all (Z⊺Y , Z⊺Z)⊺ ∈ Kqm1 . Hence,
lim sup
n→∞
Pr
 sup(Z⊺Y ,Z⊺Z)⊺∈Kqm1
∥∥∥Ûn(ZY , ZZ)− U0(ZY , ZZ)∥∥∥ > ǫ

≤ lim sup
n→∞
[
Pr
{
Ûn(ZY , ZZ) ∈ K2,
sup
(Z⊺Y ,Z
⊺
Z)
⊺
∈Kqm1
∥∥∥Û∗n(ZY , ZZ)− U0(ZY , ZZ)∥∥∥ ≥ ǫ
}
+ Pr
{
Ûn(ZY , ZZ) ∈ Kc2
}]
≤ ǫ.
Since ǫ was arbitrary, we obtain that
sup
(Z⊺Y ,Z
⊺
Z)
⊺
∈Kqm1
∥∥∥Ûn(ZY , ZZ)− U0(ZY , ZZ)∥∥∥ = oP (1).
Let BL(B) be the space of all Lipschitz continuous functions mapping B→ R which are bounded
by 1 with Lipschitz constant 1. Let EZ be expectation with respect to Z∗0 = (Z∗Y ⊺, Z∗Z⊺, Z∗A⊺)
⊺ ∼
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N(0,Σ0). Let B0 (Z∗0) = I−10
[
Z∗A − k0
{
Z∗Y , Z
∗
Z , U˜n (Z
∗
0 )
}]
and let f ∈ BL
(
R
d+p
)
. Then,
∣∣∣EZ [f {U˜n(Z∗0), B˜n(Z∗0)}− f {U0(Z∗0), B0(Z∗0 )}]∣∣∣
≤
∣∣∣EZ [f {U˜n(Z∗0), B˜n(Z∗0)}− f {U0(Z∗0 ), B˜n(Z∗0 )}]∣∣∣
+
∣∣∣EZ [f {U0(Z∗0 ), B˜n(Z∗0)}− f {U0(Z∗0 ), B0(Z∗0)}]∣∣∣
=
∣∣∣EZ [f1 {U˜n(Z∗0 )}− f1 {U0(Z∗0)}]∣∣∣+ ∣∣∣EZ [f2 {B˜n(Z∗0 )}− f2 {B0(Z∗0)}]∣∣∣
for some other f1 ∈ BL
(
R
d
)
and f2 ∈ BL (Rp). Hence,
sup
f∈BL(Rd+p)
∣∣∣EZf {U˜n(Z∗0), B˜n(Z∗0)}− EZf {U0(Z∗0), B0(Z∗0)}∣∣∣
≤ sup
f∈BL(Rd)
∣∣∣EZf {U˜n(Z∗0)}− EZf {U0(Z∗0)}∣∣∣
+ sup
f∈BL(Rp)
∣∣∣EZf {B˜n(Z∗0)}− EZf {B0(Z∗0)}∣∣∣
= An + Bn,
where we define both
An = supf∈BL(Rd)
∣∣∣EZf {U˜n(Z∗0)}− EZf {U0(Z∗0)}∣∣∣
and
Bn = supf∈BL(Rp)
∣∣∣EZf {B˜n(Z∗0)}− EZf {B0(Z∗0)}∣∣∣ .
Fix some compact K1 ⊂ Rq such that Pr {(Z∗Y ⊺, Z∗Z⊺)⊺ ∈ K1} ≥ 1− ǫ. Then,
sup
f∈BL(Rd)
∣∣∣EZ [f {U˜n(Z∗0)}− EZf {U0(Z∗0)}]∣∣∣
≤ sup
f∈BL(Rd)
∣∣∣EZ1 (Z∗0 ∈ K1) f {U˜n(Z∗0 )}− EZ1 (Z∗0 ∈ K1) f {U0 (Z∗0)}∣∣∣
+2EZ1 (Z
∗
0 ∈ K1)
= oP (1) + 2ǫ,
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which implies that An = oP (1) since ǫ was arbitrary. For any K2 ⊂ Rq+p such that Pr (Z∗0 ∈ K2) ≥
1− ǫ, previous arguments yield that
supZ∗0∈K2
∥∥∥B˜n(Z∗0 )−B0(Z∗0)∥∥∥ = oP (1).
As before, we can argue that Bn = oP (1) + 2ǫ, which implies that Bn = oP (1) since ǫ was
arbitrary. The result follows.
Theorem C.1. Let H be a compact set in a metric space with metric d and let F be a compact
subset of C[H] with respect to ‖ · ‖H . For each f ∈ F , let u(f) = argmaxh∈Hf(h), where,
when the arg max is not unique, we select one element of the arg max set either randomly or algo-
rithmically. Suppose also that there exists a closed F1 ⊂ F for which each f ∈ F1 has a unique
maximum. Then,
lim
δ↓0
sup
f∈F1
sup
g∈F :‖f−g‖H<δ
d {u(f), u(g)} = 0.
Proof of Theorem C.1. Fix ǫ > 0. For each f ∈ F1, there exists δf > 0 such that
sup
h∈H∩Bǫ{u(f)}
c
f(h) < f {u(f)} − 2δf ,
where Bǫ(u) is the open d-ball of radius ǫ around u. This follows since the compactness of F
ensures that all f ∈ F are continuous. Let g ∈ F be such that ‖f − g‖H < δf . Then, f {u(g)} >
g {u(g)}−δf ≥ g {u(f)}−δf > f {u(f)}−2δf , which implies that d {u(g), u(f)} < ǫ. We have
that ∪f∈F1 {g ∈ F : ‖g − f‖H < δf} is an open cover of F1. Since F1 is compact, there exists a
set F ǫ1 such that F ǫ1 is finite and ∪f∈Fǫ1 {g ∈ F : ‖g − f‖H < δf} still covers F1. Let {fn} ∈ F1
and {gn} ∈ F be sequences. By compactness, every subsequence has a further subsequence n′′
such that fn′′ → f0 ∈ F1 and gn′′ → g0 ∈ F so that both f0 and g0 are in a set of the form
{g ∈ F : ‖g − f‖H < δf} for some f ∈ F ǫ1. This implies that d {u(g0), u(f0)} < ǫ. Since the
subsequence was arbitrary, we have that lim supn→∞d {u(gn), u(fn)} ≤ ǫ. Since ǫ was arbitrary,
we now have that lim supn→∞d {u(gn), u(fn)} = 0, which proves the result.
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Corollary C.1. For m1 < ∞, let Kqm1 = {z ∈ Rq : ‖z‖ ≤ m1}. Let (z, u) 7→ f(z, u) and
(z, u) 7→ fn(z, u) be a fixed function and a sequence of functions, respectively, from Kqm1 × Rd to
R. Suppose there exists m2 < ∞ such that for each z ∈ Kqm1 , u(z) = argmaxu∈Rdf(z, u) < m2
and is uniquely defined. Suppose also that un(z) = argmaxu∈Rdfn(z, u) < m2 for all n large
enough, where we allow the arg max to be non-unique, but we randomly or algorithmically select
one element from the arg max set. Define Kdm2 similarly to K
q
m1
and assume that
1. supz∈Kqm1 supu∈Kdm2 |f(z, u)| <∞
2. lim supn→∞ supz∈Kqm1 supu∈Kdm2 |fn(z, u)| <∞
3. limδ↓0 supz1,z2∈Kqm1 :‖z1−z2‖<δ ‖f(z1, u)− f(z2, u)‖Kdm2 = 0
4. limδ↓0 supz1,z2∈Kqm1 :‖z1−z2‖<δ ‖fn(z1, u)− fn(z2, u)‖Kdm2 = 0
for all n large enough. Then, provided supz∈Kqm1 ‖fn(z, ·)− f(z, ·)‖Kdm2 → 0,
sup
z∈Kqm1
‖un(z)− u(z)‖ → 0
as n→∞.
Proof of Corollary C.1. By the Arzela`–Ascoli Theorem, there exists a compact K ⊂ C[H] for
H = Kdm2 , such that both f(z, ·) ∈ K and fn(z, ·) ∈ K for all n large enough. If we let F1 ={
f(z, ·) : z ∈ Kqm1
}
, we can directly apply Theorem C.1 to obtain that
lim
δ↓0
sup
z∈Kqm1
sup
g∈K:‖g−f(z,·)‖H<δ
‖u(g)− u {f(z, ·)}‖H = 0.
Because supz∈Kqm1 ‖fn(z, ·)− f(z, ·)‖Kdm2 < δ for all n large enough, the result follows.
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APPENDIX D: TECHNICAL DETAILS FOR CHAPTER 5
Proofs
Proof of Lemma 5.1. Let π be an arbitrary policy and let Z = Y − h(X). Then,
E
[
g(Z)1{sign(Z)A 6= π(X)}]
= E
(
g(Z) [1(Z < 0)1{A = π(X)}+ 1(Z ≥ 0)1{A 6= π(X)}] )
= E
[
g(Z)1{A = π(X)} {1(Z < 0)− 1(Z ≥ 0)} ]+ c
= −E[sign(Z)g(Z)1{A = π(X)}]+ c,
where c is a constant that does not depend on π. Thus,
argmin
π
E
[
g(Z)1{sign(Z)A 6= π(X)}] = argmin
π
(− E [sign(Z)g(Z)1{A = π(X)}] )
= argmax
π
E
[
sign(Z)g(Z)1{A = π(X)}],
which proves the first part of the result. To prove the second part, note that
E
[
sign(Z)g(Z)1{A = π(X)}] = E[E{sign(Z)g(Z)∣∣X, A} 1{A = π(X)}].
Define r(x, a) = E
[
sign{Y − h(X)}g{Y − h(X)}∣∣X = x, A = a]. Then,
πoptg,h = argmax
π
E
(
E [g{Y − h(X)}sign{Y − h(X)}|X = x, A = a] 1{A = π(X)})
= argmax
π
P{A = π(X)}E [r{X, π(X)}]
= argmax
π
E [r{X, π(X)}] ,
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using the fact that P (A = a|X = x) = 1/2 with probability one. Thus, πoptg,h (x) = argmaxa r(x, a).
Because g is nonnegative, even, and increasing on [0,∞),
r(x, a) = E
[
sign{m(x)− h(x) + ac(x) + ǫ}g{m(x)− h(x) + ac(x) + ǫ}]
≤ E[sign{m(x)− h(x) + |c(x)|+ ǫ}g{m(x)− h(x) + |c(x)|+ ǫ}]
= E
[
sign{Y − h(x)}g{Y − h(x)}|X = x, A = sign{c(x)}]
= r
[
x, sign{c(x)}],
using the assumption that Y = m(X)+Ac(X)+ǫ along with the relation |c(x)| = c(x)sign{c(x)}.
Thus, πoptg,h (x) = sign {c(x)}. Since πoptg,h does not depend on g or h it must hold when g(u) = |u|
and h(x) ≡ 0, which proves the result.
Proof of Lemma 5.2. The density of Z = Y−m(X) is proportional to exp [−g {Z − Aq(X)X⊺β}]
and therefore, the negative log-likelihood for β and q based on Z1, . . . , Zn is
−ℓ(β, q) ∝
n∑
i=1
g {Zi − Aiq(Xi)X⊺i β} .
We assume that X1, . . . ,Xn are unique (which occurs with probability one if X has a continuous
component). To obtain the profile log-likelihood we hold β fixed and minimize over the function
q. Note that if AiZiX⊺i β > 0 then q̂(xi) = q̂i = AiZi/X
⊺
i β minimizes g {Zi − Aiq(Xi)X⊺i β} and
furthermore g (Zi − Aiq̂iX⊺i β) = 0. On the other hand, if AiZiX⊺i β ≤ 0 then argmaxπ = q̂i = 0
minimizes g {Zi − Aiq(Xi)X⊺i β} and g (Zi − Aiq̂iX⊺i β) = g (Zi). Thus, the negative profile
log-likelihood for β is
−ℓ(β) = inf
q
{−ℓ(q, β)} =
n∑
i=1
g (Zi) 1(AiZiX
⊺
i β < 0)
=
n∑
i=1
g {Yi −m(Xi)} 1[Ai{Yi −m(Xi)}X⊺i β < 0]
=
n∑
i=1
g {Yi −m(Xi)} 1[Aisign{Yi −m(Xi)} 6= sign(X⊺i β)].
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Proof of Lemma 5.3. Assume for a contradiction that there exists a function Ψ such that the nega-
tive profile log-likelihood for the model
Y = m(X) + AΨ(X; β)η(X) + ǫ
is Eng(Z)φ {sign(Z)AX⊺β}, where Z = Y −m(X), Ψ is a function of X and β, and η : Rp →
H ⊂ R is unknown. Following the proof of Lemma 5.2, the profile likelihood for β can be shown
to be
Eng(Z)1 {ZA/Ψ(X, β) /∈ H} ,
which is discontinuous in β. However, the assumed log-likelihood is continuous in β, a contradic-
tion.
Proof of Theorem 5.1. Let m̂n ∈ M be any estimator for m and assume that M is a VC-class.
Let mβ(X, A, Y ) = g{Y − m̂n(X)}1[sign{Y − m̂n(X)}A 6= sign(X⊺β)] and let M(β) =
Emβ(X, A, Y ) and Mn(β) = Enmβ(X, A, Y ). Consider the class of sets
{
(X, A, Y ) : {Y −
m̂n(X)}AX⊺β < 0
}
β∈Rp
. This class of sets is equivalent to
([{(X, A, Y ) : {Y − m̂n(X)} > 0}A ⊓ {(X, A, Y ) : X⊺β < 0}] ⊔[{(X, A, Y ) : {Y − m̂n(X)} < 0}A ⊓ {(X, A, Y ) : X⊺β > 0}])
β∈Rp
.
Note that {(X, A, Y ) : X⊺β < 0}β∈Rp , {(X, A, Y ) : X⊺β > 0}β∈Rp , {(X, A, Y ) : A{Y −
m̂n(X)} > 0}, and {(X, A, Y ) : A{Y − m̂n(X)} < 0} are Vapnik–Cervonenkis (VC) classes of
sets (Hastie et al., 2009). The class above can be formed from pairwise intersections and unions
of VC classes of sets, and thus is also a VC class of sets by Lemma 9.7 of Kosorok (2008). By
Lemma 9.8 of Kosorok (2008), the function class {1[sign{Y − m̂n(X)}A 6= sign(X⊺β)] : β ∈
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R
p
}
is a VC class of functions. It follows from Theorem 9.3 of Kosorok (2008) that {mβ : β ∈
Rp} is a Glivenko–Cantelli (GC) class and thus supβ∈Rp |M(β)−Mn(β)| P−→ 0.
Next, note that we can write M(β) = Eg {Y −m(X)− Aq˜(X, β)X⊺β} where q˜(X, β) =
max[0, A{Y−m(X)}/X⊺β]. Thus, M(β) is continuous in β for all x such that x⊺β 6= 0 provided
that g is continuous. Let β∗ be the true value of β and assume that ‖β∗‖ = 1. Letting c(x) =
q(x)x⊺β and h(x) = m̂n(x) in the proof of Lemma 5.1, we have that
argmin
β∈Rp
M(β) = argmax
β∈Rp
Esign{m(X)− m̂(X) + q(X)sign(X⊺β)X⊺β∗ + ǫ}
·g{m(X)− m̂(X) + q(X)sign(X⊺β)X⊺β∗ + ǫ}.
Because g is nonnegative, even, and increasing on [0,∞), we have for any β ∈ Rp,
E
[
sign{m(X)− m̂n(X) + q(X)sign(X⊺β)X⊺β∗ + ǫ}
× g{m(X)− m̂n(X) + q(X)sign(X⊺β)X⊺β∗ + ǫ}
]
≤ E[sign{m(X)− m̂n(X) + q(X)sign(X⊺β∗)X⊺β∗ + ǫ}
× g{m(X)− m̂n(X) + q(X)sign(X⊺β∗)X⊺β∗ + ǫ}
]
,
endowed with equality if and only if sign(x⊺β) = sign(x⊺β∗) for almost all x ∈ X . This can only
happen when β = cβ∗ for some c > 0. If we restrict ‖β∗‖ = 1, we have that β∗ is the unique
minimum of M(β). The necessary identifiability condition holds by Lemma 14.3 (iii) of Kosorok
(2008) and the result then follows from Theorem 2.12 of Kosorok (2008).
Additional Simulation Results
Table D.1 below contains estimated MSE when the true error distribution is Laplace, with
mean zero and standard deviation four.
Table D.2 below contains estimated value when the true error distribution is Laplace, with
mean zero and standard deviation four.
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n p MLE-normal MLE-Laplace MLE-kernel OWL
100 5 0.778 0.814 0.779 1.528
15 0.621 0.723 0.621 1.825
25 0.668 0.779 0.668 2.834
250 5 0.761 0.772 0.763 1.458
15 0.548 0.597 0.548 1.108
25 0.570 0.656 0.570 1.313
500 5 0.751 0.753 0.753 1.509
15 0.522 0.545 0.521 0.836
25 0.532 0.586 0.532 0.918
Table D.1: Estimated MSE of β̂n when error distribution is Laplace.
n p MLE-normal MLE-Laplace MLE-kernel OWL
100 5 1.97 (0.329) 1.83 (0.217) 1.79 (0.214) 1.19 (0.805)
15 1.80 (0.385) 1.58 (0.426) 1.62 (0.322) 0.76 (0.622)
25 1.43 (0.383) 1.44 (0.575) 1.48 (0.397) 0.43 (0.557)
250 5 1.85 (0.231) 1.77 (0.196) 1.78 (0.276) 1.31 (0.504)
15 1.56 (0.346) 1.67 (0.349) 1.61 (0.315) 1.11 (0.529)
25 1.85 (0.299) 1.75 (0.288) 1.55 (0.511) 0.97 (0.437)
500 5 1.75 (0.254) 1.74 (0.204) 1.80 (0.279) 1.61 (0.326)
15 1.49 (0.466) 1.98 (0.431) 1.48 (0.665) 1.49 (0.519)
25 1.59 (0.613) 1.79 (0.546) 1.77 (0.446) 1.22 (0.456)
Table D.2: Estimated values with Monte Carlo standard errors when error distribution is Laplace.
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